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ABSTRACT OF DISSERTATION 
 
 
EFFECTS OF WEIGHT LOSS ON VISCERAL ADIPOSITY AND METABOLIC 
ADAPTATIONS IN DIABETIC VERSUS NON-DIABETIC WOMEN 
 
 
 Obesity increases the risk for the development of cardiovascular disease, type 2 
diabetes and other co-morbid conditions.  Type 2 diabetes also is often associated with 
excessive visceral abdominal fat.  Weight loss in obese individuals decreases the risk for 
developing the co-morbid conditions.  Individuals with type 2 diabetes often have a 
greater difficulty in controlling these complications compared to individuals without type 
2 diabetes. 
 The purpose of this study was to evaluate adherence to a medically-supervised 
low-energy diet (LED) weight loss program and changes in body composition and 
metabolic parameters after weight loss in women with and without type 2 diabetes.  
Subjects consisted of Caucasian women, between the ages of 40 to 65 years, with BMIs 
between 30 and 45 kg/m2.  There was no significant difference in BMI between the 
groups at study initiation (38.1 kg/m2, diabetics (DM) and 36.0 kg/m2, non-diabetics 
(NDM), p=0.2314).  All subjects participated in the HMR® Program for 16 weeks.  
Twenty-nine subjects completed the weight loss phase (18 diabetics, 11 non-diabetics) 
and were evaluated for change in weight, body composition, and blood parameters.  Data 
were analyzed by repeated-measures ANCOVA and student’s t-tests using SAS® version 
8.02.  DM and NDM lost 11.7% and 16% of body weight, respectively (p=0.6474).  
Results indicate DM has more total lean tissue (p=0.004), more total body fat (p=0.04), 
more total abdominal tissue (p=0.001), more visceral adipose tissue (p=0.001) and lost 
less percent body fat (p=0.04) than NDM after 16 weeks of weight loss.  After weight 
loss there was no significant difference in leptin, ghrelin or adiponectin levels.  DM had 
greater insulin (p=0.05), HOMA-IR (p<0.0001), glucose (p<0.0001), HbA1c (p<0.0001), 
resistin (p=0.04) and PAI-1 (p=0.02).  There were no differences after weight loss in lipid 
levels, blood pressure, diet compliance or exercise. 
 The data show that medically-supervised LEDs are safe and effective for treating 
obesity in individuals with type 2 diabetes.  Cardiovascular risk factors improved in both 
NDM and DM subjects with weight loss.  The findings also suggest that insulin and 
metabolically dysfunctional lean tissue may play a critical role in the complex axes 
affecting changes in body composition and inflammation in individuals with type 2 
diabetes. 
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CHAPTER ONE 
 
Introduction 
 
Statement of the Problem 
Obesity plays a pivotal role in the development of type 2 diabetes with 
approximately 75 percent of individuals with type 2 diabetes mellitus being obese (1-
3).  With the increasing prevalence of obesity it is not surprising that in the 1990’s the 
prevalence of type 2 diabetes increased by one-third (4;5).  According to the Centers 
for Disease Control, 97% of adults with diabetes have one or more lipid abnormalities 
(6).  Individuals with type 2 diabetes often have a collective group of cardiovascular 
risk factors referred to as the metabolic syndrome.  These risk factors include insulin 
resistance, hypertension, elevated triglycerides, low HDL-cholesterol, endothelial 
dysfunction, a prothrombotic state, and abdominal and visceral obesity (7).  
Complications of diabetes include blindness, kidney disease, heart disease, stroke, 
peripheral vascular disease and neuropathy (8).  Using data from the Nurses Health 
Study (9), it was estimated that as much as 80% of the incidence of type 2 diabetes 
could be attributed to the combined effect of inactivity and overweight / obesity (8). 
Objectives and Hypotheses 
Primary Objectives:  To determine changes in body composition and hormonal 
levels in obese individuals with type 2 diabetes compared to matched obese 
individuals without type 2 diabetes after the completion of a structured low-energy 
diet weight loss program.  The hypotheses are as follows: 
 1.  Obese individuals with type 2 diabetes will lose less body weight than 
obese individuals without type 2 diabetes. 
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 2.  Obese individual with type 2 diabetes will lose a greater proportion of 
abdominal fat as visceral adipose tissue compared to obese individuals without type 2 
diabetes. 
 3.  Plasma ghrelin levels in response to weight loss will not increase as much 
in individuals with type 2 diabetes as compared with individuals without type 2 
diabetes. 
 4.  Plasma leptin levels in response to weight loss will not decrease as much in 
individuals with type 2 diabetes as compared with individuals without type 2 
diabetes. 
Secondary Objectives:  To determine changes in hormonal, metabolic and lipid 
levels in obese individuals with type 2 diabetes compared to obese individuals 
without type 2 diabetes after the completion of a structured low-energy diet weight 
loss program.  The hypotheses are as follows: 
 1.  Obese individuals with type 2 diabetes will have a greater decrease in 
insulin, interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α) and C-reactive 
protein (CRP) compared to obese individuals without type 2 diabetes. 
2.  Obese individuals with type 2 diabetes will have a greater decrease in 
serum triglyceride, plasma activator inhibitor-1 (PAI-) and serum C-reactive (CRP) 
compared to obese individuals without type 2 diabetes. 
3.  Obese individuals with type 2 diabetes will have a greater increase in 
plasma adiponectin compared to obese individuals without type 2 diabetes. 
4.  Obese individuals with type 2 diabetes will have a reduction in plasma 
resistin compared to obese individuals without type 2 diabetes. 
 3 
 
 
 
 
 
CHAPTER TWO 
 
Background and Review of Literature  
 
Obesity 
Obesity is increasing in epidemic proportions in the United States and around 
the world and has become a major global health concern (10;11).  Almost two-thirds 
of adults in the United States are overweight or obese (10).   Table 2.1 outlines the 
body mass index (BMI) criteria for assessing obesity where BMI is an individual’s 
body weight in kilograms divided by their height in meters squared (kg/m2).  Obesity 
and adipose tissue are associated with several co-morbid conditions.  Figure 2.1 
outlines environmental and genetic contributions to health problems associated with 
obesity.  Specifically, obesity plays a pivotal role in the development of type 2 
diabetes with approximately 75 percent of individuals with type 2 diabetes mellitus 
being obese (1-3).  With the increasing prevalence of obesity it is not surprising that 
in the 1990’s the prevalence of type 2 diabetes increased by one-third (4;5).  More 
than 18 million Americans have diabetes which accounts for 6.3% of the United 
States population (12).  In 2002, diabetes was the sixth leading cause of death listed 
on U.S. death certificates (13).  Table 2.2 lists the top ten leading causes of death in 
the United States in 2002.  According to the Centers for Disease Control, 97% of 
adults with diabetes have one or more lipid abnormalities (6).  Individuals with type 2 
diabetes often have a collective group of cardiovascular risk factors referred to as the 
metabolic syndrome.  These risk factors include insulin resistance, hypertension, 
 4 
 
elevated triglycerides, low HDL-cholesterol, endothelial dysfunction, a prothrombotic 
state, and abdominal and visceral obesity (7).   As shown in Table 2.2 co-morbid 
conditions associated with type 2 diabetes are also some of the leading causes of 
death in the United States.  These include the number one leading cause of death, 
diseases of the heart and the third leading cause of death, cerebrovascular diseases. 
Type 2 Diabetes Mellitus 
Type 2 diabetes, is characterized by a combination of insulin resistance which 
is compounded by deficient insulin secretion (14;15).  The most common form of 
type 2 diabetes is a heterogeneous disorder with genetic and environmental factors 
contributing to a dual defect involving β-cell dysfunction and insulin resistance (16).  
In muscle and fat cells, insulin enhances the recruitment of glucose transport proteins 
(GLUT-4) to the cell surface, thereby increasing glucose uptake into the cell in the 
postprandial state (16).  The impairment in glucose transport that is characteristic of 
the insulin resistance of obesity and type 2 diabetes can worsen as a result of 
hyperglycemia (16).  Hyperglycemia “down regulates” the synthesis of GLUT-4 
proteins and inhibits the intrinsic activity of these proteins (16).  Hyperglycemia also 
inhibits insulin gene expression and insulin secretion, particularly by impairing 
glucose-stimulated insulin secretion (16).  Regardless of the pathoetiology of type 2 
diabetes, any elevation in glycemic levels will secondarily result in increased insulin 
resistance and decreased insulin secretion (17). 
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Coronary Heart Disease, Dyslipidemia, and Type 2 Diabetes 
     A.  Coronary Heart Disease (CHD) 
Coronary heart disease (CHD) is the leading cause of death in the United 
States (18).  Observational studies have shown that overweight, obesity and excess 
abdominal fat are directly related to cardiovascular risk factors and are associated 
with increased morbidity and mortality (19-24).  Obesity itself may possibly be the 
greatest risk for the development of CHD (25) and is probably a more significant risk 
factor for individuals with type 2 diabetes (26;27).  Type 2 diabetes is also an 
independent risk factor for CHD in both men and women (7).  The Framingham 
Study found that individuals with diabetes had a two- to three-fold increase risk of 
CHD compared with individuals without diabetes (28).  Other risk factors leading to 
the development of CHD include an elevated total cholesterol, low-density 
lipoprotein (LDL)-cholesterol, triglycerides, blood pressure, fibrinogen and insulin 
(29), and low levels of high-density lipoprotein (HDL)-cholesterol (22). 
Coronary heart disease is responsible for approximately 80% of deaths in 
persons with diabetes (27).  A study conducted by Gu et al. (30) using data from the 
National Health and Nutrition Examination Study (NHANES) looked at the change in 
mortality from CHD over the last 30 years.  The age-adjusted mortality rates from 
heart disease decreased 36.4% and 13.1% for men without diabetes and men with 
diabetes, respectively.  Women without diabetes also displayed a 27% decrease in 
mortality from CHD; however, women with type 2 diabetes had a 23% increase in 
age-adjusted heart disease mortality.  Other studies have found that diabetic women 
in the US have a 3-fold risk of developing CHD (31).  This indicates that diabetes 
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appears to be one of the greatest risk factors for CHD, especially in women 
(28;30;32). 
     B.  Dyslipidemia 
1.  Total Cholesterol 
Individuals are considered to have high total cholesterol with levels >200 
mg/dl and are especially at risk when levels are >240 mg/dl (33).  Manson et al.. (34) 
has determined that for every 1% increase in total cholesterol, an individuals risk for 
the development of CHD increases by approximately 2 to 3 %.   In a similar finding, 
Stamler et al. (35) stated that for every 1 mg/dl increase in total cholesterol that CHD 
risk increased by 2%.  Men and women with a BMI >25 kg/m2 are associated with 
having higher levels of total serum cholesterol (36;37).  In women, the incidence of 
hypercholesterolemia also increases with increasing BMI (38).  Several large 
longitudinal studies provide evidence that overweight, obesity and weight gain are 
associated with increased cholesterol levels (39-41).  In addition to higher body 
weight and BMI, the pattern of fat distribution appears to affect cholesterol levels 
independently of total body weight.  Total cholesterol levels are usually higher in 
persons with predominant abdominal obesity, defined as a waist-to-hip circumference 
ratio of >0.8 for women and >1.0 for men (42). 
2.  Triglycerides 
Triglyceride levels have been shown to have a strong association with BMI in 
both cross-sectional and longitudinal studies for both men and women (36;37).  
Triglyceride levels > 150 mg/dl are considered to be high and puts an individual at 
increased risk for developing CHD (3).  One study separated adults into three age 
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groups (20 to 44 years, 45 to 59 years, and 60 to 74 years) and found that individuals 
with a BMI > 30 kg/m2 is associated with increasing triglyceride levels compared 
with individuals with a BMI < 21 kg/m2.  The difference in triglycerides between the 
higher and lower BMI groups, ranged from 61 to 65 mg/dl in women (36) and 62 to 
118 mg/dl in men (37). 
3.  LDL-Cholesterol 
A serum LDL-cholesterol concentration of > 160 mg/dl is considered to be 
high and an independent risk factor for CHD (3).  This lipoprotein is the predominant 
atherogenic lipoprotein and is therefore the primary target of cholesterol-lowering 
therapy by diet, physical activity and drug therapy.  Law et al. (43) concluded that for 
either a 1% increase or 1 mg/dl increase of LDL-cholesterol that an individuals risk 
for CHD increased by 1%.  Cross-sectional data suggest a 10-unit difference in BMI, 
from 20 kg/m2 to 30 kg/m2, is associated with LDL-cholesterol levels that are higher 
by 10 to 20 mg/dl (36;37).  According to extensive epidemiological data, a 10 mg/dl 
rise in LDL-cholesterol corresponds to approximately a 10 percent increase in CHD 
risk over a period of 5 to 10 years (43). 
4.  HDL-Cholesterol 
Serum HDL-cholesterol levels are considered to be “good” cholesterol and are 
negatively associated with risk for developing coronary heart disease.  HDL-
cholesterol is believed to be able to “pull” cholesterol out of the cells and transport 
peripheral cholesterol back to the liver for catabolism.  This is often referred to as 
“reverse cholesterol transport.”  Recommended levels for men are HDL-cholesterol 
levels of > 45 mg/dl and for women > 55 mg/dl, but the protective level for HDL is > 
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60 mg/dl (3).  Cross-sectional studies have reported that HDL-cholesterol levels are 
lower in men and women with higher BMI (44;45).  A low HDL-cholesterol level 
leads to a higher LDL:HDL ratio that enhances the risk of CHD.  Longitudinal studies 
have found that changes in BMI are associated with changes in HDL-cholesterol.  A 
BMI change of 1 unit is associated with an HDL-cholesterol change of 1.1 mg/dl for 
young adult men and an HDL-cholesterol change of 0.69 mg/dl for young adult 
women (46).  Frick et al. (47) concluded that for every 1% decrease in HDL-
cholesterol an individual’s risk of CHD increased by 3.1%.  Stamler et al. (35) 
reached similar findings in that there is a 2% to 3% increase in the risk of developing 
CHD for every 1 mg/dl decrease in HDL-cholesterol. 
     C.  Type 2 Diabetes and Dyslipidemia 
According to the Centers for Disease Control, 97% of adults with diabetes 
have one or more lipid abnormalities (6).  Table 2.3 lists the ATP III clinical 
identification requirements for an individual to be diagnosed with the metabolic 
syndrome (48).  The presence of the metabolic syndrome is equal to a risk for 
vascular disease with that of a high-risk LDL-cholesterol concentration of 150 to 220 
mg/dl (49).  Individuals with the metabolic syndrome often have elevations in C-
reactive protein and plasminogen activator inhibitor-1 (PAI-1) indicating 
proinflammatory and prothrombotic states (48). 
Individuals with type 2 diabetes usually do not have LDL-cholesterol levels 
different from those in non-diabetic patients.  However, the LDL-cholesterol particles 
in individuals with diabetes are usually small, dense, and oxidized LDL-cholesterol 
and of particular interest in the risk for CHD.  Clinical studies have shown that these 
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lipoprotein particles are particularly atherogenic and tend to be present in greater 
proportion in hypertriglyceridemic patients with insulin resistance associated with 
abdominal obesity (50-53).  Triglyceride levels are often increased and HDL-
cholesterol decreased in individuals with type 2 diabetes as well, which may be the 
best predictor of vascular disease in these subjects (54). 
Longitudinal epidemiological studies have shown that the risk for 
cardiovascular disease mortality in type 2 diabetic subjects is at least twice that of 
persons without diabetes and that this relative risk is generally higher in women than 
in men (28;55).   
Abdominal Obesity and Body Composition 
 Abdominal obesity is a distinct and independent risk factor for the 
development of type 2 diabetes (1;29;56-58).  Abdominal obesity, particularly 
visceral adipose tissue, increases both metabolic disorders and the cardiovascular 
risks of dyslipidemia, hypertension, and cardiovascular disease (19;20;59-62).  
Visceral fat accumulation is influenced by factors such as age, menopause, stress, 
smoking, alcohol consumption, socioeconomic status and genetic factors (63;64).  
Specifically, accumulation of visceral adipose tissue at the L4-L5 level, characterized 
by waist circumferences of above 110 cm2 for women and approximately 125 cm2 is 
associated with distinct elevations in the risk factors for cardiovascular disease and 
type 2 diabetes (65;66).  Other studies have shown that type 2 diabetes is associated 
with more accumulation of visceral abdominal fat compared with obese non-diabetic 
subjects with similar body weight (67;68). 
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Several studies have reported that weight loss induces a greater proportion of 
fat losses as visceral fat compared to subcutaneous fat.  Yip et al. (69) reported that 
non-diabetic women lost 16.5 + 6.6 kg, with a 28.3% reduction in total abdominal 
adipose tissue, a 31% reduction in visceral adipose tissue and a 26.0% reduction in 
subcutaneous adipose tissue.  Zamboni et al. (70) reported that obese women with a 
weight loss of 6.6 kg visceral fat by decreased 40% while subcutaneous fat was 
reduced 23%.  Limited research is available in individuals with type 2 diabetes; 
however, Takami et al. (71) found similar results in individuals with type 2 diabetes.  
These individuals with a minimal weight loss of 2-3 kg lost 25.8% of their abdominal 
fat as visceral adipose tissue and 17.2% as subcutaneous abdominal tissue.  Others 
also showed that obese subjects with an initial abundance of visceral fat do not lose 
more weight but lose more visceral fat than subjects with less visceral fat (63).  One 
may speculate that since individuals with type 2 diabetes have a greater proportion of 
their abdominal tissue as visceral fat that these individuals should lose more weight as 
visceral adipose tissue then obese individuals of the same body weight with less 
visceral adipose tissue. 
Due to the increase in health risks related to obesity and particularly obesity 
with type 2 diabetes, it is important that these individuals lose the excess body fat to 
decrease the associated metabolic abnormalities accompanying type 2 diabetes 
mellitus.  These metabolic disturbances decrease with weight loss (72); however, 
obese individuals with type 2 diabetes often have greater difficulty losing weight than 
obese individuals without type 2 diabetes (73-75).  This phenomenon is not fully 
understood.  Several contributing factors could be responsible for the difficulties for 
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individuals with type 2 diabetes.  One potential contributing factor in losing weight 
could be that often individuals with type 2 diabetes have followed demanding diet 
regimens for many years and have “diet fatigue” making it difficult for these 
individuals to follow a rigorous energy-deficient diet.  Also, diabetic individuals are 
often on medications to control the metabolic abnormalities and consequently these 
same medications may promote weight gain.  Oral anti-diabetes agents sulfonylureas, 
meglitinides, and thiazolidinediones and insulin tend to be associated with weight 
gain (76).  The one exception to this is the use of metformin.  Metabolic 
abnormalities present with type 2 diabetes and visceral adiposity, such as 
hyperglycemia and hyperinsulinemia, make it more difficult to lose weight and 
maintain weight lost.  This may also include abnormalities in non-glucose regulatory 
hormones affecting energy balance.  Another possible factor for this could be the way 
in which the body regulates energy balance through the central nervous system 
(CNS).  The CNS plays a fundamental role in the regulation of body weight and 
energy balance by: 1. affecting feeding behavior and physical activity; 2. affecting the 
autonomic nervous system controlling various aspects of metabolism, and 3.  
affecting the neuroendocrine system by controlling the secretion of hormones (77).  
The hormones of the neuroendocrine system used in the body weight regulation and 
energy balance are quite complex and the cascade of events causing certain 
individuals to be in a state of either positive or negative energy balance are still not 
fully understood.  Some of the hormones involved in this complex system include 
leptin, ghrelin, insulin, neuropeptide Y, and growth hormone.  Overall, a disruption in 
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this complex neuroendocrine pathway will affect the mechanisms by which body 
weight and energy balance are regulated. 
Adipose and Stomach Hormones 
     A.  Leptin 
The hormone leptin, a product of the ob gene, is named leptin from the Greek 
word “leptos” meaning thin (78).  The most important variable that determines 
circulating leptin concentrations is body fat mass (79).  Leptin is produced 
predominantly in subcutaneous adipose tissue compared with visceral adipose tissue 
(80).  Its role is to increase energy expenditure and inhibit food intake by decreasing 
the release of neuropeptide Y from the hypothalamus (81).  If leptin levels are low 
during a period of positive energy balance an individual is prone to obesity (82).  
However, leptin levels have been found to be significantly greater in obese than non-
obese subjects (78;80;83).  Recent data have indicated that this is likely the result of 
desensitization for the leptin signal, now referred to as leptin resistance (78;84).   
Leptin production occurs after increases in insulin in response to feeding and a 
decrease in leptin concentrations follows decreases in insulin during fasting (85;86). 
Leptin levels decrease by approximately 20 to 40% when individuals lose 
approximately 10% of their body weight (87-89).  In individuals with type 2 diabetes, 
leptin levels do not drop as dramatically.  Williams et al. (90) found that with an 
approximate 7.4% weight loss leptin levels decreased 20% in individuals with type 2 
diabetes.  These researchers also noted that leptin levels increased after sulfonylureas 
were reinitiated.  Because leptin has been found to inhibit food intake and increase 
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energy expenditure, the administration of leptin is thought to be a potential 
pharmacotherapy for obesity.  However, since leptin is produced by adipose tissue,  
leptin levels are often high in obese individuals and does not suppress food intake 
(87).   Pharmacologic trials of the administration of leptin into obese individuals to 
reduce food intake subsequently were not able to reduce body weight, most likely due 
to some biological change that occurs over time to the excess of leptin in the 
body(91).  Another possible explanation is leptin’s interactions with other 
neuroendocrine hormones that affect body weight regulation. 
     B.  Ghrelin 
The hormone ghrelin, which is thought to play an important role in this 
complex energy balance system, is an endogenous ligand for the growth-hormone 
secretagogue receptor (GHS-R) (92).  Ghrelin was named for its ability to provoke 
growth hormone secretion (the suffix “ghre” means grow) (93).  Ghrelin has profound 
orexigenic, adipogenic, and somatotropic properties, increasing food intake and body 
weight.  
Ghrelin has been found to be produced primarily in the stomach and then 
secreted into the blood stream (94).  Within the stomach, ghrelin is produced by 
enteroendocrine cells in the oxyntic mucosa (93-98).  The orexigenic actions of 
intracerebroventricular ghrelin appear to be meditated through hypothalamic 
neuropeptide Y (NPY) and agouti-related protein circuits (99).  States of positive 
energy balance are associated with a decrease in ghrelin levels.  Tschöp et al. (100) 
found that circulating ghrelin levels are decreased in individuals with obesity.  Other 
studies have found that these levels are also decreased during acute overfeeding (100-
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102).  On the contrary, an increase in circulating ghrelin levels have been observed in 
fasting patients and in chronic under-nutrition such as with individuals with anorexia 
nervosa (96;103).  Pre-meal rise of circulating ghrelin levels suggest it has a role as a 
hunger signal triggering meal initiation and this signal could be mediated by GHS-R 
subtypes (104).  Tschöp et al. (100) also observed that ambient ghrelin levels in lean 
Pima Indians was significantly lower than obese Caucasians and that obese Pima 
Indians had even lower fasting plasma ghrelin levels.  Pima Indians were used in this 
study due to their high rate of obesity and type 2 diabetes.  Fasting ghrelin levels were 
also found to be negatively correlated with fasting plasma levels of insulin and leptin.  
In response to weight loss, Cummings et al. (105) found plasma ghrelin levels to 
increase approximately 24 percent. 
Several mechanisms for the interaction between leptin and ghrelin have been 
postulated in the complex neuroendocrine system of energy balance.  One suggested 
mechanism is the activation of neuropeptide Y (106).   NPY stimulates food intake 
and promotes the net deposition of adipose mass (107). Leptin acts to inhibit NPY, 
while ghrelin activates NPY in the hypothalamus.  The antagonistic action is 
suggested by comparison of levels with obese and lean states.  Leptin levels are 
higher in obese individuals compared with non-obese individuals, whereas ghrelin 
levels are lower in obese compared to lean individuals.  The levels of leptin and 
ghrelin in obese verses lean adults are demonstrated in Figures 2.2a and 2.2b, 
respectively.  
The evidence is inconclusive related to alterations of leptin levels in type 2 
diabetes (90;108-111).  After weight loss leptin levels dramatically decline.  This is 
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mostly likely do to the changes in abdominal adipose tissue.   However, we speculate 
that individuals with type 2 diabetes would exhibit less of a decline in serum leptin 
concentrations compared with obese subjects since diabetic individuals should lose a 
greater proportion of their body fat as visceral fat compared with that of subcutaneous 
adipose tissue, where leptin is predominantly produced.  Figure 2.3 shows leptin 
levels in individuals with and without type 2 diabetes before and after weight loss.  
We predict that subjects in this study will follow the same pattern resulting in a 
smaller decrease in leptin levels in women with type 2 diabetes than obese women 
without type 2 diabetes. 
Limited information is available on changes in ghrelin level for individuals 
with type 2 diabetes with or without weight loss.  Boden et al. (112) found that 
diabetic subjects on a low-carbohydrate diet lost 1.65 kg in 14 days and that insulin 
and leptin levels were statistically significantly lower at the end of the low-
carbohydrate diet than before the diet, while ghrelin levels increased marginally. 
Figure 2.4 illustrates currently available data and our hypothesized response for 
fasting ghrelin levels after weight loss in obese type 2 diabetic women.  Because 
Tschöp et al. (100) also found that Pima Indians had lower ghrelin levels than 
Caucasians, we hypothesized that obese women with type 2 diabetes will have lower 
fasting ghrelin levels than that of obese women without type 2 diabetes.  As stated 
earlier, Cummings et al. (105) found that ghrelin levels increased after weight loss.  
Therefore, it is hypothesized that ghrelin levels will rise less dramatically in 
individuals with type 2 diabetes than individuals without type 2 diabetes. 
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Insulin Resistance 
Besides the variations in the neuroendocrine hormones, other important 
metabolic variations exist as a consequence of obesity and type 2 diabetes.  Many of 
these are associated with the excessive accumulation of abdominal adipose tissue.  An 
increase in serum insulin levels is the most obvious in individuals with type 2 
diabetes.  Insulin is an anti-lipolytic hormone which stimulates glucose uptake and 
triglyceride biosynthesis.  Insulin levels have been found to decrease in obese diabetic 
and non-diabetic individuals during weight loss (113-116) reflecting an increase in 
insulin sensitivity.  Insulin sensitivity has a critical role in diabetes and is inversely 
related to degree of obesity. 
Methods to test insulin sensitivity are often time-consuming and very 
expensive.  The hyperinsulinemic insulin clamp, the “gold standard” for measuring 
insulin sensitivity, requires four hours of subject time and involves several 
intravenous lines, two infusions and about 40 blood glucose and insulin 
measurements (117).  A simplified technique the homeostasis model assessment 
(HOMA-IR) has been found to be correlated with the hyperinsulinemic-euglycemic 
clamp technique (118;119).  The HOMA-IR method for the determination of insulin-
sensitivity derives an estimate of insulin sensitivity from the mathematical modeling 
of fasting plasma glucose and insulin concentrations (120). 
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Inflammatory and Thrombotic Cytokines 
     A.  Tumor necrosis factor-alpha (TNF-α), Interleukin-6 (IL-6), C-reactive 
protein (CRP), Plasminogen activating inhibitor-1 (PAI-1) 
 Adipose tissue is an important organ which produces cytokines that are 
involved in inflammatory and thrombotic pathways.  Examples of such cytokines 
include tumor necrosis factor- alpha (TNF-α), interleukin-6  (IL-6),  C-reactive 
protein (CRP), and plasminogen activating inhibitor-1 (PAI-1) (121).  It has been 
proposed that these “adipokines” may be an important factor linking central obesity to 
other risk components of the metabolic syndrome (122). 
 Subcutaneous adipose tissue produces the cytokines TNF-α (123) and IL-6 
(124).  TNF-α, a pro-inflammatory cytokine, is associated with insulin resistance and 
is correlated with the amount of body fat accumulation (125).  Obese individuals 
express 2.5-fold more TNF-α mRNA in subcutaneous fat tissue than lean controls, 
with a significant correlation between TNF-α mRNA and BMI (126;127).  Dandona 
et al. (128) found a strong positive correlation between TNF-α mRNA expression in 
fat tissue and the level of insulin.  The TNF-α system is complex and is often 
associated with increased energy expenditure and weight loss (129;130); however, 
data on the circulating levels of TNF-α in obese and individuals with type 2 diabetes 
are conflicting (129;130).  IL-6 is believed to increase the level of CRP seen in 
obesity (131-133).  IL-6 and CRP are increased in obesity (134) and are acute phase 
reactants associated with inflammation and an increased risk for cardiovascular 
disease (135) and may also play a role in insulin resistance (136). 
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Bastard et al. (136) found that weight loss in obese non-diabetic individuals 
slightly, but significantly decreased IL-6 levels from 2.78 pg/ml to 2.32 pg/ml (p 
=0.05) after a weight loss of approximately 5-6 kg.  A similar nonsignificant decline 
in CRP levels was also observed.  Before weight loss, CRP levels were 6.3 + 1.1 mg/l 
while after weight loss levels decreased to 4.3 + 0.9 mg/l (p = 0.14).  An increase in 
insulin levels, as seen in type 2 diabetes, have also been found to amplify the 
production of proinflammatory cytokines (137).  
Other metabolic alterations exist in individuals with type 2 diabetes increasing 
cardiovascular disease risk.  Increased levels of PAI-1 have been associated with 
obesity (138) insulin resistance and type 2 diabetes (139).  The Insulin Resistance 
Atherosclerosis Study (IRAS) (140) found that plasma CRP and PAI-1 levels were 
higher in insulin-resistant subjects who later developed type 2 diabetes than in 
subjects who did not.  Circulating PAI-1 levels are also elevated in patients with 
cardiovascular disease and may affect the progression of this disease (141).  
Individuals with type 2 diabetes often have abnormally high serum triglyceride levels 
and plasminogen activator inhibitor-1 (PAI-1) (142;143).  In plasma, PAI-1 promotes 
clot formation, which plays a key role in the pathogenesis of myocardial infarction, 
stroke, and other cardiovascular events (144-147).  Excessive serum insulin 
associated with type 2 diabetes and visceral adipose tissue, inhibits the mobilization 
of nonesterified fatty acids by decreasing the rate of lipolysis and consequently 
increasing the rate of resynthesis of triglycerides from nonesterified fatty acids that 
are formed from lipolysis (148).  The presence of visceral adiposity, insulin resistance 
and type 2 diabetes also increases the levels of PAI-1 (149;150).  Metabolic products 
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such as triglycerides, free fatty acids, glucose, insulin, and TNF-α can stimulate PAI-
1 release from fat and other tissues (151-159).   Both visceral and subcutaneous 
adipose tissue express PAI-1 (138); however, PAI-1 is primarily secreted by visceral 
adipose tissue (160).  PAI-1 increases thrombosis and decreases the breakdown of 
blood clotting leading to greater adhesion of platelets to the endothelial wall (150).  
Weight loss decreases both triglyceride and PAI-1 levels in obese and type 2 diabetic 
individuals (161;162). 
     B.  Adiponectin 
Adiponectin a recently discovered 244-amino acid, adipose-specific protein 
(163) is found in high concentrations in peripheral circulation (164).  Adiponectin is 
primarily released by subcutaneous adipose tissue compared with visceral adipose 
tissue (165).  Adiponectin secretion is stimulated by insulin (78) and it has been 
shown that serum levels of adiponectin correlate with systemic insulin sensitivity 
(166).  It is believed that reduced levels of adiponectin may play a role in the 
pathogenesis of obesity and type 2 diabetes (166); however, a physiological role has 
not been fully established. 
Decreased adiponectin concentrations are associated with insulin resistance 
and hyperinsulinemia (78).  In contrast to leptin, adiponectin levels are significantly 
reduced not only in obese subjects (122;167;168), but also in patients with some of 
the disease states associated with obesity, such as type 2 diabetes (168;169) and 
coronary heart disease (170).  In addition, high adiponectin concentrations are 
associated with a reduced risk of type 2 diabetes (171).  Adiponectin levels are 
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inversely associated with central or overall adiposity, as well as hyperlipidemia and 
insulin resistance independently of BMI (172;173). 
Data are inconsistent in the literature as to adiponectin and its correlations 
between various metabolic markers.  Yamamoto et al. (172) found that plasma 
adiponectin was negatively correlated with BMI, systolic and diastolic blood 
pressure, fasting plasma glucose, insulin, insulin resistance, total cholesterol, LDL-
cholesterol,  triglycerides and uric acid and positively correlated with HDL-
cholesterol in normal-weight subjects.  Cnop et al. (174) found similar results.  These 
researchers found plasma adiponectin concentration was negatively correlated with 
BMI, percentage of body fat, fasting insulin concentration, and plasma triglycerides 
but positively with HDL (174). 
Shetty et al. (175), found a positive correlation of adiponectin with HDL and a 
negative correlation adiponectin with triglycerides, CRP, and PAI..  However, there 
was no association between adiponectin with total cholesterol, LDL-cholesterol and 
TNF-α.  Consistent with Shetty and colleagues, other data indicate that adiponectin 
has been associated with markers of inflammation, such as CRP and TNF-α 
(176;177).  Overall, this adipocyte-derived cytokine may exert anti-inflammatory, 
anti-fibrotic and anti-atherogenic effects and may be beneficial in the treatment of 
insulin resistance, diabetes, vascular complications and atherosclerosis (178). 
Research findings vary related to weight reduction and adiponectin change in 
non-diabetic and diabetic patients (179).  Valsamakis et al. (180) found a 27% 
increase in serum adiponectin (p= 0.04) with a 5.4% weight loss in Caucasian non-
diabetic women.  In contrast, Wolfe et al. (181) concluded that after a weight loss of 
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3.4 + 2.1 kg weight loss adiponectin concentrations decreased significantly by 16.2% 
(p=0.04).  Finally, Monzillo et al. (182) found that adiponectin levels increased 
significantly in subjects with type 2 diabetes (p=0.01), but not in individuals with 
impaired glucose tolerance or normal glucose tolerance. 
     C.  Resistin 
Resistin is a member of the newly discovered cysteine-rich secretory protein 
family referred to as RELM or FIZZ.  Resistin is more highly expressed in both 
abdominal visceral and subcutaneous adipose tissue compared with adipose tissue 
from other areas of the body (183).   Several small studies have reported that 
circulating resistin levels are increased in human obesity (184-187) and diabetes 
(188-192). A study in rats conducted by Shuldiner (193) demonstrated that obesity 
induced by diet as well as in genetic models of obesity and insulin resistance is 
associated with increased resistin levels (193).  Resistin has also been found to 
increase blood glucose and insulin concentrations in mice (193).  Furthermore, 
resistin gene expression is markedly down-regulated by treatment with the anti-
diabetic drugs thiazolidinediones, which improve target-tissue sensitivity to insulin.  
A possible role for resistin in the inflammatory processes is suggested (78). 
 Steppan et al. (194) have proposed that resistin is increased in type 2 diabetes 
and suggested that it is a potential link between obesity and insulin resistance.  
However, the role of resistin in obesity and insulin resistance in humans is 
controversial.  Youn et al. (190) found that there is more serum resistin protein in 
obese than lean individuals; however resistin concentrations were elevated in patients 
with type 2 diabetes but were not associated with insulin resistance or obesity.  These 
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researchers also found that BMI is a significant predictor of insulin resistance, but 
resistin adjusted for BMI was not.  On the contrary,  Silha et al. (195) demonstrated a 
significant correlation between resistin levels and HOMA-IR in obese subjects 
independent of BMI.  Overall, there is controversy about whether if resistin plays a 
role in insulin resistance or is just associated with obesity.   
 The effect of weight loss on resistin levels has also shown conflicting results 
and the majority of the studies have been conducted in non-diabetic subjects only.  
Valsamakis et al. (180) found a 16.8% decrease in serum resistin (p=0.02) with a 
5.4% weight loss in Caucasian non-diabetic women.  Similarly, Azuma et al. (185) 
found that in non-diabetic individuals who lost 1 kg or more of fat mass, resistin 
levels decreased significantly (-17 + 19%, p<.0.01).  In contrast Wolfe et al. (181) did 
not find a significant change in resistin in healthy, normal weight women after weight 
loss.  And finally, Monzillo et al. (182) found that in insulin-resistant individuals 
there was no significant change in resistin levels after a weight loss of 6.9 + 0.1 kg.  
Figure 2.5 provides a schematic summary of the adiposity and stomach signals on 
their positive or negative effects on weight and cardiovascular risk. 
Weight Loss 
     A.  Very-Low-Energy Diets (VLED) and Low-Energy Diets (LED) 
Very-low energy diets (VLED) and low-energy diets (LED) are medically-
supervised diet programs.  VLEDs provide 500 to 800 kcal/day, whereas low-energy 
diets (LED) provide 800 to 1200 kcal/day.  The active phase of these programs 
commonly lasts from 12 to 16 weeks.  During this time, VLEDs promote a weight 
loss of approximately 14 to 23 kg and 9 to 13 kg with LEDs.  In three of the four 
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studies comparing VLEDs to hypocaloric-balanced diets, VLEDs resulted in 4 to 12 
kg greater weight loss than the reduced-energy diets consisting of 1,000 to 1,800 
kcal/day at the end of the active weight loss phase (196-198).  These comprehensive, 
medically-supervised diets have been found safe and appropriate for the treatment  of 
obesity in individuals with type 2 diabetes (199), however, due to increased expense 
of the VLED, LED are commonly used in clinical practice (200). 
Often individuals who follow conventional weight reducing diet techniques 
lose minimal amounts of body weight.  For example, Markovic et al. (161) found a 
6.2 + 0.4 kg weight loss with a caloric restriction of 1,000 kcal/day.  Metz et al. (201) 
found that women lost 4.8 + 3.0 kg following a 10-week prepared meal plan and 
individuals following a 10-week self-selected mixed-food plan lost 2.8 + 2.8 kg.  
Faith et al. (202) summarized weight loss treatment by behavior therapy and 
conventional reducing diet techniques.  They reported more positive results from the 
5 studies they summarized and concluded that individuals lost 8.5 kg during a 21.3 
week treatment. 
Individuals with type 2 diabetes have a more difficult time losing weight with 
the conventional and behavioral approaches to weight loss compared to non-diabetics.  
McCarron et al. (203) found that with a prepared meal plan (Campbell’s Center for 
Nutrition and Wellness meal program [CCNW]) women with type 2 diabetes lost 4.8  
+ 3.0 kg and individuals who consumed a self-selected diet based on exchange lists 
lost 2.8 + 2.8 kg of body weight.  In a continuation of the study, Pi-Sunyer et al. (73) 
compared the CCNW and self-selected diet programs in individuals with type 2 
diabetes and found that weight losses were 3.4 + 3.1 kg and 2.9 + 2.8 kg, 
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respectively.  Wing et al. (204) found similar results in individuals with type 2 
diabetes.  During a 16-week energy restricted diet, subjects lost 4.7 + 3.9 kg of body 
weight.  In one study type 2 diabetic women were able to lose as much weight as non-
diabetic subjects (6.8 kg); however, the type 2 diabetic subjects were not able to 
maintain the weight loss as well as the non-diabetic women (75). 
     B.  Type 2 Diabetes Mellitus and Weight Loss 
Treatment goals for individuals with type 2 diabetes are to promote weight 
loss and to improve glycemic control, thus the initial treatment choice for individuals 
who are overweight or obese with type 2 diabetes is weight loss.  Weight loss 
improves insulin sensitivity due to increased non-oxidative glucose disposal (205).  
Consequently, type 2 diabetic individuals display improved glycemic control and 
reduce insulin resistance with weight loss (206;207).  Weight loss in these individuals 
will also lower blood pressure and improve their serum lipid concentrations (208). 
Several researchers have shown that VLED treatment may be beneficial in 
obese type 2 diabetics, both from weight and glycemic control points of view 
(113;199;209;210).  Previous studies have shown that during VLED treatment, 
reduction in blood glucose levels occurs rapidly with the first 7 to 14 days (199;210).  
Capstick et al. (211) found that after a 12 week VLED program with type 2 diabetics 
that blood glucose levels fell rapidly at the onset of the VLED.  The median fasting 
and postprandial blood glucose levels fell by 25% and 20% respectively after 2 days 
of treatment.  There was a significant decrease in weight, waist circumference, 
HbA1c, systolic blood pressure, fasting plasma insulin, and total cholesterol and 
triglyceride levels.  All subjects discontinued using insulin and the use of oral diabetic 
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agents decrease dramatically.  Moreover, reduction in waist circumference following 
a VLED treatment is also important.  As recent data suggest, a high waist 
circumference increases the risk of cardiovascular disease (212). 
In a quantitative analysis of individuals with type 2 diabetes and the use of 
LED therapy, Anderson et al. (213) found that a greater weight loss was associated 
with a significant increase in HDL-cholesterol values (+3.9, 95% CI, 0.1 to 7.8) while 
lesser weight loss was associated with a significant decrease in HDL-cholesterol 
values (-5.9, 95% CI, -9.4 to -2.3).  This is consistent with our previous analysis 
conducted in individuals without type 2 diabetes (25). 
Greenfield et al. (214) reported that a 10-day total fast with weight loss of 
5.1% of initial body weight decreased fasting plasma glucose values in type 2 diabetic 
subjects by 64% (from 17.2 mmol/L to 6.1 mmol/L).  Anderson et al. (213) quantified 
10 studies of subjects treated with a VLED for 4 to 6 weeks.  Subjects lost 9.6% of 
initial body weight and after 2 weeks of VLED treatment, fasting plasma glucose 
decreased by approximately 50% of their fasting plasma glucose.  This decrease in 
plasma glucose remained throughout the VLED treatment.  Anderson et al. (213) also 
quantified the fasting plasma glucose response in type 2 diabetes during LED weight 
loss programs.  The results indicated that fasting plasma glucose values decrease 
approximately 30% with a weight loss of 10 kg.  However, consistent with previous 
studies (113;209), they concluded that greater weight loss was associated with greater 
improvements in plasma glucose  values.  Anderson and Konz (25) estimated that for 
every 1 kg of weight loss in individuals with type 2 diabetes you can expect 
approximately a 0.2 mM (3.6 mg/dl) decrease in fasting glucose concentrations. 
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The importance of alleviating these co-morbid risk factors associated with 
type 2 diabetes has stimulated the research presented here to evaluate the effects of a 
low-energy diet (LED) weight loss program on the health risk factors associated with 
type 2 diabetes.
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Table 2.1 Classification of Body Mass Index (BMI) to Assess Obesity. 
WHO 
Classification
Popular 
Description BMI (kg/m2)
Risk of           
Co-Morbidities
Underweight Thin < 18.5
Low (but risk of 
other problems 
increased)
Healthy Weight Normal 18.5 - 24.9 Average
Overweight > 25.0
     Pre-obese Overweight 25.0 - 29.9 Increased
     Obese Class I Mild Obesity 30.0 - 34.9 Moderate
     Obese Class II Moderate Obesity 35.0 - 39.9 Severe
     Obese Class III Severe Obesity > 40.0 Very severe
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Table 2.2 Deaths and Percentage of Total Deaths for the 10 Leading Causes of 
Death:  United States, 2002.  Taken from the National Vital Statistics Report (13). 
 
Rank Cause of Death # of Deaths
Percentage of 
Total Deaths
All causes 2,443,387 100
1 Diseases of heart 696,947 28.5
2 Malignant neoplasms 557,271 22.8
3 Cerebrovascular diseases 162,672 6.7
4 Chronic lower respiratory diseases 124,816 5.1
5 Accidents (unintentional injuries 106,742 4.4
6 Diabetes Mellitus 73,249 3
7 Influenza and pneumonia 65,681 2.7
8 Alzheimer's disease 58,866 2.4
9
Nephritis, nephrotic syndrome and 
nephrosis 40,974 1.7
10 Septicemia 33,865 1.4
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Table 2.3 ATP III Clinical Identification of the Metabolic Syndrome (48). 
Risk Factor Defining Level
Abdominal obesity, given as waist circumference
     Men >102 cm (>40 inches)
     Women >88 cm (>35 inches)
Triglycerides >150 mg/dL
HDL cholesterol
     Men <40 mg/dL
     Women <50 mg/dL
Blood pressure >130 / >85 mmHg
Fasting glucose >110 mg/dL  
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Figure 2.1 Pathogenesis of Health Problems Associated with Obesity.  Adapted 
from Bray (215). 
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Figure 2.2 Serum Ghrelin (a) and Leptin (b) Levels in Lean and Obese 
Individuals With and Without Type 2 Diabetes. 
 
(a) Ghrelin     
 
 
 
 
 
 
 
*Data from Tschöp et al. (100) 
(b)  Leptin 
 
 
 
 
 
 
 
 
 
*Data from Misra et al. (216) 
*Leptin values are expressed as square root transformations 
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Figure 2.3 Changes in Leptin Response to Weight Loss. 
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Figure 2.4 Changes in Ghrelin Response to Weight Loss. 
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Figure 2.5 Schematic Summary of Hormone and Adipokines on the 
Hypothalamus. 
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CHAPTER THREE 
 
Experimental Design and Methods 
 
Overview 
 
 Obese, Caucasian women with and without type 2 diabetes participated in the 
study.  Subjects were between the ages of 40 and 65 years with a BMI between 30 
and 45 kg/m2.   Subjects without type 2 diabetes mellitus were matched with women 
with type 2 diabetes for age and BMI.  Subjects participated in a 16-week medically-
supervised low-energy diet (LED) weight loss program after a 2 to 4-week run-in 
period to determine body composition, current metabolic parameters, and to regulate 
diabetic medications. 
Study Participants 
Caucasian women with a BMI between 30 and 45 kg/m2, between the ages of 
40 and 65 years were recruited to participate in the study.  Subjects were not currently 
dieting or taking weight loss medications.  The health of each subject was stable 
without severe coronary artery disease, cerebrovascular disease or recent myocardial 
infarction. 
     A.  Inclusion Criteria 
• Women ages 40 to 65 years; 
• Caucasian; and 
• BMI 30 to 45 kg/m2. 
B.  Exclusion Criteria 
• Pregnancy, lactation or plans to become pregnant in the next 6 months;  
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• TSH  >6 µU/ml; 
• Severe coronary artery disease, cerebrovascular disease or recent myocardial 
infarction or any other serious medical condition; 
• Recent history of alcohol abuse with current intake of > 2 drinks per day; 
• Use of weight reducing agents, such as phentermine, sibutramine, orlistat, 
bupropion, or an herbal weight loss product within the last eight weeks; 
• Psychosis or other major psychiatric problems including severe depression; 
• Chronic corticosteroid therapy; 
• Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) or COX 
inhibitors which include the following:  Advil®, Aleve®, Naprosyn®, Celebrex®, 
Voltaren®, Lodine®, Indocin®, Orudis®, Oruvail®, Daypro®, Relafen®, Clinoril®, 
Tolectin®, Vioxx®, or Bextra® ; 
• Currently taking thiazolidinedione medications (Rosiglitizone, Pioglitazone); 
• Uncontrolled hypertension with: 
o systolic blood pressure >140 mmHg; or 
o diastolic blood pressure >90 mmHg 
• Those who, in the opinion of the principal investigator, have a risk of non-
compliance with study procedures. 
C. Exclusion criteria specific for subjects with type 2 diabetes 
• HbA1c < 6.0% or >10%. 
D.  Exclusion criteria specific for subjects without type 2 diabetes 
• A combination of 2 or more of the following: 
o Triglyceride >150 mg/dl 
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o HDL <50 mg/dl 
o High blood pressure (systolic blood pressure >130 mmHg, diastolic blood 
pressure >85 mmHg); or 
o Fasting blood glucose levels >110 mg/dL (6.1 mmol/L). 
Participation of Women and Members of Minority Groups 
           Caucasian women were selected for study because approximately 80 percent 
of participants in our community who attend the Health Management Resources 
weight-loss program are Caucasian women.  Body composition for various ethnic 
groups is also different.  Weinsier et al. (217) found despite similar weight losses, 
Caucasian women lost a greater percentage of abdominal fat as intraabdominal fat 
and less subcutaneous abdominal fat compared with black women; therefore to 
reduce heterogeneity in this pilot study only Caucasian subjects were recruited. 
Participation of Children 
            Children did not partake in this study because they do not meet the entry 
criteria of the study.  Also, the body composition of prepubertal individuals is 
different from adults and thus the changes would not be comparable. 
Recruiting Potential Subjects 
            Participants were recruited by newspaper advertisements in Lexington 
Kentucky and surrounding communities.  Announcements were posted in the Medical 
Center of the University of Kentucky.  In addition, physicians at University of 
Kentucky Medical Center were asked to inform obese patients of the study for their 
possible recruitment.  Potential research candidates were screened by phone to 
determine the individual’s age, gender, and general health status.  Subjects were then 
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asked to attend an Orientation at HMR and if the subject was still interested a 
screening visit was scheduled. 
Weight Loss Protocol 
            Research subjects participated in the Health Management Resources (HMR®) 
weight loss program. HMR® is a commercial medically-supervised low-energy diet 
(LED) program consisting of dietary supplements and entrees providing complete 
nutrition.  Table 3.1 lists the macronutrient composition of the HMR® 800 
supplements for the LED consisting of 800 kcal/day if five shakes are consumed.  
Individuals attending HMR® are categorized into risk groups depending on initial 
BMI, age, medical history and presence of other co-morbid conditions associated 
with obesity such as hypertension, coronary heart disease, and diabetes.  In this 
research study, subjects met the requirements of the medically-supervised risk group 
and were prescribed the minimum 800 kcal/day LED.  Subjects consumed only 
HMR® products during the sixteen-week weight-loss phase allowing for control over 
dietary intake.  Individuals participated in either the 3 + 2 HMR® program which 
consists of a minimum of 3 HMR 800® shakes and 2 entrees or consumed a minimum 
of five shakes per day.  During the LED program, two HMR® vitamins were 
prescribed each day.  Patients had the option to supplement with other HMR weight 
loss products as well such as Benefit Bar® or HMR Chicken soup®. 
            The HMR® program (218) insists that individuals attend weekly classes and 
make midweek phone calls to aid in the individual's accountability for their weight 
loss.  Individuals must also keep daily records of the number of meal replacements 
consumed, caloric intake, and daily physical activity.  This information is collected 
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by the health educator and recorded into a form referred to as “Patient at a Glance”. 
Other information collected in the Patient at a Glance form is if the individual meet 
the requirements of The Triple ImperativeTM.  Figure 3.1 explains the requirements 
for an individual to meet The Triple ImperativeTM.  The Triple ImperativeTM includes 
the skills that control the highest degree of variability in an individual’s weight loss 
efforts.  Finally, the number of days the individual meets their daily requirements of 
meal replacements, physical activity and not consuming food products not on the diet 
are recorded on the Patient at a Glance form.  This is referred to as the number of 
days “in the box.”  The most common side effects of a LED program include 
dizziness, low energy, bowel changes, muscle cramps and cold intolerance (218). 
Weight Loss Safety 
              The use of a LED in this population has been determined to be safe.  For 
example, a woman 5'2" would not be at risk for the following reasons: 
1. If this woman had a BMI of 30 kg/m2 her body weight would be approximately 
164 lbs or 74.5 kg.  At an optimal BMI of 22 kg/m2 her ideal body weight would 
be 122 lbs. 
2. Using the recommended equations for women between the ages of 31 to 60 by the 
World Health Organization (WHO)(219) for estimating basal metabolic rate 
(BMR):  BMR = (0.0342  X  74.5 kg + 3.5377) X 240 kcal/day = 1461 kcal/day 
3. For the given body weight, the amount of energy burned walking one mile can be 
calculated by:   Body weight (lbs)  X  2/3  = kcal/mile 
164 X 2/3 = 109 kcal/mile 
      This would result in approximately 765 kcal energy expenditure per week. 
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4. The total daily energy needs would equal 2226 kcal.  When you subtract the 800-
1000 kcal provided by the dietary supplements, the individual is in a caloric 
deficit of 1326 kcal.  This caloric restriction would approximate a 2.5 lb per week 
weight loss.  With an anticipated 2.5 lb. per week weight loss the individual 
would be expected to lose 40 lbs or approximately 15% of their initial body 
weight.  This would result in an anticipated end body weight of 124 lbs and thus 
the individual would not be at risk during this study. 
Study Procedures 
Table 3.2 outlines procedures completed at each visit throughout the trial.  
Visits are described according to week of the study.  Week -3 is the screening visit 
and is considered Baseline. Week -1 is the first visit at the General Clinical Research 
Center to obtain Baseline body composition and blood measurements.  This visit is 
sometime prior to the initiation of the weight loss diet. Week 0 is the initiation of the 
weight loss diet.  Weeks 1 through 16 are the weeks the subjects are active in the 
weight loss program. 
Body Composition Analysis 
Body composition analysis was conducted at the University of Kentucky 
General Clinical Research Center (GCRC) and the Diagnostic Radiology Department 
at the University of Kentucky Medical Center.  Total and regional body composition 
was measured with dual-energy x-ray absorptiometry (DEXA), air displacement 
plethysmography (BOD POD®) and computer tomography (CT) scans.  As shown in 
Table 2, body composition analysis was conducted at weeks -1, 8, and 16 for DEXA 
and BOD POD® and at weeks -1 and 16 for CT.   
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     A.  Dual-Energy X-Ray Absorptiometry (DEXA) 
The procedure for the DEXA scan was that as Kamel et al. (220) who used a 
standard whole body DEXA examination, which included total body and three 
regional measurements of trunk (chest, abdomen and pelvis), arms and legs to analyze 
body composition according to the three-compartment model (fat mass, lean mass and 
bone mineral content).  The standard soft tissue analysis was performed using the 
software provided by the manufacturer.  The GE Lunar ProdigyTM (Madison, WI) was 
used to conduct the scans. Total body fat was estimated for each subject in kilograms.   
Subjects were informed not to wear any metal for the scan.  The scan takes 
approximately 12 minutes.  
     B.  Air Displacement Plethysmography (BOD POD®) 
The procedure to determine total body volume and percent body fat using the 
BOD POD®  requires subjects will sit quietly in a specifically designed chamber (Life 
Measurement Instruments, Concord, CA) using an air displacement technique.  The 
BOD POD® chamber has a clear plastic window at the level of the subjects’ face so 
that they may view the room outside of the chamber and receive directions by hand 
gestures from the technician.  The first two air displacement measurements consist of 
the subject sitting quietly for approximately one minute.  The third measurement their 
thoracic lung volume measurements are determined using a spirometer technique.  
This technique requires the subject to breath normally into a plastic tube for 2 
inhalations and one exhalation followed by 3 puffs.  The total measurement times 
took approximately 5-10 minutes. 
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     C.  Computer Tomography (CT) 
             The visceral and subcutaneous abdominal fat masses were determined by 
abdominal CT scans by the department of Diagnostic Radiology at the University of 
Kentucky Medical Center using a Siemens Somatom Plus 4 and a Plus 10 (Munich, 
Germany).  Computer tomography procedures were followed as performed by 
Akazawa et al. (221), for the determination of the separation of abdominal fat tissues.  
The CT scan was performed at the L4-L5 lumbar with the subject resting in the 
supine position.  The total area of the cross-sectional fat region (i.e., including both 
subcutaneous and visceral fat) at the umbilical level were traced inside the skin to 
calculate the total number of pixels showing CT values between -50 and -150 HU.  
The visceral fat area was traced manually along the inside of the abdominal wall and 
the number of pixels showing the same range of CT values will be calculated for this 
region.  The reading of the abdominal scans was conducted by a radiology resident at 
the University of Kentucky Medical Center. 
Body Weight, Waist Circumference and Blood Pressure 
            Body weight was measured on an electronic scale to the nearest 0.1 pound.  
Waist circumference was be determined by obtaining the minimum circumference 
(minimum circumference between the lower-rib margin and the iliac crest, mid-waist) 
and the maximum hip circumference while standing with their heels together.  This 
was conducted by the same person at the screening visit and the final visit at the 
GCRC.  Blood pressure, measured using a sphygmomanometer, was obtained at the 
screening visit and at each visit to the GCRC.  At the weight loss clinic, a registered 
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nurse measured body weight and blood pressures of each subject prior to each weekly 
behavioral HMR® class. 
Physical Exams and Blood Analysis 
             Physical examinations including a health history and an electrocardiogram 
(ECG) were conducted at the screening visit at the Metabolic Research Group (MRG) 
and at the final visit at the GCRC. Limited physical examinations were performed at 
weeks 4, 8, and 12.   The physical exams performed at HMR® were conducted by 
both attending physicians and medical residents.  Fasting blood samples were taken at 
the GCRC at weeks  -1, 8, and 16 and analyzed at the laboratory for a complete 
metabolic panel, a lipid profile, a complete blood count with differential and platelets 
(CBC), and measurements of ghrelin, leptin, insulin, interleukin-6 (IL-6), tumor 
necrosis factor- alpha (TNF-α), plasminogen activator inhibitor-1 (PAI-1), C-reactive 
protein (CRP), adiponectin, resistin, HbA1c, and follicle-stimulating hormone (FSH).  
At weeks 4 and 12 standard safety blood tests consisting of a complete metabolic 
profile, lipid profile and CBC were taken at HMR®.  At week -3, the screening visit 
blood tests consisting of a complete metabolic profile, lipid profile, and CBC were 
taken along with TSH to check for thyroid defects.   
  Screening and safety laboratory measurements were conducted by Quest 
Diagnostics and LabCorp.  Leptin, adiponectin, resistin, IL-6, TNF-α, CRP and FSH 
values were determined by the General Clinical Research Center Core Laboratory. 
Leptin, adiponectin, high sensitivity IL-6 and high sensitivity TNF-α were analyzed 
with Elisa assays from R & D Systems (Minneapolis, MN) and resistin, CRP and 
FSH were analyzed using Elisa techniques from ALPCO Diagnostics (Windham, 
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NH).  Total ghrelin and total plasminogen activating inhibitor-1 were analyzed by 
LINCO Diagnostic Services, Inc. (St. Charles, MO).  Total ghrelin was analyzed with 
RIA in pg/ml.  Total PAI-1 was analyzed by Human Adipokine Lincoplex in pg/ml.  
Insulin, complete metabolic panel and lipid profiles were analyzed by the University 
of Kentucky Clinical Laboratory. 
Statistical Analysis 
           The contrast of interest used to determine effect size was the differences in the 
amount of body weight that obese women with type 2 diabetes compared to obese 
women without type 2 diabetes lose after a weight-reducing LED. This contrast is 
likely to also give meaningful trends in ghrelin and body composition.  Data are not 
available to provide adequate means and standard deviations to determine these 
contrasts. However, the present research will be able to provide a solid basis for 
further research and hypothesis development in these areas.   
            Power analysis was conducted using a two-sample t-test to determine the 
number of subjects required for the study.  After review of the literature regarding 
changes in body weight in obese women with type 2 diabetes and obese women 
without type 2 diabetes, means of 9.2 kg and 12.3 kg change in body weight were 
used to determine power with a standard deviation of 3.8.  The test was 1-sided and 
utilized a power of 0.8 and an alpha of .05.  The power analysis revealed that with a 
beta of .80, 20 subjects would be needed in each group to find significance.  We 
choose 25 subjects to participate in each group to allow for less than a 20 percent 
attrition rate. 
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           Analysis of baseline scores of the dependent variables was analyzed using a 
one-way ANOVA to determine if obese individuals with type 2 diabetes and obese 
individuals without type 2 diabetes mellitus are comparable. 
            The original statistical analysis of the primary outcome variables body weight, 
decreased leptin response and increased ghrelin response were to be analyzed by 
repeated-measures analysis using the PROC MIXED model of SAS version 8.02.  
The variable of initial body weight and several of the other outcome measurements 
such as subcutaneous and visceral adipose tissue were determined to be significantly 
different at baseline.  Thus, the PROC MIXED model was not an appropriate analysis 
for this study.  Instead we modified the mixed model to include baseline as a 
covariate and thus used analysis of covariance (ANCOVA) to determined changes in 
the outcomes.  The ANCOVA analysis is a combined regression analysis with an 
analysis of variance and thus takes differences in baseline values into account.  All 
primary and secondary outcome variables were analyzed by ANCOVA analysis.  
Two-sample student’s t-test assuming unequal variances were also used to determine 
if there were absolute differences in the outcome variables for each time point since 
the sample sizes for each group were not the same.  Pearson’s correlation was used to 
determine relationships between variables at week 16. 
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Table 3.1  Nutrient Compositions of the HMR® Dietary Supplements Based on 
the Consumption of 5 Packets per Day. 
 
  
Nutrient  HMR 800 
Calories, kcal  800 
Protein, g  80 
Carbohydrate, g  97 
Fat, g  10 
Fiber, g  2 to 5 
Cholesterol, g  65 
Sodium, mg  1250 
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Table 3.2 Outline of the Procedures and Measurements Taken Throughout the 
Clinical Trial. 
 
 
Week -3 -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Body Weight, Waist 
Circumference and 
Blood Pressure X X X X X X X X X X X X X X X X X X X
Physical Exam X Xa Xa Xa X
Blood Tests Xb Xc Xd Xd Xc Xd Xc
Body Composition X Xe X
a Limited medical visits will be conducted at week 4, 8, and 12. 
b Includes dietary history, screening and safety blood tests consisting of a complete 
metabolic profile, lipid profile, CBC with differentiation and platelets, HbA1c and 
FSH. 
c Includes a complete metabolic panel, lipid profile, CBC with differentiation and 
platelets, ghrelin, leptin, insulin, HOMA-IR, adiponectin, resistin,  IL-6, TNF-α, 
tPAI-1, CRP, HbA1c, and FSH. 
d Includes screening and safety blood tests consisting of a complete metabolic profile, 
lipid profile, and CBC with differentiation and platelets.  At week 4 and 12 this will 
be taken at the HMR facility. 
e Includes only DXA and BOD POD® at week 8, DEXA and CT scans will both be 
conducted at weeks -1 and 16. 
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Figure 3.1 Requirements of The Triple ImperativeTM which the HMR® Program 
Considers the Skills Necessary to Control the Greatest Degree of Variability in an 
Individual’s Weight Management Efforts. 
 
The Triple ImperativeTM 
 
1.  Minimum of 2,000 calories of physical activity (PA) per week. 
 
 
2.  Minimum of 35 servings of vegetables and fruits per week 
     (for Healthy Solutions® and Maintenance only, not considered for this study) 
 
3.  Use of meal replacements 
 
- Weight loss:  minimum of 35 meal replacements per week 
- Maintenance:  minimum of 14 meal replacements per week 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 49 
 
CHAPTER FOUR 
 
Results 
 
Participant Characteristics 
Forty-two subjects were screened for the study. Of these 42 subjects, 8 
subjects failed the screening criteria and 32 subjects were randomized into the study. 
One individual chose not to participate in the study prior to randomization.  Three 
individuals discontinued from the study, one due to family issues and the others were 
not committed to the weight loss diet.  Twenty-nine subjects have completed the 
study.   The attrition rate for this study was 9.4%.   
  Table 4.1 presents characteristics of the study participants who completed the 
study.  Eleven Caucasian non-diabetic females without the metabolic syndrome 
between the ages of 40 to 57 years and 18 Caucasian diabetic females between the 
ages of 41 to 64 years were recruited for the study.  The mean Body Mass Index 
(BMI) was 36.1 + kg/m2 and 38.0 kg/m2, for non-diabetic and diabetic subjects, 
respectively.  The mean Body Mass Index (BMI) for completers was 36.1 + 3.9 kg/m2 
and 38.1 + 3.7 kg/m2 for non-diabetic and diabetic women, respectively.  Study 
participants were matched for age and BMI. 
Weight Loss 
  In a completer’s analysis, non-diabetic subjects lost 15.4 kg of body weight 
resulting in a 16.0% decrease.  Diabetic subjects lost 12.2 kg of body weight resulting 
in an 11.7% decrease.  The average and the range of weight lost in kg are 
demonstrated in Figure 4.1 for completers.  Figure 4.2 shows the percent reduction in 
body weight at weeks 0, 4, 8, 12, and 16.   Analysis with two-sample t-test found 
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diabetic subjects weighed significantly more than non-diabetic subjects prior to 
weight loss, 105.6 kg and 96.4 kg (p=0.04), respectively.  After initial weight was 
adjusted using ANCOVA, there was no significant difference in the total body weight 
in kg at baseline (p=0.5694), week 16 (p=0.6474) or percent weight loss (p=0.2621) 
after 16 weeks of weight loss between the two groups. 
  Using the intention-to-treat (ITT) or last-observation-carried-forward (LOCF) 
analyses, there was no significant difference in baseline weight between non-diabetic 
and diabetic subject, 96.4 kg and 104.5 kg, respectively (p=0.1087).  However, using 
the ITT analysis weight losses were significantly different between non-diabetic and 
diabetic subjects.  Non-diabetic subjects lost significantly more weight (-16.0%) than 
diabetic subjects (-10.9%, p=0.0029). 
Body Mass Index (BMI) 
  Body mass index (BMI) was one of the parameters used to match the non-
diabetic and diabetic subjects.  In completer’s there was no significant difference in 
BMI values between non-diabetic and diabetic subjects before weight loss, 36.1 
kg/m2 and 38.1 kg/m2, respectively(p=0.2314).  Baseline BMI values for ITT subjects 
were not significantly different, 36.1 kg/m2 and 38.0 kg/m2, for non-diabetic and 
diabetic subjects, respectively (p=0.2329).  After 16-weeks of weight loss both 
groups were still considered to be obese.  The non-diabetic completer subjects had 
reduced their BMI to 30.1 kg/m2 which was a 16.7% reduction; while diabetic 
completer subjects reduced their BMI to 33.0 kg/m2 which was a 13.3% reduction.  
There was no significant difference in BMI between the groups at week 16 
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(p=0.0720).  ANCOVA analysis found no significance difference between the groups 
at week 0 (p=0.2216) or at week 16 (p=0.0608). 
  In non-diabetic subjects, BMI was positively correlated with leptin 
(p=0.0018), insulin (p=0.0466), and HOMA-IR (p=0.0362).  In diabetic subjects, 
BMI was positively correlated with leptin (p=0.0018) and there was trend that BMI 
was positively correlated with insulin (p=0.0654), HOMA-IR (p=0.0950), and CRP 
(p=0.0697).  In diabetic subjects, BMI was positively correlated with percent body fat 
(p=0.0176), subcutaneous adipose tissue (p=0.0114), visceral adipose tissue 
(p=0.003), and total fat (p<0.0001).  In non-diabetic subjects, BMI was positively 
correlated with percent body fat (p=0.0079), subcutaneous adipose tissue (p<0.0001), 
and total fat (p<0.0001) and was approaching a significant positive correlation with 
visceral adipose tissue (p=0.0604).  BMI was approaching a significant positive 
correlation with lean tissue in non-diabetic (p=0.0612), but not in diabetic subjects 
(p=0.3523). 
Body Composition Measurements 
     A.  Dual-Energy X-Ray Absorptiometry (DEXA) 
  Dual-energy x-ray absorptiometry (DEXA) was used to measure total percent 
body fat; percent body fat in the trunk; total fat; total fat in the trunk; total lean 
tissue; and total lean tissue in the trunk.  Values of all body composition baseline 
values and changes throughout the study are shown in Table 4.2. 
1.  Percent Body Fat-Total 
    Total percent body fat determined by DEXA found that non-diabetic subjects 
had significantly greater percent body fat compared to diabetic subjects, 49.9% and 
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45.9% (p=0.0036), respectively.  Figure 4.3 illustrates the percent body fat 
determined by DEXA at week 0, week 8 and week 16.  There was a significant 
difference in the change of percent body fat between non-diabetic and diabetic 
subjects.  Non-diabetic subjects decreased by 7.4, while diabetic subjects percent 
body fat decreased by 4.2 (p=0.043).  This is apparent since there is no significant 
difference in total percent body fat between non-diabetic and diabetic subjects at 
week 16, 42.6% and 42.1% (p=0.8416), respectively.  Adjusting for baseline percent 
body fat levels, ANCOVA analysis found no significant difference between groups 
after 16 weeks of weight loss. 
  In diabetic subjects percent body fat was positively correlated with 
subcutaneous adipose tissue (p=0.0035) and total fat (p=0.0001) and negatively 
correlated with lean tissue (p=0.0185).  There was no correlation between percent 
body fat and visceral adipose tissue (p=0.1363) in diabetic subjects.  Percent body fat 
was also found to be positively correlated with leptin (p=0.0011) in diabetic subjects, 
but no significant correlation was found between percent body fat and resistin 
(p=0.7121), ghrelin (p=0.6273), or HOMA-IR (p=0.4128).  In non-diabetic subjects 
percent body fat was positively correlated with subcutaneous adipose tissue 
(p=0.0282), visceral adipose tissue (p=0.0350) and total fat (p=0.0151), but was not 
correlated with lean tissue (p=0.3568).  Percent body fat was found to be positively 
correlated with leptin (p=0.0455), but not correlated with resistin (p=0.9718) in non-
diabetic subjects.  A trend that percent body fat was negatively correlated with ghrelin 
(p=0.0995) and HOMA-IR (p=0.0673) was observed in the non-diabetic subjects.  
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Percent body fat was not found to be correlated with CRP, IL-6, TNF-α, or 
adiponectin in either diabetic or non-diabetic subjects. 
2.  Percent Body Fat-Trunk 
    Percent body fat in the trunk of non-diabetic and diabetic subjects was 
significantly different at baseline, 51.2% and 47.3% (p=0.0135), respectively.  Non-
diabetic subjects significantly decreased their percent body fat in the trunk compared 
to diabetic subjects, -8.0% and 4.1% (p=0.0495), respectively.  As found with total 
percent body fat, there was no significant difference in the percent body fat found in 
the trunk between non-diabetic and diabetic subjects at week 16, 43.2% and 43.2% 
(p=0.9765), respectively.  This is consistent with the ANCOVA analysis that found 
no significant difference between the groups at week 16 (p=0.4258).  Figure 4.4 
shows the percent trunk fat determined by DEXA of study completers at week 0, 
week 8 and week 16. 
3. Total Fat 
    The DEXA measurements found no significant difference in total fat at 
baseline between non-diabetics and diabetic subjects, 47.4 kg and 47.3 kg (p=0.9693), 
respectively.  Figure 4.5 illustrates total body fat in kg determined by DEXA at week 
0, week 8 and week 16.  There was also no significant difference found at week 16 
for non-diabetics and diabetic subjects, 33.6 kg and 37.8 kg (p=0.1816), respectively.  
However, percent change in total fat was found to be significant after 16 weeks of 
weight loss.  Non-diabetic subjects decreased their total fat by 29.3% while diabetic 
subjects decreased their total fat by 20.6% (p=0.0295).  These results are consistent 
with the ANCOVA analysis.  After adjusting for baseline fat levels at 16 weeks there 
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was a significant difference in total fat content between non-diabetic and diabetic 
subjects (p=0.0338).  Total fat was positively correlated with lean tissue in non-
diabetic subjects (p=0.05), but not in diabetic subjects (p=0.9333). 
4. Trunk Fat 
    The amount of fat in the trunk determined by DEXA measurements found 
that there was no significant difference at baseline between non-diabetic and diabetic 
subjects, 24.7 kg and 25.8 kg (p=0.4977), respectively.  At week 16 a significant 
difference was found in the amount of trunk fat between the groups.  Non-diabetic 
subjects had 16.7 kg of trunk fat and diabetic subjects had 20.6 kg of trunk fat 
(p=0.0353).  The percent change in trunk fat was found to be significantly difference 
between the groups.  Non-diabetic subjects decreased trunk fat by 32.1% and diabetic 
subjects decreased trunk fat by 20.8% (p=0.0495).  ANCOVA analysis found that at 
week 16 the amount of trunk fat between the groups was approaching significance 
(p=0.0584).  Figure 4.6 shows the amount of trunk fat at week 0, week 8 and week 16 
in individuals who completed the study. 
5. Total Lean Tissue 
    The total amount of lean tissue in the body was measured by DEXA.  Figure 
4.7 illustrates total lean tissue in kg determined by DEXA at week 0, week 8 and 
week 16.  At baseline non-diabetic subject had significantly lower total lean tissue 
than diabetic subjects, 44.6 kg and 53.2 kg (p=0.0018), respectively.  This finding 
was also true at week 16.  Non-diabetic subjects had 42.1 kg of lean tissue and 
diabetic subjects had 49.3 kg (p=0.0036).  The percent change in total lean tissue 
however was not significant after 16 weeks of weight loss (p=0.5430).  After 
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adjusting for baseline measurement, ANCOVA analysis found no significant 
difference between the groups at week 16 (p=0.8661). 
6. Trunk Lean Tissue 
    The amount of lean tissue found in the trunk was significantly lower in non-
diabetic than diabetic subjects, 22.6 kg and 28.5 kg (p=0.0013), respectively.  A 
significant difference in amount of lean tissue in the trunk was also found at week 16.  
Non-diabetics had 20.9 kg of lean tissue in the trunk while diabetics had 25.7 kg 
(p=0.0005).  The percent change in lean tissue in the trunk was found not to be 
significantly difference between non-diabetic and diabetic subjects after 16 weeks of 
weight loss, -7.1% and -7.8% (p=0.8548), respectively.  After adjusting for baseline 
values, ANCOVA found that there was no significant difference between the groups 
at baseline (p=0.1876) or at week 16 (p=0.1141).  Figure 4.8 shows the amount of 
lean tissue in the trunk at week 0, week 8 and week 16 for individuals who completed 
the study. 
7. Total Trunk Tissue 
    The total amount of trunk tissue at baseline was significantly lower in non-
diabetic than diabetic subjects, 47.3 kg and 56.8 kg (p=0.024), respectively.  A 
significant difference in the amount of total trunk tissue was also found at week 16.  
Non-diabetic subjects had 37.7 kg of tissue in the trunk while diabetic subjects had 
46.2 kg (p=0.001).  Figure 4.9 shows the total trunk tissue at week 0, week 8 and 
week 16.  The percent change in total trunk tissue was not found was significantly 
different after 16 weeks of weight loss, -20.2% and -16.7% (p=0.36), respectively.  
After adjusting for baseline values, ANCOVA analysis found that there was not 
 56 
 
significant difference between the groups at baseline (p=0.1145).  However, after 
adjusting for baseline values, non-diabetic subjects were found to have significantly 
less trunk tissue than diabetic subjects (p=0.0123). 
     B. Air Displacement Plethysmography (BOD POD®) 
1.  Percent Body Fat 
 There was no significant difference between non-diabetic and diabetic 
subjects in total percent body fat as determined by air displacement plethysmography 
using the BOD POD® prior to weight loss (52.7% and 49.6%, respectively p=0.0924).  
Figure 4.10 shows percent body fat determined by air displacement plethysmography 
at week 0, week 8 and week 16.  After 16 weeks of weight loss non-diabetic subjects 
decreased their percent body fat to 40.2% and diabetic subjects decreased percent 
body fat to 43.9% (p=0.1308).  However, using ANCOVA procedures and adjusting 
for initial percent body fat diabetic subjects lost significantly less percent body fat 
than non-diabetic subjects (p=0.0091). 
2.  Total Fat 
    The BOD POD® measurements found no significant difference in total fat at 
baseline between non-diabetics and diabetic subjects, 49.7 kg and 50.1 kg (p=0.9093), 
respectively.  Figure 4.11 illustrates total body fat in kg determined by BOD POD® at 
week 0, week 8 and week 16.  There was significant difference found at week 16 for 
non-diabetics and diabetic subjects, 32.1 kg and 39.2 kg (p=0.0433), respectively.  
Percent change in total fat was also found to be significantly different after 16 weeks 
of weight loss.  Non-diabetic subjects decreased their total fat by 35.9% while 
diabetic subjects decreased their total fat by 21.8% (p=0.0042).  These results are 
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consistent with the ANCOVA analysis.  After adjusting for baseline fat levels at 16 
weeks there was a significant difference in total fat content between non-diabetic and 
diabetic subjects (p=0.0074). 
3.  Total Lean 
    The total amount of lean tissue in the body was measured by BOD POD®.  
Figure 4.12 illustrates total lean tissue in kg determined by BOD POD® at week 0, 
week 8 and week 16.  At baseline non-diabetic subject had significantly lower total 
lean tissue than diabetic subjects, 46.1 kg and 52.1 kg (p=0.0148), respectively.  This 
finding was not true at week 16.  Non-diabetic subjects had 46.8 kg of lean tissue and 
diabetic subjects had 49.7 kg (p=0.2433).  The percent change in total lean tissue 
however was significant after 16 weeks of weight loss (p=0.0273).  Non-diabetic 
subjects increased lean tissue mass by 1.9%; while diabetic lean tissue mass 
decreased by 4.8%.  After adjusting for baseline measurement, ANCOVA analysis 
was approaching a significant difference between the groups at week 16 (p=0.0532). 
     C.  Computer Tomography (CT) 
1.  Total Abdominal Fat 
 The total amount of abdominal adipose tissue in cm2 at week 0 and week 16 
determined by computer tomography is illustrated in Figure 4.13.  At baseline, there 
was no significant difference in the amount of total abdominal adipose tissue between 
non-diabetic and diabetic subjects at baseline, 717.7 cm2 and 730.4 cm2 (p=0.7833), 
respectively.  Non-diabetic subjects lost 15.4 kg of body weight with a 30.0% 
reduction in total abdominal tissue (p=0.1595), while diabetic subjects lost 12.2 kg of 
body weight with a 23.5% reduction in total adipose tissue (p=0.1595), as shown in 
 58 
 
Table 4.2.  After 16 weeks of weight loss there was no significant difference in the 
amount of total abdominal fat in non-diabetic and diabetic subjects, 508.7 cm2 and 
555.0 cm2 (p=0.3603), respectively.  ANCOVA analysis adjusting for baseline found 
not significant difference between the groups after 16 weeks of weight loss 
(p=0.2131).  Figure 4.15 reveals the change in subcutaneous, visceral and total 
abdominal fat loss by abdominal computer tomography. 
2.  Visceral Adipose Tissue 
  The amount of visceral adipose tissue in cm2 at week 0 and week 16 for non-
diabetic and diabetic subjects is shown in Figure 4.14.  At baseline diabetic subjects 
had significantly greater amounts of visceral adiposity compared with non-diabetic 
subjects prior to weight loss, 208.3 cm2 and 177.4 cm2 (p=0.0009), respectively.  This 
was also true after 16 weeks of weight loss. Diabetic subjects had 132.4 cm2 of 
visceral adipose tissue while non-diabetics subjects had 79.4 cm2 of visceral adipose 
tissue (p=0.0036).  There was no significant difference in the percentage reduction in 
visceral adipose tissue between non-diabetic and diabetic subjects, 33.3% and 34.3% 
(p=0.8749), respectively.  The ANCOVA analysis also indicated that after adjusting 
for baseline values, the amount of visceral adipose tissue was not significantly 
different at week 16 between non-diabetic and diabetic subjects, 109.7 cm2 + 9.4 and 
113.9 cm2 + 7.0 (p=0.7457), respectively. 
  Visceral adipose tissue was not correlated with insulin, HOMA-IR, resistin or 
ghrelin in either diabetic or non-diabetic subjects, but was positively correlated with 
leptin in both diabetic (p=0.0325) and non-diabetic (p=0.0046) subjects. 
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3.  Subcutaneous Adipose Tissue 
  The amount of subcutaneous adipose tissue in cm2 at week 0 and week 16 for 
non-diabetic and diabetic subjects is shown in Figure 4.14.  Unlike the visceral 
adipose tissue stores, subcutaneous tissue stores were not significantly different prior 
to the study.  Non-diabetics had 600.3 cm2 subcutaneous adipose tissue and diabetic 
subjects 522.1 cm2 (p=0.0879).  After 16 weeks of weight loss, non-diabetic subjects 
lost a significantly greater percentage of subcutaneous adipose tissue than diabetic 
subjects, 29.0% and 18.2% (p=0.0333), respectively.  There was no significant 
difference in the amount of subcutaneous adipose tissue at week 16 between the non-
diabetic and diabetic groups, 422.6 cm2 and 429.4 cm2 (p=0.8769), respectively.  
However, when the 16 week subcutaneous adipose tissue stores were adjusted for 
baseline, diabetic subjects had significantly greater subcutaneous adipose stores than 
non-diabetic subjects.  The adjusted values for non-diabetic subjects were 393.0 cm2 
and 444.8 cm2 for diabetic subjects (p=0.0394). 
  Subcutaneous adipose tissue was positively correlated with insulin (p=0.0423) 
and HOMA-IR (p=0.0379) in non-diabetic subjects, but not in diabetic subjects.  In 
non-diabetic subjects, subcutaneous adipose tissue was found to be positively 
correlated with leptin (p=0.0005) and in diabetic subjects a positive correlation was 
approaching significance (p=0.0675).  Subcutaneous adipose tissue was positively 
correlated with CRP (p=0.0154) in diabetic subjects but no correlation was observed 
in the non-diabetic subjects (p=0.9820).  Subcutaneous adipose tissue was not found 
to be correlated to adiponection in diabetic subjects (p=0.2385) but a negative 
correlation was observed in the non-diabetic subjects (p=0.0309). 
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  Before weight loss non-diabetic subjects visceral to subcutaneous fat ratio 
(V/S) was 0.20, while diabetics had a significantly higher ratio of 0.43 (p=0.0005).  
The rat%io of both groups decreased with weight loss; however, diabetic subjects had 
a significantly greater ratio of visceral to subcutaneous adipose tissue.  The ratios 
were 0.19 and 0.33 for non-diabetics and diabetics respectively (p=0.003).  There was 
no significant difference in either non-diabetic (p=0.6446) or diabetic (p=0.1350) 
subjects in the change of the V/S ratio after weight loss. 
     D.  Waist Circumference 
  Waist circumference measurements were not significantly different prior to 
weight loss between non-diabetic and diabetic subjects (110.5 cm, 117.9 cm, 
p=0.1648).  Figure 4.14 displays the absolute waist circumference in centimeters for 
diabetic and non-diabetic individuals at week 0 and week 16.  Figure 4.15 shows that 
total change in centimeters and percent change in waist circumference for diabetic 
and non-diabetic subjects.  After 16-weeks of weight loss non-diabetics decreased 
waist circumference by 16.4%, while diabetic subjects decreased waist circumference 
by 7.8% (p=0.0103).  The non-diabetic subjects waist circumference at week 16 was 
91.3 cm and the diabetic subjects waist circumference was 106.1 cm and was found to 
be a significant difference (p=0.0004).  After the ANCOVA analysis and adjusting for 
baseline values, non-diabetic subjects significantly had smaller waist circumferences 
than diabetic subjects (93.0 + 2.8 and 106.7 + 2.3, p=0.0012), respectively. 
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Blood Parameters 
     A.  Insulin / HOMA-IR 
  As expected, individuals with type 2 diabetes had significantly different serum 
insulin and HOMA-IR results than individuals without type 2 diabetes.  Figure 4.18 
and Figure 4.19 displays insulin and HOMA-IR results for week 0, week 8 and week 
16, respectively.  Prior to weight loss diabetic insulin levels were 21.0 µU/ml while 
non-diabetic individuals insulin levels were 14.4 µU/ml (p=0.0447).  After 16 weeks 
of weight loss, insulin levels decreased by 30.1% and 28.7% in non-diabetic and 
diabetic subjects respectively.  The ANCOVA calculation found that after adjusting 
for baseline insulin, there was no difference between diabetic and non-diabetics with 
weight loss (p=0.2637).   HOMA-IR levels were also significantly different at 
baseline, 5.3 and 7.9 (p<0.0001), for non-diabetics and diabetics respectively.  
HOMA-IR increased by 1.8% in non-diabetic subjects and decreased by 10.2% in 
diabetic subjects (p=0.0007).  ANCOVA analysis revealed no significant different 
HOMA-IR after 16 weeks of weight loss (p=0.1764).  Baseline insulin and HOMA-
IR values and changes are shown in Table 4.3. 
  In diabetic subjects, insulin was negatively correlated with resistin (p=0.0309) 
and approaching a negative correlation with ghrelin (p=0.0843).  Insulin was not 
associated with body composition measurements in the diabetic subjects but was 
positively correlated with subcutaneous adipose tissue (p=0.0423) and total fat 
(p=0.0436) in non-diabetic subjects.  A trend for a positively correlation between 
insulin and percent body fat was also observed.  Insulin was not correlated with CRP, 
IL-6, TNF-α or adiponectin in either diabetic or non-diabetic subjects.  The only 
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correlation observed with insulin in the non-diabetic subjects was HOMA-IR 
(p<0.001). 
     B.  Glucose and HbA1c 
 Serum glucose and HbA1c levels were significantly higher before and after 
weight loss in diabetic versus non-diabetic subjects.  Figure 4.20 and Figure 4.21 
illustrates glucose and HbA1c levels, respectively, at week 0, week 8 and week 16.  
At baseline non-diabetic subjects glucose levels were 98.8 mg/dl and diabetic glucose 
levels were 187.2 mg/dl (p<0.0001).  After 16 weeks of weight loss, glucose levels 
were still significantly lower in non-diabetic subjects than diabetic subjects, 92.9 
mg/dl and 136.6 mg/dl (p<0.0001), respectively.  However, after adjusting for 
baseline glucose levels, ANCOVA analysis found no significant difference in glucose 
levels at week 16 (p=0.1941).  HbA1c measurements are reflected in the glucose 
levels as well.  HbA1c measurements were also significantly higher before and after 
weight loss in diabetic versus non-diabetic subjects.  At baseline non-diabetic subjects 
HbA1c was 5.2% and diabetic subjects had HbA1c levels of 8.1% (p<0.0001).  After 
16 weeks of weight loss, non-diabetic subjects HbA1c remained unchanged at 5.3% 
and diabetic subjects decreased HbA1c levels to 6.5%.  This difference was still 
found to be significant using t-tests (p<0.0001).  However, similar to glucose levels, 
after adjusting for baseline HbA1c levels, ANCOVA analysis found no significant 
difference in HbA1c levels at week 16 (p=0.7051).  Baseline glucose and HbA1c 
values and changes are shown in Table 4.3. 
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     C.  Leptin 
  At baseline, although not significant, non-diabetic subjects had greater plasma 
leptin levels than diabetic subjects, 64039.2 pg/ml and 50457.5 pg/ml (p=0.142), 
respectively.  Plasma leptin levels decreased by 66.9% in non-diabetic patients and 
46.1% in diabetic subjects (p=0.018).  There was no significant difference in leptin 
levels between the groups at week 0, week 8 or week 16; however, the ANCOVA 
analysis when adjusting week 8 and week 16 for baseline leptin levels became 
significant at week 16.  Non-diabetic subjects leptin levels were 16546 pg/ml + 
3734.0 and for diabetic subjects 29812 pg/ml + 2890.2 (p=0.0105).  Figure 4.22 
illustrates the change in leptin levels in both non-diabetic and diabetic subjects at 
week 0, week 8 and week 16.  Baseline leptin values and changes are shown in Table 
4.4. 
  Leptin was not correlated to HOMA-IR in non-diabetic (p=0.4624) subjects 
but was approaching a significant correlation in diabetic subjects (p=0.0872).  In non-
diabetic subjects leptin was negatively correlated with adiponectin (p=0.0425), but no 
correlation was observed in diabetic subjects (p=0.3219).  Leptin was also correlated 
positively to weight in both diabetic (p=0.0110) and non-diabetic subjects 
(p=0.0139).  No other correlations with leptin were observed. 
     D.  Ghrelin 
  Plasma ghrelin levels increased by 22.5% and 26.1%, in non-diabetic and 
diabetic subjects respectively.  At week 0, diabetic subjects had significantly lower 
ghrelin levels than the non-diabetic subjects, 643.6 pg/ml and 837.8 pg/ml 
(p=0.0425), respectively.  However, after adjusting for baseline ghrelin levels 
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ANCOVA determined that after 16 weeks of weight loss there was no significant 
difference between the groups (p=0.8305).  Figure 4.23 depicts the ghrelin levels at 
week 0, week 8, and week 16 for diabetic and non-diabetic subjects.  Baseline ghrelin 
values and changes are shown in Table 4.4. 
  Ghrelin was positively correlated with adiponectin in diabetic subjects 
(p=0.0125), but no correlation was observed in the non-diabetic subjects (p=0.1711).  
Ghrelin was not found to be correlated with any of the other outcome measurements.  
     E.  Adiponectin 
  Plasma adiponectin levels were significantly lower in diabetic subjects than 
non-diabetic subjects, 11532.0 ng/ml and 6701.4 ng/ml (p=0.0326), respectively at 
baseline.  During the study, adiponectin levels decreased in non-diabetic subjects by 
17.2% and increased by 15.3% in diabetic subjects (p=0.005).  The adiponectin levels 
at week 16 were 10743.5 ng/ml for non-diabetic subjects and 7698.2 ng/ml 
(p=0.1013).  ANCOVA analysis agreed with the description statistics that after 
adjusting for baseline there was no significant difference between to two groups after 
16 weeks of weight loss (p=0.4197).  Figure 4.24 illustrates the change in adiponectin 
levels in both non-diabetic and diabetic subjects at week 0, week 8 and week 16.   
Baseline adiponectin values and changes are shown in Table 4.4. 
  Adiponectin was positively correlated with ghrelin in the diabetic subjects 
(p=0.0125) and negatively correlated with leptin in the non-diabetic subjects 
(p=0.01425).  No other correlations were observed with adiponectin levels in either 
diabetic or non-diabetic subjects. 
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     F.  Resistin 
              Plasma resistin levels were significantly different at the beginning of the 
study between non-diabetic and diabetic subjects, 4.6 ng/ml and 5.7 ng/ml 
(p=0.0358), respectively.  The levels of resistin did not change after weight loss.  
Resistin levels of the non-diabetic subjects was 4.7 ng/ml and for diabetic subjects 6.1 
ng/ml.  Descriptive statistics state that these levels were still significantly different at 
week 16 (p=0.039).  The percent change was -0.2% and 10.0% for non-diabetic and 
diabetic subjects respectively (p=0.2605).  After adjusting for baseline levels, 
ANCOVA analysis revealed that at week 16 there was not a significant difference 
between the two groups (p=0.127).  Figure 4.25 shows the change in resistin levels in 
both non-diabetic and diabetic subjects at week 0, week 8 and week 16.  Baseline 
resistin values and changes are shown in Table 4.4. 
  Resistin was negatively correlated to insulin (p=0.0309) and HOMA-IR 
(p=0.0038) in diabetic subjects but no correlation was observed in non-diabetic 
subjects.  No other correlations were observed with resistin in either diabetic or non-
diabetic subjects. 
     G.  Interleukin-6 (IL-6) 
  At baseline,  high sensitivity IL-6 levels were approaching significance with 
non-diabetic having higher IL-6 levels than diabetic subjects, 4.0 pg/ml and 2.3 pg/ml 
(p=0.057), respectively.  IL-6 levels decreased in both non-diabetic and diabetic 
subjects, -1.0 and -0.3 pg/ml (p=0.2520), respectively.  The percent change for non-
diabetic subjects was 0.3%, while for diabetic subjects IL-6 levels decreased by 4.5% 
(p=0.4258).  ANCOVA analysis found no significant difference in IL-6 level between 
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non-diabetic and diabetic at week 16 after adjusting for baseline measurements, 3.0 
pg/ml and 2.0 pg/ml (p=0.0961), respectively.  Baseline IL-6 values and changes are 
shown in Table 4.4.  IL-6 was not found to be correlated to any of the outcome 
measurements in either diabetic or non-diabetic subjects. 
     H.  Tumor Necrosis Factor-α (TNF-α) 
  There was no significant difference in TNF-α levels prior to weight loss, 1.2 
pg/ml and 1.3 pg/ml (p=0.286) for non-diabetic and diabetic subjects respectively.  
Overall, there was no change in serum high sensitivity TNF-α levels in either non-
diabetic or diabetic subjects (0.3 and 0.0 respectively p=0.1560).  At week 16 no 
significant difference in absolute TNF-α levels.  The percent change for non-diabetics 
was 25.1% and 10.1% for diabetics (p=0.2556).  ANCOVA analysis further verified 
this non-significance in TNF-α levels between the groups after weight loss 
(p=0.3795).  Baseline TNF-α values and changes are shown in Table 4.4. 
  TNF-α was approaching a significant correlation with CRP in diabetic 
subjects (p=0.0915), but not in the non-diabetic subjects (p=0.5691).  There were no 
other correlations observed between TNF-α and any of the other outcome 
measurements. 
     I.  Plasminogen Activating Inhibitor-1 (PAI-1) 
  Figure 4.26 shows PAI-1 levels for week 0, week 8 and week 16.  There was 
no significant difference between non-diabetic and diabetic subjects on baseline 
plasma total plasminogen activating inhibitor-1 (PAI-1), 9696.9 pg/ml and 12219.39 
pg/ml (p=0.1132), respectively.  At week 16 a significant difference was seen 
between the two groups, 5768.6 pg/ml and 7736.5 pg/ml (p=0.0105), for non-diabetic 
 67 
 
and diabetic subjects respectively.  However, no significant decrease was observed 
with the percent decreases in PAI-1 levels.   There was a 26.2% decrease in non-
diabetic subjects and a 25.4% decrease in the diabetic subjects (p=0.4819).  
ANCOVA analysis found a close significance between the two groups at week 16 
after adjusting for baseline values (p=0.057).  Baseline PAI-1 values and changes are 
shown in Table 4.4. 
  PAI-1 levels were positively correlated with percent body (p=0.0073) and 
negatively correlated with lean tissue (p=0.0681) in diabetic subjects.  PAI-1 was 
approaching a significant negative correlation with lean tissue in the non-diabetics 
(p=0.0893), but no correlation was observed with percent body fat (p=0.6397).  In 
diabetic subjects a negative correlation between PAI-1 and ghrelin was approaching 
significance (p=0.0673).  This was not observed in the non-diabetic subjects 
(p=0.9366). 
     J.  C-Reactive Protein (CRP) 
  There were no significant difference in serum high sensitivity CRP levels at 
baseline, 7162.4 ng/ml and 6346.4 ng/ml (p=0.3419), for non-diabetic and diabetics 
respectively.  There was no significant difference in the level of CRP at week 16, 
5288.1 ng/ml and 4262.2 ng/ml (p=0.3622), respectively for non-diabetics and 
diabetic subjects.  Percent reduction in CRP levels decreased by 33.1% and 21.2% in 
non-diabetic and diabetic subjects non-significantly (p=0.4637).  ANCOVA analysis 
for adjusting baseline confirms there was no significant difference between the two 
groups (p=0.7404).  Baseline CRP values and changes are shown in Table 4.4. 
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  CRP was positively correlated to subcutaneous adipose tissue in diabetic 
subjects (p=0.0154), but not in non-diabetic subjects (p=0.9820).  CRP was 
approaching a significant positive correlation to BMI in diabetic subjects (p=0.0697), 
but not in non-diabetic subjects (p=0.7675).  No other correlations with CRP were 
observed in either the diabetic or non-diabetic subjects. 
     K.  Follicle-Stimulating Hormone (FSH) 
           Serum follicle stimulating hormone (FSH) levels were not significantly 
different in non-diabetic and diabetic subjects at the beginning of the study 
(42.9mIU/ml, 26.4 mIU/ml, p=0.0596).  Both groups increased FSH levels during the 
study.  FSH levels increased by 19.5% in non-diabetic subjects and 32.5% in diabetic 
subjects (p=0.2231).  FSH levels at week 16 were also not found to be significantly 
different between non-diabetic and diabetic subjects, 50.4 mIU/ml and 31.5 mIU/ml 
(p=0.0573), respectively.  ANCOVA analysis verified this non-significant finding at 
week 16 (p=0.6825).  Baseline FSH values and changes are shown in Table 4.3. 
     L.  Lipids 
1.  Total Cholesterol 
    Figure 4.27 exhibits total cholesterol levels for diabetic and non-diabetic 
individuals at week 0, week 8 and week 16.  There was no significant difference in 
total cholesterol levels in non-diabetic and diabetic subjects before or after the weight 
loss phase.  Total cholesterol levels decreased in both non-diabetic and diabetic 
subjects.  Total cholesterol in non-diabetic subjects decreased by 41.2 mg/dl, resulting 
in a -17.9%.  Although there was no significant difference in total cholesterol 
(p=0.3011) or percent change (p=0.1581) in total cholesterol levels between groups 
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before or after weight loss, diabetic subjects saw only a 14.4 mg/dl decrease, resulting 
in a -7.4%.  ANCOVA analysis confirmed the t-test and found no significant 
difference between total cholesterol levels at week 16 (p=0.2223).  Baseline 
cholesterol values and changes are shown in Table 4.5. 
2.  Low-Density Lipoprotein Cholesterol (LDL-Cholesterol) 
    LDL-cholesterol levels at week 0, week 8 and week 16 for diabetic and non-
diabetic individuals are illustrated in Figure 4.28. There was no significant difference 
in LDL-cholesterol levels at baseline between non-diabetic and diabetic subjects, 128 
mg/dl and 122.6 mg/dl (p=0.5099), respectively.  Non-diabetic subjects LDL-
cholesterol levels decreased by 13.6%, while diabetic subjects had a 6.9% increase 
(p=0.0925).  ANCOVA analysis adjusting for baseline LDL-cholesterol levels found 
no significant difference between groups at week 16.  Baseline LDL-cholesterol 
values and changes are shown in Table 4.5. 
3.  High-Density Lipoprotein Cholesterol (HDL-Cholesterol) 
    HDL-cholesterol levels at week 0, week 8 and week 16 are shown in Figure 
4.29.  Non-diabetic subjects had significantly higher HDL-cholesterol levels than 
diabetic subjects at baseline, 52.1 mg/dl and 37.8 mg/dl (p=0.0009), respectively.  At 
week 16, there was no significant difference in HDL-cholesterol levels between the 
groups (p=0.135).  After weight loss, percent change in HDL-cholesterol levels was 
significantly different between non-diabetic and diabetic subjects.  High-density 
lipoprotein cholesterol levels decreased by 16.2% in non-diabetics and increased by 
0.9% in diabetic subjects (p=0.0001).  Adjusting for baseline HDL-cholesterol levels, 
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ANCOVA analysis found no significant difference between the groups at week 16 
(p=0.217).  Baseline HDL-cholesterol values and changes are shown in Table 4.5. 
4.  Triglycerides 
    Triglyceride levels at week 0, week 8 and week 16 are shown in Figure 4.30 
for diabetic and non-diabetic subjects.  At baseline diabetic subjects had significantly 
higher triglyceride levels than non-diabetic subjects, 228.8 mg/dl and 125.1 mg/dl 
(p=0.0012), respectively.  At week 16 non-diabetic subjects triglyceride levels were 
still significantly lower than diabetic subjects, 100.0 mg/dl and 146.3 mg/dl 
(p=0.0359), respectively. There was no significant difference in the percent decrease 
in triglyceride levels after weight loss between non-diabetic subjects and diabetic 
subjects, -13.1% and -34.5% (p=0.0734), respectively.  As stated previously, diabetic 
subjects had significantly greater triglyceride levels prior to weight and after 
adjusting for baseline, ANCOVA analysis found no significant difference between 
the groups at week 16 (p=0.8693).  Baseline triglyceride values and changes are 
shown in Table 4.5. 
Blood Pressure 
  Systolic blood pressure levels were not significantly different in non-diabetic 
and diabetic subjects at baseline, 117.6 mmHg and 122.6 mmHg (p=0.1224), 
respectively.  After 16 weeks of weight loss systolic blood pressure was not 
significantly different between non-diabetic and diabetic subjects, 118.4 mmHg and 
122.1 mmHg (p=0.4043), respectively.   Diastolic blood pressure levels were also 
not significantly different in non-diabetic and diabetic subjects at baseline, 73.5 
mmHg and 77.8 mmHg (p=0.1505), respectively.  Week 16 diastolic blood 
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pressures were not significantly different between non-diabetic and diabetic 
subjects, 73.8 mmHg and 75.2 mmHg (p=0.6811), respectively. Baseline systolic 
and diastolic blood pressure levels and their changes are shown in Table 4.5. 
Dietary Compliance 
  Dietary compliance was accessed by self-reported meal replacement use and 
physical activity expenditure which was recorded by HMR personnel in the Patient 
at a Glance form.  According to the Patient at a Glance form, both diabetic and non-
diabetic subjects complied with the HMR program.  Figure 4.31 shows the average 
number of meal replacements, entrees, bars and total meal replacements consumed 
for diabetic and non-diabetic subjects at week 16.  There was no significant 
difference in the number of meal replacements consumed.  Figure 4.32 illustrates the 
average weekly number of kcal expended by physical activity at week 0, week 8 and 
week 16 by diabetic and non-diabetic subjects.  There was no significant difference 
in the amount of physical activity reported between the groups.   There also was no 
significant difference in weekly attendance, mid-week phone call, number of days 
“in the box”, and in meeting the Triple ImperativeTM. 
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Table 4.1 Baseline Characteristics of Subjects who Completed the Study. 
(Mean + SD) 
 
Variable Non-Diabetic Diabetic
Number enrolled 11 18
Age (years) 50.5 + 5.6 52.4 + 6.7
Weight (kg) 96.4 + 13.3 105.6 + 12.6
Body mass index (kg/m2) 36.1 + 3.9 38.1 + 3.7  
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Table 4.2 Baseline Values and Absolute and Percentage Change from Week 0 at 
16 Weeks for Body Composition Measurements of Study Completers. Data were 
analyzed by unadjusted student’s t-tests and are expressed as mean (SE).  Statistical 
probability of p<0.05 was considered to be significant.  *Significantly different 
between non-diabetic and diabetic subjects. 
 
Variable
Week 0 Change % Change Week 0 Change % Change
DXA % Total Body Fat
49.9 
(0.8)
-7.4     
(1.0) N/A
45.9* 
(1.0)
-4.2*    
(1.1) N/A
DXA % Trunk Fat
51.2 
(1.0)
-8.0     
(1.6) N/A
47.3* 
(1.1)
-4.1*    
(1.6) N/A
DXA Total Fat (kg)
47.4 
(2.3)
-13.8    
(1.2)
-29.3     
(2.4)
47.3 
(1.7)
-9.5*    
(1.3)
-20.6*    
(2.9)
DXA Trunk Fat (kg)
24.7 
(1.4)
-8.0     
(1.1)
-32.1     
(3.9)
25.8 
(0.8)
-5.3*    
(1.0)
-20.8*    
(3.8)
DXA Total Lean (kg)
44.6 
(1.6)
-2.5     
(0.8)
-5.4      
(1.6)
53.2* 
(1.9)
-3.9     
(1.2)
-6.9      
(1.9)
DXA Trunk Lean (kg)
22.6 
(0.9)
-1.7     
(0.5)
-7.1      
(2.2)
28.5* 
(1.3)
-2.7     
(1.2)
-7.8      
(3.2)
DXA Trunk Tissue (kg)
47.3 
(2.8)
-9.6     
(1.2)
-20.2     
(2.1)
56.8* 
(2.8)
-10.6 
(2.7)
-16.7     
(3.1)
BOD POD® (% Body Fat)
52.7 
(1.4)
-12.5    
(1.4) N/A
49.6 
(1.0)
-5.7*    
(1.1) N/A
BOD POD® Total Fat (kg)
49.7 
(2.5)
-17.6    
(1.5)
-35.9     
(3.0)
50.1 
(1.7)
-10.9*   
(1.6)
-21.8*    
(3.3)
BOD POD® Total Lean (kg)
46.1 
(1.7)
0.7      
(1.1)
1.9       
(2.5)
52.1* 
(1.6)
-2.4*    
(1.6)
-4.8*     
(1.2)
CT Total Abdominal Fat (sq cm2)
717.7 
(34.5)
-208.9 
(20.8)
-30.0     
(3.7)
730.4 
(30.0)
-175.4 
(20.3)
-23.5     
(2.5)
CT Visceral Fat (sq cm2)
177.4 
(11.5)
-38.0    
(5.4)
-33.3     
(4.6)
208.3* 
(17.7)
-75.9*   
(11.4)
-34.3     
(4.0)
CT Subcutaneous Fat (sq cm2)
600.3 
(32.2)
-170.9   
(21.5)
-29.0     
(4.0)
522.1 
(28.3)
-99.5*   
(11.0)
-18.2*    
(1.9)
Waist Circumference (cm)
110.5 
(5.0)
-19.2    
(4.0)
-16.4     
(2.7)
117.9 
(2.7)
-11.9    
(2.4)
-7.8*     
(1.1)
Non-Diabetic (n=11) Diabetic (n=18)
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Table 4.3 Baseline Values and Changes from Week 0 at 16 Weeks for Fasting 
Glucose and Insulin Resistance Measurements of Study Completers. Data were 
analyzed by unadjusted student’s t-tests and are expressed as mean (SE).  Statistical 
probability of p<0.05 was considered to be significant.  *Significantly different 
between non-diabetic and diabetic subjects. 
 
Variable
Week 0 Change % Change Week 0 Change % Change
Insulin (mU/ml)
14.4      
(2.8)
-5.5      
(3.0)
-30.1     
(11.8)
21.0* 
(2.4)
-7.8      
(2.1)
-28.7     
(7.2)
HOMA-IR
5.3       
(0.1)
0.1       
(0.1)
1.8       
(1.9)
7.9*     
(0.4)
-0.9*     
(0.3)
-10.2*    
(2.5)
Glucose (mg/dl)
104.0     
(3.0)
-5.9      
(1.9)
-5.5      
(1.7)
187.2* 
(15.6)
-50.6*    
(12.5)
-22.0*    
(4.5)
HbA1c
5.2       
(0.2)
0.1       
(0.1) N/A
8.1*      
(0.4)
-1.6*     
(0.4) N/A
Non-Diabetic (n=11) Diabetic (n=18)
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Table 4.4 Baseline Values and Absolute and Percentage Change from Week 0 at 
16 Weeks for Fasting Cytokines and FSH of Study Completers. Data were analyzed 
by unadjusted student’s t-tests and are expressed as mean (SE).  Statistical probability 
of p<0.05 was considered to be significant.  *Significantly different between non-
diabetic and diabetic subjects. 
 
Variable
Week 0 Change % Change Week 0 Change % Change
Leptin (pg/ml)
64039.2 
(7328.7)
-44075.3  
(5463.6)
-66.9     
(5.9)
50457.5 
(4988.8)
-22734.3* 
(3479.4)
-46.1*    
(5.7)
Ghrelin (pg/ml)
837.8 
(90.0)
173.8 
(108.9)
22.5 
(13.7)
643.6* 
(57.0)
166.4 
(40.5)
26.1   
(5.2)
Adiponectin (ng/ml
11532.0 
(1894.0)
-1875.5    
(968.3)
-17.2     
(9.6)
6701.4* 
(640.9)
996.8* 
(410.5)
15.3*    
(4.8)
Resistin (ng/ml)
4.6     
(0.3) 0.1     (0.2)
-0.2      
(5.0)
5.6*     
(0.5)
0.4        
(0.4)
10.0    
(7.2)
IL-6 (pg/ml)
4.0      
(1.0)
-1.0       
(1.0)
0.3    
(22.7)
2.3     
(0.3)
-0.3       
(0.3)
-4.5      
(10.8)
TNFα (pg/ml)
1.2     
(0.1) 0.3     (0.2)
25.1 
(17.8)
1.3     
(0.1)
0.0        
(0.1)
10.1 
(13.7)
PAI-1 (pg/ml)
9696.9 
(1646.9)
-3928.3 
(1338.8)
-26.2 
(12.4)
12219.4 
(1171.6)
-4556.6 
(1341.9)
-25.4 
(10.6)
CRP (ng/ml)
7162.4 
(1653.9)
-1784.9 
(758.6)
-33.1     
(8.2)
6346.4 
(1073.5)
-1720.3 
(675.2)
-21.2     
(9.4)
FSH (mlU/ml)
42.9    
(8.3) 7.5     (3.5)
19.5    
(9.6)
26.4    
(5.7) 5.1      (1.9)
32.5 
(13.8)
Non-Diabetic (n=11) Diabetic (n=18)
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Table 4.5 Baseline Values and Changes from Week 0 at 16 Weeks for Fasting 
Lipid Values and Blood Pressure of Study Completers.  Data were analyzed by 
unadjusted student’s t-tests and are expressed as mean (SE).  Statistical probability of 
p<0.05 was considered to be significant.  *Significantly different between non-
diabetic and diabetic subjects. 
 
Variable
Week 0 Change
% 
Change Week 0 Change
% 
Change
Cholesterol (mg/dL)
214.0  
(12.5)
-41.2 
(12.0)
-17.9 
(5.5)
201.9 
(3.1)
-14.4 
(2.8)
-7.3     
(4.0)    
LDL-Cholesterol (mg/dL)
128.6 
(10.2)
-23.8 
(9.8)
-13.6 
(8.4)
122.6 
(2.9)
1.6    
(3.2)
6.9   
(3.0)
HDL-Cholesterol (mg/dL)
59.4 
(2.5)
-8.5     
(2.2)
-16.2    
(3.8)
47.6* 
(2.5)
-0.1*    
(1.0)
0.9*   
(2.9)
Triglycerides (mg/dL)
125.1 
(20.0)
-25.1    
(16.0)
-13.1 
(9.4)
228.8* 
(20.1)
-82.5*   
(16.7)
-34.5 
(6.1)
Systolic Blood Pressure (mmHg)
117.6 
(2.7)
9.8   
(2.4) 0.7  (2.8)
122.6 
(3.0)
-2.3     
(3.9)
6.0   
(3.3)
Diastolic Blood Pressure (mmHg)
73.5 
(1.2)
0.4   
(2.1)
0.6   
(2.8)
77.8 
(2.0)
-2.6     
(3.2)
3.3   
(4.2)
Non-Diabetic (n=11) Diabetic (n=18)
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Figure 4.1 Average and Individual Weight Losses in Non-Diabetic and Diabetic 
Subjects Who Completed the HMR® Weight Loss Program. 
 
Weight
0
5
10
15
20
25
30
Average
kg
Diabetic
Non-Diabetic
 
 
 
 
 78 
 
Figure 4.2 Percent Weight Loss of Non-Diabetic and Diabetic Subjects Who 
Completed the HMR® Weight Loss Program. 
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† Unadjusted analysis conducted by student’s t-test found to be significantly different 
between diabetic and non-diabetic subjects. 
‡  Adjusted analysis conducted by ANCOVA for week 16 found to be significantly 
different between diabetic and non-diabetic subjects. 
Statistically probability of p<0.05 was considered to be significant. 
 
 
  † †
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Figure 4.3 Percent Body Fat Determined by DEXA of Study Completers. 
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† Unadjusted analysis conducted by student’s t-test found to be significantly different 
between diabetic and non-diabetic subjects. 
‡ Adjusted analysis conducted by ANCOVA for week 16 found to be significantly 
different between diabetic and non-diabetic subjects. 
Statistical probability of p<0.05 was considered to be significant. 
† 
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Figure 4.4 Percent Trunk Fat Determined by DEXA for Study Completers. 
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† Unadjusted analysis conducted by student’s t-test found to be significantly different 
between diabetic and non-diabetic subjects. 
‡ Adjusted analysis conducted by ANCOVA for week 16 found to be significantly 
different between diabetic and non-diabetic subjects. 
Statistical probability of p<0.05 was considered to be significant.  
† 
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Figure 4.5 Total Body Fat in kg Determined by DEXA of Study Completers. 
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† Unadjusted analysis conducted by student’s t-test found to be significantly 
different between diabetic and non-diabetic subjects. 
‡ Adjusted analysis conducted by ANCOVA for week 16 found to be significantly 
different between diabetic and non-diabetic subjects. 
Statistical probability of p<0.05 was considered to be significant.
‡ 
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Figure 4.6 Trunk Fat in kg Determined by DEXA for Study Completers. 
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† Unadjusted analysis conducted by student’s t-test found to be significantly different 
between diabetic and non-diabetic subjects. 
‡ Adjusted analysis conducted by ANCOVA for week 16 found to be significantly 
different between diabetic and non-diabetic subjects. 
Statistical probability of p<0.05 was considered to be significant. 
 
† 
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Figure 4.7 Total Lean Tissue in kg Determined by DEXA of Study Completers. 
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† Unadjusted analysis conducted by student’s t-test found to be significantly 
different between diabetic and non-diabetic subjects. 
‡ Adjusted analysis conducted by ANCOVA for week 16 found to be significantly 
different between diabetic and non-diabetic subjects. 
Statistical probability of p<0.05 was considered to be significant. 
a 
b 
a 
† † †
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Figure 4.8 Trunk Lean Tissue in kg Determined by DEXA of Study Completers. 
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† Unadjusted analysis conducted by student’s t-test found to be significantly different 
between diabetic and non-diabetic subjects. 
‡ Adjusted analysis conducted by ANCOVA for week 16 found to be significantly 
different between diabetic and non-diabetic subjects. 
Statistical probability of p<0.05 considered to be significant. 
 
† 
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Figure 4.9 Total Trunk Tissue Determined by DEXA of Study Completers. 
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† Unadjusted analysis conducted by student’s t-test found to be significantly 
different between diabetic and non-diabetic subjects. 
‡ Adjusted analysis conducted by ANCOVA for week 16 found to be significantly 
different between diabetic and non-diabetic subjects. 
Statistical probability of p<0.05 was considered to be significant.
† 
† ‡  
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Figure 4.10 Percent Body Fat Determined by Air Displacement Plethysmography 
(BOD POD®) of Study Completers. 
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† Unadjusted analysis conducted by student’s t-test found to be significantly 
different between diabetic and non-diabetic subjects. 
‡ Adjusted analysis conducted by ANCOVA for week 16 found to be 
significantly different between diabetic and non-diabetic subjects. 
Statistical probability of p<0.05 was considered to be significant. 
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Figure 4.11 Total Fat in kg Determined by BOD POD® of Study Completers. 
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† Unadjusted analysis conducted by student’s t-test found to be significantly 
different between diabetic and non-diabetic subjects. 
‡ Adjusted analysis conducted by ANCOVA for week16 found to be significantly 
different between diabetic and non-diabetic subjects. 
Statistical probability of p<0.05 was considered to be significant.
† ‡ 
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Figure 4.12 Total Lean Tissue Determined by BOD POD® of Study Completers. 
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† Unadjusted analysis conducted by student’s t-test found to be significantly different 
between diabetic and non-diabetic subjects. 
‡ Adjusted analysis conducted by ANCOVA for week 16 found to be significantly 
different between diabetic and non-diabetic subjects. 
Statistical probability of p<0.05 was considered to be significant.
† 
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Figure 4.13 Total Abdominal Adipose Tissue Determined by Computer 
Tomography of Study Completers. 
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† Unadjusted analysis conducted by student’s t-test found to be significantly different 
between diabetic and non-diabetic subjects. 
‡ Adjusted analysis conducted by ANCOVA for week 16 found to be significantly 
different between diabetic and non-diabetic subjects. 
Statistical probability of p<0.05 was considered to be significant. 
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Figure 4.14 Total Subcutaneous and Visceral Adipose Tissue in Study Completers. 
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† Unadjusted analysis conducted by student’s t-test found to be significantly different 
between diabetic and non-diabetic subjects. 
‡ Adjusted analysis conducted by ANCOVA for week 16 found to be significantly 
different between diabetic and non-diabetic subjects. 
Statistical probability of p<0.05 was considered to be significant. 
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Figure 4.15 Subcutaneous, Visceral and Total Abdominal Fat Loss Determined by 
Computer Tomography of Study Completers. 
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† Unadjusted analysis conducted by student’s t-test found to be significantly 
different between diabetic and non-diabetic subjects. 
‡ Adjusted analysis conducted by ANCOVA for week 16 found to be significantly 
different between diabetic and non-diabetic subjects. 
Statistical probability of p<0.05 was considered to be significant. 
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Figure 4.16 Waist Circumference of Study Completers. 
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† Unadjusted analysis conducted by student’s t-test found to be significantly 
different between diabetic and non-diabetic subjects. 
‡ Adjusted analysis conducted by ANCOVA for week 16 found to be significantly 
different between diabetic and non-diabetic subjects. 
Statistical probability of p<0.05 was considered to be significant. 
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Figure 4.17 Percent Reduction in Waist Circumference and Total Change in 
Centimeters of Study Completers. 
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† Unadjusted analysis conducted by student’s t-test found to be significantly 
different between diabetic and non-diabetic subjects. 
‡ Adjusted analysis conducted by ANCOVA for week 16 found to be significantly 
different between diabetic and non-diabetic subjects. 
Statistical probability of p<0.05 was considered to be significant. 
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 Figure 4.18 Insulin Levels at Week 0, Week 8 and Week 16 of Study Completers. 
(Mean + SE) 
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† Unadjusted analysis conducted by student’s t-test found to be significantly 
different between diabetic and non-diabetic subjects. 
‡ Adjusted analysis conducted by ANCOVA for week 16 found to be significantly 
different between diabetic and non-diabetic subjects. 
Statistical probability of p<0.05 was considered to be significant. 
† 
†† 
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Figure 4.19 HOMA-IR Results at Week 0, Week 8 and Week 16 of Study 
Completers. (Mean + SE) 
 
0
1
2
3
4
5
6
7
8
9
Week 0 Week 8 Week 16
Diabetic
Non-Diabetic
 
† Unadjusted analysis conducted by student’s t-test found to be significantly 
different between diabetic and non-diabetic subjects. 
‡ Adjusted analysis conducted by ANCOVA for week 16 found to be significantly 
different between diabetic and non-diabetic subjects. 
Statistical probability of p<0.05 was considered to be significant.
† † 
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Figure 4.20 Glucose Levels at Week 0, Week 8 and Week 16 of Study Completers. 
(Mean + SE) 
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† Unadjusted analysis conducted by student’s t-test found to be significantly 
different between diabetic and non-diabetic subjects. 
‡ Adjusted analysis conducted by ANCOVA for week 16 found to be significantly 
different between diabetic and non-diabetic subjects. 
Statistical probability of p<0.05 was considered to be significant. 
† 
† 
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Figure 4.21 HbA1c Values at Week 0, Week 8 and Week 16 of Study Completers. 
(Mean + SE) 
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† Unadjusted analysis conducted by student’s t-test found to be significantly 
different between diabetic and non-diabetic subjects. 
‡ Adjusted analysis conducted by ANCOVA for week 16 found to be significantly 
different between diabetic and non-diabetic subjects. 
Statistical probability of p<0.05 was considered to be significant. 
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Figure 4.22 Leptin Levels at Week 0, Week 8 and Week 16 of Study Completers. 
(Mean+ SE) 
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† Unadjusted analysis conducted by student’s t-test found to be significantly different 
between diabetic and non-diabetic subjects. 
‡ Adjusted analysis conducted by ANCOVA for week 16 found to be significantly 
different between diabetic and non-diabetic subjects. 
Statistical probability of p<0.05 was considered to be significant. 
 
 
‡
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Figure 4.23 Ghrelin Levels at Week 0, Week 8 and Week 16 of Study Completers. 
(Mean + SE) 
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† Unadjusted analysis conducted by student’s t-test found to be significantly different 
between diabetic and non-diabetic subjects. 
‡ Adjusted analysis conducted by ANCOVA for week 16 found to be significantly 
different between diabetic and non-diabetic subjects. 
Statistical probability of p<0.05 was considered to be significant. 
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Figure 4.24 Adiponectin Levels at Week 0, Week 8 and Week 16 of Study 
Completers. (Mean + SE) 
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† Unadjusted analysis conducted by student’s t-test found to be significantly different 
between diabetic and non-diabetic subjects. 
‡ Adjusted analysis conducted by ANCOVA for week 16 found to be significantly 
different between diabetic and non-diabetic subjects. 
Statistical probability of p<0.05 was considered to be significant. 
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Figure 4.25 Resistin Levels at Week 0, Week 8 and Week 16 of Study Completers. 
(Mean + SE) 
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† Unadjusted analysis conducted by student’s t-test found to be significantly different 
between diabetic and non-diabetic subjects. 
‡ Adjusted analysis conducted by ANCOVA for week 16 found to be significantly 
different between diabetic and non-diabetic subjects. 
Statistical probability of p<0.05 was considered to be significant. 
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Figure 4.26 Total Plasminogen Activating Inhibitor-1 (PAI-1) Levels at Week 0, 
Week 8 and Week 16 of Study Completers. (Mean + SE) 
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† Unadjusted analysis conducted by student’s t-test found to be significantly 
different between diabetic and non-diabetic subjects. 
‡ Adjusted analysis conducted by ANCOVA for week 16 found to be significantly 
different between diabetic and non-diabetic subjects. 
Statistical probability of p<0.05 was considered to be significant.
† 
† ‡ 
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Figure 4.27 Total Cholesterol Levels at Week 0, Week 8 and Week 16 of Study 
Completers. (Mean + SE) 
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† Unadjusted analysis conducted by student’s t-test found to be significantly 
different between diabetic and non-diabetic subjects. 
‡ Adjusted analysis conducted by ANCOVA for week 16 found to be significantly 
different between diabetic and non-diabetic subjects. 
Statistical probability of p<0.05 was considered to be significant. 
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Figure 4.28 LDL-cholesterol Levels at Week 0, Week 8 and Week 16 of Study 
Completers. (Mean + SE) 
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† Unadjusted analysis conducted by student’s t-test found to be significantly 
different between diabetic and non-diabetic subjects. 
‡ Adjusted analysis conducted by ANCOVA for week 16 found to be significantly 
different between diabetic and non-diabetic subjects. 
Statistical probability of p<0.05 was considered to be significant. 
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Figure 4.29 HDL-cholesterol at Week 0, Week 8 and Week 16 of Study 
Completers. (Mean + SE) 
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† Unadjusted analysis conducted by student’s t-test found to be significantly 
different between diabetic and non-diabetic subjects. 
‡ Adjusted analysis conducted by ANCOVA for week 16 found to be significantly 
different between diabetic and non-diabetic subjects. 
Statistical probability of p<0.05 was considered to be significant. 
† 
† † 
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Figure 4.30 Triglyceride Levels at Week 0, Week 8 and Week 16 of Study 
Completers. (Mean + SE) 
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† Unadjusted analysis conducted by student’s t-test found to be significantly 
different between diabetic and non-diabetic subjects. 
‡ Adjusted analysis conducted by ANCOVA for week 16 found to be significantly 
different between diabetic and non-diabetic subjects. 
Statistical probability of p<0.05 was considered to be significant. 
† 
† 
† 
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Figure 4.31 Meal Replacement Use for Diabetic and Non-Diabetic Subjects.  The 
Average at Week 16 of Study Completers. (Mean + SE) 
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† Unadjusted analysis conducted by student’s t-test found to be significantly 
different between diabetic and non-diabetic subjects. 
‡ Adjusted analysis conducted by ANCOVA for week 16 found to be significantly 
different between diabetic and non-diabetic subjects. 
Statistical probability of p<0.05 was considered to be significant. 
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Figure 4.32 Average Weekly Physical Activity for Diabetic and Non-Diabetic 
Subjects at Week 0, Week 8, and Week 16 as Reported and Recorded into the Patient 
at a Glance Data Sheets of Study Completers.  (Mean + SE) 
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† Unadjusted analysis conducted by student’s t-test found to be significantly 
different between diabetic and non-diabetic subjects. 
‡ Adjusted analysis conducted by ANCOVA for week 16 found to be significantly 
different between diabetic and non-diabetic subjects. 
Statistical probability of p<0.05 was considered to be significant. 
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CHAPTER FIVE 
 
Discussion 
 
  The overall goal of the present study was to assess differences after weight 
loss in body composition and other metabolic parameters in women with type 2 
diabetes compared to women without type 2 diabetes.  Individuals with type 2 
diabetes are at increased risk of morbidity and mortality and thus the importance of 
eliminating these co-morbid conditions associated with obesity and type 2 diabetes 
are of utmost importance in improving overall health and quality of life.  This study 
attempted to decipher why women with type 2 diabetes often have a more difficult 
time losing weight, the differences between diabetic and non-diabetic individuals in 
body composition changes, specifically changes in abdominal visceral and 
subcutaneous adipose changes, changes in proinflammatory and prothrombotic 
markers and, finally, in improvements of lipid levels. 
Weight Loss 
  The primary hypothesis that obese individuals with type 2 diabetes would lose 
less body weight than obese women without type 2 diabetes was not fully supported 
by analyses of women who completed the study.  As stated previously, individuals 
with type 2 diabetes have a more difficult time losing weight with the conventional 
and behavioral approaches to weight loss compared with non-diabetic individuals 
(73;203;204).  We found that women with type 2 diabetes, after adjusting for initial 
body weight, lost less weight, but not significantly so compared to women without 
type 2 diabetes in a medically-supervised weight loss program.  Non-diabetic subjects 
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lost 15.4 kg of body weight and diabetic subjects lost 12.2 kg of body weight.  The 
BMI changes were consistent with body weight changes. There was no significant 
difference in BMI units in diabetic or non-diabetic subjects before or after the weight 
loss phase indicating that diabetic subjects lost similar amount of weight to the non-
diabetic subjects. 
  The intention-to-treat (ITT) or last-observation-carried-forward (LOCF) 
analyses indicated that diabetic subjects were not able to lose as much percentage 
body weight as the non-diabetic subjects.  All of the non-diabetic subjects completed 
the 16-week weight loss program, while 3 of the diabetic subjects terminated the 
program early.  The fact that all individuals who ended the program early were 
diabetic subjects could explain why previous researcher (73;203;204) have concluded 
that individuals with type 2 diabetes often have a greater difficulty losing weight than 
non-diabetic subjects. 
  The results of this study demonstrate that for women who complete a 
structured, medically-supervised low-energy diet (LED) weight loss program, there is 
no significant difference in success of weight loss.  We also concluded that 
medically-supervised LED weight loss programs are a safe and effective method of 
weight loss for women with type 2 diabetes.  In the present study, women with type 2 
diabetes who completed the study consumed the same amount of shakes, entrees, bars 
and total meal replacements as non-diabetics. 
  Individuals with type 2 diabetes have an increased risk for cardiovascular 
disease (222), peripheral vascular disease (222) and peripheral neuropathy (222), 
often increasing the difficulty to initiate and maintain physical activity.  The ability of 
 111 
 
individuals with type 2 diabetes to perform the required physical activity in this 
medically-supervised LED may help explain the success in weight loss observed in 
these individuals.  As seen in the results of physical activity, non-diabetic and 
diabetic women both consistently attended weekly classes and made their mid-week 
phone calls.  At 16 weeks both groups had an average of 6.6 days that were “in the 
box” and the majority of individuals were able to following the Triple ImperativeTM 
requirements. Osteoarthritis is also common in obese individuals with and without 
type 2 diabetes, often making physical activity more painful.  In this study 4 women 
with type 2 diabetes had arthritis and another 5 reported back, leg and joint pain.  One 
subject with type 2 diabetes had Charcot’s or neuropathic joint disease, which is a 
progressive destructive arthritis associated with loss of pain sensation, proprioception, 
or both (223).  This woman had 2 toes amputated and was still able to do most of the 
required physical activity.  One woman without type 2 diabetes reported having 
arthritis and 2 subjects without type 2 diabetes reported back, leg and joint pain.  
Despite the higher incidence of arthritis and joint pain in the subjects with type 2 
diabetes, there was no difference in the amount of physical activity conducted.  At 
week 8 and week 16, both non-diabetic and diabetic women were doing more than the 
minimum 2000 kcal required by the HMR® program.   
  Anderson et al. (224) found that VLED and LED were safe and effective 
methods of weight loss for individuals with diabetes.  In a study of 40 subjects with 
type 2 diabetes, subjects lost an average of 15.7 kg with a decrease in insulin use, 
anti-diabetes and hypertensive medications with no serious side effects.  Reynolds et 
al. (225) also found that medically-supervised VLED and LED were safe and 
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effective methods of weight loss for individuals with diabetes.  In a retrospective 
review of consecutive patients enrolled in these programs, it was found that there was 
no difference in the amount of weight loss in non-diabetic and diabetic subjects who 
completed 12 weeks of the weight loss program (225).  These results are consistent 
with the findings of the present study.  Other researchers have also found VLEDs to 
be safe and effective for individuals with type 2 diabetes (226-230). 
Body Composition Measurements 
  Various procedures for body composition analysis cannot be compared 
directly due to different underlying principles.  DEXA uses a 3-compartment body 
composition model consisting of bone mineral content, fat and lean tissue, while 
BOD POD® is based on a 2-compartment model based on body density (231).  
Comparison between these body composition techniques generally yield high 
correlations for percent body fat but may differ in the absolute values obtained (231).  
Weyers et al. (231) studied body composition changes after weight loss using DEXA 
and BOD POD® measurements.  These researchers found that there was no 
significant differences in changes in percent body fat, fat mass and fat-free mass in 
response to weight loss between the methods.  However, Hendel et al. (232) 
explained the differences in percent body fat between DEXA and BOD POD® could 
be due to incomplete scanning of the entire body using DEXA which would account 
for errors in the DEXA estimates of percent body fat.  In the present study DEXA 
scanning of the obese subjects was incomplete.  The DEXA scan was originally made 
for non-obese women to measure bone mineral density and was not designed for 
larger individuals.  Many of the women in the present study did not completely fit on 
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the table.  The majority of the scans had one or both of the arms slightly missing from 
the scan/ body composition calculations.  The CT technique and results also differ 
from DEXA and BOD POD®.  This procedure produces radiographic images of the 
abdomen which allows for differentiation between subcutaneous and visceral adipose 
tissue accumulation.  The CT results are not expressed as a percentage or mass (e.g., 
kg), but in area (cm2).  Although the results of these procedures cannot be directly 
compared, trends in their findings can be useful to validate the changes in body 
composition. 
  It must be noted that in the present study, though the methods of body 
composition can not be directly compared, the results of the data were very consistent 
between the body composition measurements.  This has provided strength in the 
study design and provided further confirmation of the results. 
Baseline Comparison of Body Composition 
  The hypothesis that obese individuals with type 2 diabetes will lose a greater 
proportion of abdominal fat as visceral abdominal fat compared to obese individuals 
without type 2 diabetes was examined.  Several body composition measurements 
were conducted to examine changes in the amount and type of adipose tissue 
following weight loss in the study subjects.  Dual-energy x-ray absorptiometry 
(DEXA) was used to measure total percent body fat; percent body fat in the trunk; 
total fat; total fat in the trunk; total lean tissue; and total tissue in the trunk.  Air-
displacement plethysmography (BOD POD®) was used to measure percent body fat, 
and abdominal computer tomography (CT) was used to measure total abdominal 
adipose tissue and subcutaneous and visceral abdominal adipose tissue. 
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  Diabetic individuals have more lean tissue and less fat than non-diabetic 
individuals.  Diabetic individuals also have less abdominal subcutaneous adipose 
tissue than non-diabetic individuals.  However, diabetic individuals have significantly 
more visceral adipose tissue than non-diabetic individuals.  Diabetic subjects have 
significantly more total lean tissue (p=0.002) than non-diabetic subjects.  Adjusting 
for differences in body weight, diabetic subjects have a non-significantly higher 
percentage of lean body tissue with DEXA and BOD POD® measurements.  Results 
from our measurements are consistent with those from the literature. 
  It is unclear why diabetic subjects have relatively more lean tissue than non-
diabetic subjects.  This could somehow be related to the insulin resistant state and 
impaired metabolism of glucose and fatty acids by skeletal muscle in type 2 
diabetes(233-235).  One possible explanation for dysregulation of local lipolytic 
activity and development of insulin resistance in skeletal muscle may be due to an 
inverse relationship between intramuscular triglyceride content and insulin resistance 
(236).  Kelley et al. (237) found that mitochondria tended to be smaller and have a 
reduced activity of complex 1 of the electron transport chain in individuals with type 
2 diabetes.  The researchers concluded that this impaired functional capacity of 
mitochondria may be a major determinant in the pathogenesis of skeletal muscle 
insulin resistance in type 2 diabetic individuals.  Mitochondrial dysfunction in 
skeletal muscle in individuals with type 2 diabetes has been reported by other 
researchers as well (238-240).Glucose toxicity alters protein function through 
glycosylation of tissue proteins and may decrease enzyme and other vital protein 
functions (241;242).  In the present study, the greater amount of lean tissues in the 
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women with type 2 diabetes could contribute to the variations in adipose tissue 
concentrations and insulin resistance compared with the women without type 2 
diabetes.   
  The fat mass of diabetic subjects is relatively lower than that for non-diabetic 
subjects.  Diabetic subjects have a non-significant lower percentage of body fat than 
non-diabetic subjects by DEXA and BOD POD®.  In addition, diabetic subjects have 
less truncal fat and less subcutaneous fat by CT than non-diabetic subjects.  Our 
results are similar to those reported by Halvatsiotis (243).  Halvatsiotis et al. (243) 
compared baseline body composition measurements of individuals with type 2 
diabetes to weight-matched controls.  Although not significant, DEXA measurements 
of lean mass (FFM) in kg found that diabetic subjects had slightly greater total lean 
tissue than the non-diabetic subjects.  Total fat mass was found to be significantly 
greater in non-diabetic subjects then the diabetic subjects.  There was no significant 
difference in the amount of total abdominal adipose tissue determined by CT and 
diabetic subjects had significantly greater visceral adipose tissue at baseline than the 
non-diabetic subjects.  The results of these baseline findings are consistent in the 
study population of the present study.  In contrast,  Markovic et al. (161) assessed 
early and late changes in lipid levels induced by energy restriction versus fat loss in 
obese individuals with and without type 2 diabetes.  Percent of total abdominal fat 
determined by DEXA and waist circumference was not found to be different prior to 
weight loss.   
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Body Composition Changes with Weight Loss 
  With weight loss, diabetic subjects lose slightly more lean tissue than non-
diabetic subjects by DEXA and BOD POD®.  These changes are consistent after 
adjusting for baseline difference in body weight.  Diabetic subjects also lose less total 
and truncal fat as measured by DEXA, BOD POD® and CT than non-diabetic 
subjects.  While diabetic subjects lose equivalent amounts of visceral adipose tissue, 
as a percentage of weight loss on initial values, the absolute loss of visceral adipose 
tissue is greater in diabetic than non-diabetic subjects is unclear. 
  DEXA measurements found diabetic subjects had significantly more total lean 
tissue than non-diabetic subjects after 16 weeks of weight loss (p=0.004). The 
percentage change in total lean tissue was not significantly different after 16 weeks of 
weight loss.  This was also found after adjusting for baseline measurements, 
ANCOVA analysis found no significant difference between the groups at week 16.  
Unlike the DEXA results, analysis of total lean tissue after 16 weeks of weight loss 
with BOD POD® found no significant difference in the amount of total lean tissue in 
non-diabetic and diabetic subjects.  The percent change in total lean tissue however 
found diabetics subjects lost significantly more lean tissue than non-diabetic 
(p=0.027).   ANCOVA analysis, adjusting for baseline values was approaching 
significance at week 16 with diabetic subjects having more lean tissue than non-
diabetic subjects.  The differences between the DEXA and BOD POD® are most 
likely due to incomplete scanning of the subjects in the DEXA analysis.  The overall 
results indicate that diabetic subjects had more total lean tissue than non-diabetic 
subjects after weight loss.   
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Percent and Total Body Fat 
  Total percent body fat was measured by DEXA and BOD POD®.  The DEXA 
analysis indicated that after 16 weeks of weight loss diabetic subjects lost 
significantly less percent body fat than non-diabetic subjects (p=0.043).  However, 
after adjusting for baseline values there was no significant difference in absolute 
percent body fat between non-diabetic and diabetic subjects after 16 weeks of weight 
loss.  BOD POD® analysis found no significant difference in the amount of percent 
body fat lost between non-diabetic and diabetic subjects.  However, after adjusting for 
baseline values, ANCOVA analysis found that diabetic subjects lost significantly less 
percent body fat than non-diabetic subjects (p=0.009). Differences between DEXA 
and BOD POD® results have already been discussed.  The overall conclusion is 
diabetic subjects lost less percent body fat than non-diabetic subjects, but not after 
adjusting for baseline values. Diabetic and non-diabetic subjects had the same amount 
of percent body fat after weight loss. 
  DEXA measurements of total fat indicated no significant difference in total 
body fat at week 16 between non-diabetic and diabetic subjects.  Non-diabetics 
significantly decreased their percentage change in total body fat compared to diabetic 
subjects after 16 weeks of weight loss (p=0.029).  After adjusting for baseline values 
diabetic subjects had significantly greater total fat than non-diabetic subjects 
(p=0.007).  BOD POD® measurements of total fat found diabetic subjects had more 
total body fat at week 16 than non-diabetic subjects (p=0.043).  Non-diabetic subjects 
significantly decreased their percentage change in total fat compared to diabetic 
subjects (p=0.004).  After adjusting for baseline values diabetic subjects had 
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significantly more total fat than non-diabetic subjects after 16 weeks of weight loss 
(p=0.007).  Overall, results indicate that diabetic subjects had more total body fat than 
non-diabetic subjects and diabetic subjects did not decrease their total body fat as 
much as non-diabetic subjects after 16 weeks of weight loss. 
  Our observations in percentage body fat and total fat are similar to 
Funkhouser et al. (244).  In a study conducted by Funkhouser et al. (244) these 
researchers found that in 19 healthy obese women, a 13.1 kg weight loss resulted in a 
-5.9 percent of body fat analyzed by DEXA.  These results are consistent with the 
non-diabetic subjects studied in the present study.  Blaak et al. (245) studied 27 
women and 8 men with type 2 diabetes and compared body composition changes 
after a VLED.  The researchers found that with a 12.0 kg weight loss, percentage of 
body fat determined by underwater weighing decreased by -5.4.  This is consistent 
with the findings of Funkhouser et al. (244) and the present findings in the non-
diabetic subjects.  Underwater weighing is based on a 2-compartment model as is the 
BOD POD®.  Comparing the present results of diabetic subjects using the BOD 
POD® analysis to Funkhouser and et al. (244) findings, the diabetic subjects in the 
present study lost more percentage body fat per kg of weight loss. 
Abdominal Adipose Tissue 
  Abdominal fat was determined by DEXA and CT measurements after 16 
weeks of weight loss.  DEXA measurements found that at week 16 diabetic subjects 
had significantly more trunk fat than non-diabetic subjects (p=0.035).  The percentage 
change in trunk fat was significantly lower in diabetic than non-diabetic subjects 
(p=0.05).  Diabetic subjects had significantly more lean tissue in the trunk than non-
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diabetic subjects after 16 weeks of weight loss (0.0005).  The percentage change in 
lean tissue in the trunk was not found to be significantly different between non-
diabetic and diabetic subjects.  The amount of total trunk tissue determined by DEXA 
found that diabetic subjects had significantly more than non-diabetic subjects 
(p=0.001).  The percentage change in trunk tissue was not found to be different in 
diabetic than non-diabetic subjects.  After adjusting for baseline values diabetic 
subjects had significantly more total trunk tissue than non-diabetic subjects (p=0.12).  
Analysis of total abdominal adipose tissue by CT was found not to be significantly 
different between diabetic and non-diabetic subjects after 16 weeks of weight loss.  
After adjusting for baseline there was no difference in the amount of total abdominal 
tissue between diabetic and non-diabetic subjects.  Waist circumferences were 
significantly greater in diabetic than non-diabetic subjects after 16 weeks of weight 
loss (p=0.0004).  The percentage change in waist circumference was significantly less 
in diabetic than non-diabetic subjects after 16 weeks of weight loss (p=0.0103).  After 
adjusting for baseline values diabetic subjects had significantly greater waist 
circumferences than non-diabetic subjects (p=0.001).  Overall, the results of the total 
abdominal tissue found that diabetic subjects had significantly more abdominal tissue 
than non-diabetic subjects after 16 weeks of weight loss.  These results are consistent 
with Stoney et al. (246) who compared regional body fat distribution in women with 
and without type 2 diabetes.  The results indicated that total body fat were similar 
between the two groups, the women with type 2 diabetes had significantly less lower-
body fat, greater waist circumferences and abdominal fat than the women without 
type 2 diabetes.  These researchers concluded that a reduced capacity to deposit 
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and/or conserve lower-body fat may be an independent factor associated with the 
metabolic manifestations of the insulin resistance syndrome in women with type 2 
diabetes. 
  Visceral and subcutaneous adipose tissue measurements were by CT.  After 
16 weeks of weight loss diabetic subjects had significantly greater amount of visceral 
adipose tissue than non-diabetic subjects (p=0.004).  After adjusting for baseline 
values there was no significant difference in the amount of visceral adipose tissue in 
diabetic and non-diabetic subjects.  After 16 weeks of weight loss there was no 
significant difference in the amount of subcutaneous adipose tissue between diabetic 
and non-diabetic subjects.  After adjusting for baseline values diabetic subjects had 
significantly greater subcutaneous adipose tissue than non-diabetic subjects 
(p=0.034).  Overall, the changes in visceral adipose tissue were not significantly 
different between the groups after weight loss, but diabetic subjects had significantly 
greater visceral adipose tissue stores than the non-diabetic subjects.  After 16 weeks 
of weight loss there was no difference in subcutaneous adipose tissue stores in 
diabetic and non-diabetic subjects.  After adjusting for baseline values diabetic 
subjects had significantly less subcutaneous adipose tissue than non-diabetic subjects 
(p=0.0394).    The explanations for these differences are uncertain. To determine the 
number of subjects needed to see if there was a difference in percentage change in 
visceral adipose tissue a sample size calculation was conducted.  Using a power of 0.8 
and an alpha of 0.05, the sample size to determine differences in percentage change of 
visceral adipose tissue between diabetic and non-diabetic subjects would require 4070 
subjects per group for a total of 8140 subjects. After 16 weeks of weight loss there 
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was no significant difference in the amount of subcutaneous adipose tissue between 
diabetic and non-diabetic subjects.  This greater number of subjects needed to 
determine this difference suggests that percentage of visceral adipose tissue change 
with weight loss is the same in diabetic and non-diabetic subjects.  A sample size 
determination of percentage change in subcutaneous adipose tissue with the same 
power and alpha would be 17 subjects for each group for a total of 34 subjects.  This 
lower number reflects the significant difference found in subcutaneous adipose tissue 
in the present study. 
  Despres and Lamarche (247) suggested that a visceral fat accumulation 
greater than 130 cm2 could be associated with a decrease in insulin sensitivity.  In the 
present study both diabetic and non-diabetics had visceral fat accumulation greater 
than this, 208.3 cm2 and 177.42 cm2, respectively.  It should be noted that Karelis et 
al. (248) also found that metabolically healthy obese women had significantly higher 
visceral adipose accumulation (141 + 53 cm2).  Despres and Lamarche (65) also 
concluded that abdominal visceral fat accumulation greater than 100 cm2 was 
associated with increased risk factor for coronary heart disease.  Williams et al. (249) 
found similar results in pre- and postmenopausal women and found that intra-
abdominal fat accumulation greater than 110 cm2 were at an increased risk for 
coronary heart disease.  In the present study, after weight loss visceral adipose tissue 
accumulation was still greater than 130 cm2 in diabetic subjects (132.4 cm2), while 
the non-diabetics had decreased their visceral fat accumulation to 79.4 cm2.  Thus, the 
diabetic subjects in the present study are at a greater risk of developing coronary heart 
disease than the non-diabetic subjects. 
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  Karelis et al. (248) compared body composition in women considered to be 
metabolically healthy but obese to obese individuals with risks for the metabolic 
syndrome.  These researchers found that despite similar levels of total body fatness, 
metabolically healthy obese individuals showed 49% less visceral adipose tissue (as 
measured from CT) than at-risk subjects with the metabolic syndrome.  The 
metabolically healthy women showed a more favorable lipid profile, including lower 
fasting triglycerides, higher HDL-cholesterol and lower glucose and insulin 
concentrations.  These results agree with findings of other researchers (250;251) that 
the amount of visceral fat is an important factor associated with variations in insulin 
sensitivity.  Excessive visceral fat has been associated with a decrease in insulin 
sensitivity, which could lead to an increase risk of cardiovascular disease (252). In the 
study by Karelis et al. (248)the higher levels of insulin sensitivity in the metabolically 
healthy but obese individuals may be due to lower amount of visceral fat despite the 
presence of large amount of total body fatness.  In the present study, there was no 
significant difference in the change in abdominal visceral adipose tissue between non-
diabetic and diabetic subjects.  The diabetic subjects had significantly more visceral 
adipose tissue at baseline and after 16 weeks of weight which would account for their 
decrease in insulin sensitivity. 
  Miyashita et al. (253) found that individuals consuming a low-carbohydrate 
diet of approximately 1000 kcal/day with a 9 kg weight loss, visceral-to-subcutaneous 
adipose tissue ratio (V/S) was significantly decreased from 0.69 to 0.47 (p<0.05).  
The amount of carbohydrate used in this diet is consistent with the carbohydrate 
content used in the HMR® program.  In the present study, before weight loss non-
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diabetic subjects had a V/S ratio of 0.20 while diabetic subjects had a significantly 
higher ratio of 0.43.  Both groups significantly decreased the V/S ratio to 0.19 and 
0.33 for non-diabetic and diabetics respectively; however, there was no significant 
difference in the amount of change. 
Effects of Weight Loss in Ghrelin Values 
  The hypothesis that plasma ghrelin levels in response to weight loss would not 
increase as much in individuals with type 2 diabetes as compared with individuals 
without type 2 diabetes was supported at week 16 after ghrelin values were adjusted 
for baseline.  However, diabetic subjects had significantly lower ghrelin levels at 
baseline.  Figure 4.11 depicting the rise of ghrelin levels due to weight loss, is 
consistent with the predicted levels in Figure 2.4.  Overall, despite nonsignificant 
differences after 16 weeks of weight loss, women with type 2 diabetes continually 
had lower levels of ghrelin and both groups did not increase ghrelin levels to normal. 
  Current research involving this newly discovered hormone is inconclusive and 
incomplete.  Recent studies show that levels of ghrelin (254;255) are inversely related 
to insulin resistance; visceral adipose tissue accumulation is believed to down-
regulate ghrelin (254).  Pöykkö et al. (256;257) measured fasting plasma ghrelin 
concentrations in 1,045 individuals of the Oulu Project Elucidating Risk of 
Atherosclerosis (OPERA) study.  The mean fasting plasma ghrelin concentration of 
the study cohort was 668 pg/ml (range 117-1513). Results indicated that ghrelin 
levels were lower in subjects with type 2 diabetes, which is consistent with previous 
studies (100;258).  This study also demonstrated adiposity to be an important 
determinant of ghrelin concentrations.  Therefore, the lower ghrelin concentrations in 
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type 2 diabetic subjects could be due to their higher adiposity.  The results of the 
study suggested that low ghrelin is independently associated with elevated blood 
pressure level and insulin concentration and the prevalence of type 2 diabetes.  
Similar to Pöykkö and colleagues (256;257), Katsuki et al. (259) evaluated 18 obese 
and 18 non-obese patients with type 2 diabetes to investigate ghrelin’s possible role in 
abdominal adiposity, insulin levels and insulin resistance in individuals with type 2 
diabetes.  These researchers found that ghrelin levels are significantly associated with 
abdominal adiposity, fasting serum levels of insulin and insulin resistance in patients 
with type 2 diabetes.  However, instead of adiposity as the determinant of ghrelin 
concentration, they concluded that hyperinsulinemia associated with insulin 
resistance decreases plasma levels of active ghrelin in patients with type 2 diabetes.  
Other research has also concluded that insulin is the prime regulator of ghrelin 
concentrations and that insulin may be the lead candidate for a long-term mediator of 
ghrelin responses to weight change (260;261). 
  In other studies, the association of ghrelin to visceral adipose tissue and 
insulin has not been shown.  Hansen et al. (262) studied eight obese Caucasian 
women with a mean age of 48.6 + 3.5 years attending a 6-month weight loss course 
organized by The Danish Heart Association.  These researchers found that individuals 
lost 5% of their initial body weight, resulting in an 8% reduction in total body fat and 
that plasma ghrelin levels increased by 12%.  The increase in ghrelin was positively 
correlated to the weight reduction but not to the decrease in intra-abdominal fat area, 
plasma insulin or leptin.   The possibly discrepancy between these results and other 
studies could be due to the small sample size and also not including individuals with 
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type 2 diabetes into the study.  It may be that the genetic factors that predispose 
certain individuals to type 2 diabetes may also affect an individual’s ghrelin 
production and metabolic responses.  Purnell et al. (261) examined the relationship of 
ghrelin levels to body composition and parameters of glucose and lipid metabolism.  
They found no relationship of ghrelin to percentage body fat, total fat mass, lean 
mass, intraabdominal fat or leptin levels.  They concluded that ghrelin levels best 
reflect body weight rather than specific amounts of fat or body fat distribution and 
that ghrelin levels correlated negatively with insulin and positively with insulin 
resistance.  These results could explain why individuals with type 2 diabetes have 
lower ghrelin levels than non-diabetic individuals.   
  There are currently no published studies directly examining the effects of 
weight loss on ghrelin levels in individuals with type 2 diabetes.  It has been 
postulated that ghrelin may function as an adiposity signal contributing to weight 
regain in post-obese subjects, as evidenced by the increase in circulating ghrelin 
levels that accompanies voluntary or disease-induced weight loss (96;105;262).  The 
present study found that individuals with type 2 diabetes had significantly lower 
ghrelin concentrations prior to weight loss which is in agreement with other studies  
(256;257;259;261). 
Effects of Weight Loss in Leptin Levels 
  The hypothesis that plasma leptin levels in response to weight loss will not 
decrease as much in individuals with type 2 diabetes as compared with individuals 
without type 2 diabetes was not supported by this study.  In the present study, plasma 
leptin levels decreased by 66.9% in non-diabetic subjects and 46.1% in diabetic 
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subjects.  After adjusting for baseline measurements, leptin levels were still found to 
be significantly lower in non-diabetic subjects than diabetic subjects after 16 weeks of 
weight loss (p=0.0105).  
  There are conflicting reports as to whether plasma leptin is associated with 
total body, subcutaneous or visceral adipose tissue (263-269).  Recent studies have 
suggested that it is subcutaneous adipose tissue and not visceral adipose tissue which 
shows a close association with serum or plasma leptin (263;264;266;270).  Vettor et 
al. (34) found that in 15 obese women and 10 normal control women that leptin 
concentrations were highly significantly correlated with BMI and total and 
subcutaneous adipose tissue and significantly less with visceral adipose mass.  
Kobayashi et al. (271) found that in women abdominal subcutaneous adipose tissue 
mass was a more important determinant of serum leptin than was visceral fat mass 
and no relationship between serum leptin levels and lipid parameters of total 
cholesterol, LDL-cholesterol, HDL-cholesterol and triglyceride levels were shown. 
  In contrast, Ronnemaa et al. (269) suggested that visceral adipose tissue was 
of special importance in the regulation of leptin levels after investigating 23 healthy 
identical twin pairs.  A study by Gower et al. (272) also showed that in 54 
postmenopausal women, visceral adipose tissue was independently related to serum 
leptin levels after adjusting for subcutaneous adipose tissue, leg fat and lean mass.  
The conflicting results between researchers as to whether leptin is more closely 
associated with subcutaneous or visceral adipose tissue are most likely due to the 
small sample sizes of the studies.  Another explanation for the contradictory findings 
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is that subcutaneous adipose makes up a greater proportion of abdominal adipose 
tissue than visceral adipose tissue and thus may skew the results. 
  Results of the present study show that individuals with type 2 diabetes may 
have alterations in leptin production and metabolic effects in the body.  It is known 
that fasting leptin levels correlate with fasting insulin concentrations (273) and thus 
may be one of the target points of the complex axis of metabolic disturbances found 
in individuals with type 2 diabetes, leading to increased risk of other co-morbid 
conditions such as coronary heart disease. 
Effects of Weight Loss in Inflammatory Cytokines 
  Findings regarding the hypothesis that obese individuals with type 2 diabetes 
will have a greater decrease in insulin, IL-6, TNF-α or CRP levels in individuals with 
type 2 diabetes or without type 2 diabetes were not what was expected.  First, 
obviously, women with type 2 diabetes had higher insulin levels prior to weight loss; 
however, analysis found that there was no difference between the groups at 16 weeks.  
In the present study, insulin levels decreased by 30.1% and 28.7% in non-diabetic and 
diabetic subjects, respectively.  These results are consistent with previous findings 
that insulin levels decrease in both obese diabetic and non-diabetic individuals during 
weight loss (113-116).  The importance of reducing insulin concentrations has been 
apparent.  Insulin has been shown to play a role in the long-term regulation of body 
adiposity (274) and also may mediate the production and effects of cytokines such as 
ghrelin (261), leptin (86;275), and CRP (140). 
  In the present study no difference was found in IL-6, TNF-α or CRP before or 
after weight loss.  Levels of these inflammatory cytokines all decreased with weight 
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loss but non-significantly.  Subjects were told not to consume anti-inflammatory 
medications during the study.  These medications obviously effect the cytokine levels 
of IL-6, TNF-α and CRP.  It was originally thought that levels of these cytokines 
would be increased in obese individuals but significantly greater in obese individuals 
with type 2 diabetes.  Of the 29 subjects in the present study, 15 subjects took anti-
inflammatory medications throughout the study.  Ten of the subjects taking anti-
inflammatory medications were diabetic and 5 non-diabetic.  The majority of 
individuals took over-the-counter aspirin, ibuprofen or Tylenol.  However, 6 
individuals took either Vioxx® or Celebrex® during the study.  The use of these 
medications can explain why there was no difference found in IL-6, TNF-α or CRP 
levels before or after the 16 weeks of weight loss. 
  Putz et al. (276) has stated that CRP concentrations are elevated in obesity and 
may be the effect of IL-6 release from adipocytes and higher insulin resistant states 
(140).  Hak et al. (140) found that CRP is elevated in subjects with the metabolic 
syndrome and appears to progressively increase when glucose metabolism 
deteriorates.  Mc Laughlin et al. (277) also found that CRP concentrations are 
elevated in obese and/or hyperinsulinemic individuals.  These researchers show that 
CRP levels were higher in obese individuals with insulin resistance compared to 
obese individuals without insulin resistance.  After weight loss CRP concentrations 
decreased only in the insulin resistant women.  These researchers concluded that CRP 
concentrations are elevated predominantly in obese individuals who are also insulin 
resistant and fall parallel with weight loss-associated improvements in insulin 
resistance.  The relation between CRP concentrations and insulin resistance is 
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independent of obesity.  In the present study, if subjects had not taken anti-
inflammatory medications one would expect that the women with type 2 diabetes 
would have seen a greater decline in CRP levels as their insulin resistance improved 
as shown from the improved HOMA-IR values. 
  Xenachis et al. (278) studied 48 morbidly obese subjects who were placed on 
an 800 kcal formula diet and found that TNF-α levels decreased with weight loss.  
Dandona et al. (279) found that serum TNF-α concentrations are greater in obese 
versus lean subjects before and after weight loss.  The fall in serum TNF-α 
concentrations may contribute to the restoration of insulin sensitivity in obese patients 
who lose weight (280).  These results agree with several other studies that serum 
TNF-α levels decrease with body weight reduction (281;282).  TNF-α has been 
proposed as a mediator of obesity-related insulin resistance (127;283).  Katsuki et al. 
(125) found that TNF-α concentrations were significantly higher in obese individuals 
with type 2 diabetes as compared to non-obese or non-obese individuals with type 2 
diabetes.  After weight loss, TNF-α levels significantly decreased in subjects with 
type 2 diabetes but were unchanged in both the non-obese and non-obese subjects 
with type 2 diabetes.  These researchers suggest that serum TNF-α level may play an 
important role in the mechanism of insulin resistance associated with obesity.  So, as 
found with CRP concentrations, TNF-α concentrations may play a greater role in 
insulin sensitivity than adiposity with insulin sensitivity. 
  Esposito et al. (284) studied 120 healthy obese women to determine the effect 
of a lifestyle and weight loss program on its effects of vascular inflammatory 
markers.  As with other researchers (136;282), IL-6 levels were found to be correlated 
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with body weight.  Serum IL-6 concentrations were found to decrease with weight 
loss.  Kopp et al. (285) also found similar results in individuals with varying degrees 
of glucose intolerance after weight loss with gastroplastic surgery.  At baseline these 
researchers found that IL-6 concentrations were more closely related to HbA1c, 
whereas CRP concentrations were more closely related to glucose-stimulated insulin 
release.  The inflammatory markers of IL-6, CRP and TNF-α were all significantly 
correlated with insulin resistance.  After gastroplastic surgery, a significant weight 
reduction was produced and levels of IL-6 and CRP were also significantly reduced. 
Effects of Weight Loss in Thrombotic Cytokines 
  The hypothesis that obese individual with type 2 diabetes will have a greater 
decrease in serum triglyceride, PAI-1 and resistin compared to obese individuals 
without type 2 diabetes had varying findings.  Triglyceride levels were significantly 
greater in individuals with type 2 diabetes.  This is to be expected since triglyceride 
levels >150 mg/dl was one of the exclusion criteria used to exclude a non-diabetic 
subject from the study.  Also, visceral adipose tissue mass has a positive relationship 
with triglycerides (286-288) and an inverse relationship with serum HDL-cholesterol 
(288), while subcutaneous adipose tissue does not have any correlation (269).  
Contrary to these findings, Kobayashi et al. (271) studied 26 men and 26 women and 
found that visceral adipose tissue mass had a positive relationship with serum total 
cholesterol and LDL-cholesterol; however, visceral adipose tissue mass was only 
associated with triglycerides in men and not women.  These findings are consistent 
with other studies (24;289).  Despite the triglyceride exclusion criteria for non-
diabetic subjects in the present study, it could be speculated that the higher 
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triglyceride levels seen in the diabetic subjects could be due to significantly more 
visceral adipose tissue and less subcutaneous adipose tissue than the non-diabetic 
subjects.   However, after adjusting for baseline there was no significant difference 
between the groups after 16 weeks of weight loss.  Obese subjects did have a greater 
decrease in serum triglyceride levels but they were not different after adjusting initial 
values.  Non-diabetic subjects decreased triglyceride levels by 15.1 mg/dl resulting in 
a 13.1% decrease.  Diabetic subjects decreased triglyceride levels by 82.5 mg/dl 
resulting in a 34.5% decrease in triglyceride levels.  These results are consistent with 
many other findings.  Serum triglyceride levels decreased from approximately 15% to 
as much as 50% during VLED treatment, depending upon initial levels  
(229;230;290-292). 
  Marckmann et al. (162) found that weight loss decreases PAI-1 levels in 
individuals with and without type 2 diabetes.  The results of the present study found 
that PAI-1 levels were not significantly different between diabetic and non-diabetic 
subjects, but PAI-1 levels did decrease in both diabetic and non-diabetic women.  At 
the end of the weight loss phase PAI-1 levels in diabetic subjects were approaching 
statistically greater significance than non-diabetic subjects.  With adequate sample 
size a significant difference in PAI-1 levels are expected.  A rationale for the increase 
in PAI-1 levels in the diabetic subjects is most likely associated with increased 
growth factors such as insulin and TNF-α along with metabolic products such as 
triglycerides, free fatty acids, and glucose, all of which can stimulate PAI-1 
expression (151-155;158;293;294). 
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  Skurk et al. (295) found that IL-6, leptin and adiponectin are associated with 
impaired fibrinolysis in overweight hypertensive humans.  In the present study, 
diabetic subjects had higher insulin and lower leptin and adiponectin levels than their 
non-diabetic counterparts, which may provide evidence of an association between 
body fatness, insulin, leptin and adiponectin as key regulators of risk for developing 
cardiovascular disease.  Also, in a study of obese children and adolescents, Ikezaki et 
al. (254) found that down-regulation of ghrelin secretion may be a consequence of 
higher insulin resistance associated with visceral fat accumulation and elevated PAI-1 
concentrations.  In the present study baseline ghrelin levels were significantly lower 
in diabetic subjects than non-diabetes and were still lower after 16 weeks of weight 
loss and thus may further have contributed to the higher insulin resistance, greater 
visceral fat mass and elevated PAI-1 concentrations in the diabetic subjects. 
  Several small studies have reported that circulating resistin levels are 
increased in human obesity (184-187) and diabetes (188-192); however, other data 
dispute these findings (296-298).  Previous studies of the effect of weight loss on 
resistin levels have also been controversial.  The results of the present study are 
consistent with Wolfe et al. (181) and Monzillo et al. (182) in that no significant 
reduction was found in resistin levels with weight loss.  In the present study, plasma 
resistin levels were significantly greater in individuals with type 2 diabetes than in 
individuals without type 2 diabetes which is consistent with the findings of Steppan 
and colleagues (194).  However, with weight loss resistin levels did not decrease in 
either group.  Silha et al. (195) found that there was a significant correlation between 
resistin levels and HOMA-IR in obese subjects independent of BMI.  These results 
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may indicate that resistin levels are a predictor for type 2 diabetes.  Resistin seems to 
reflect insulin resistance despite an individual’s BMI.  This would explain why levels 
did not decrease with weight loss but rather is an independent factor associated with a 
risk for developing type 2 diabetes. 
  Shetty et al. (175) found a negative correlation between serum resistin and 
HDL, a positive correlation of serum resistin to CRP; these correlations remained 
significant after adjusting for type 2 diabetes.  The results also indicated that the 
positive association of resistin to CRP also remained significant despite adjustments 
for sex and BMI, suggesting that resistin’s proinflammatory properties may be 
independent of overall obesity.  However, resistin’s association with inflammatory 
markers appear to be independent of BMI, suggesting that resistin may have a direct 
proinflammatory role or mediate its effects via yet-to-be discovered obesity-
independent mechanism. 
  Heilbronn et al. (299) found that serum resistin concentrations were increased 
in response to supraphysiological doses of insulin in both obese and obese diabetic 
subjects.  Although the effect was modest, it suggests that resistin expression may be 
acutely regulated by insulin.  These results indicate that resistin concentrations were 
up-regulated by insulin concentration thus implying that higher fasting insulin 
concentrations should result in higher serum resistin concentrations.  That study 
however, does not support a role for resistin as a major mediator of insulin sensitivity 
in humans. 
  Stejskal et al. (300) examined differences in resistin levels among persons 
with type 2 diabetes, with systemic inflammation and healthy persons.   The study 
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found that in the healthy subjects there was a significant correlation between leptin 
and resistin; however, in individuals with type 2 diabetes no significant correlation 
was found between resistin, insulin sensitivity markers, BMI or leptin.  The 
researchers concluded that concentrations of resistin in persons with type 2 diabetes 
do not differ from concentrations of healthy subjects.  This is consistent with the 
findings of the present study.  No significant difference was found between the obese 
diabetic subjects and non-diabetic subjects at week 16 after adjusting for initial 
resistin levels. 
Effects of Weight Loss in Adiponectin Values 
  The hypothesis that obese individuals with type 2 diabetes will have a greater 
increase in plasma adiponectin compared to obese individuals without type 2 diabetes 
is reflected by the current findings of adiponectin levels.  As expected, women with 
type 2 diabetes had significantly lower adiponectin levels at the beginning of the 
study.  After adjusting for baseline there was no significant difference between 
adiponectin levels after weight loss.  An interesting point to recognize is that as 
expected, adiponectin levels increased in women with type 2 diabetes after weight 
loss, but although non-significantly, decreased in obese women without type 2 
diabetes.  These results are consistent with Monzillo et al. (182) who also found that 
adiponectin levels increased in individuals with type 2 diabetes but not in individuals 
without type 2 diabetes or who had impaired glucose intolerance without type 2 
diabetes.  Wolfe et al. (181) also found in normal, healthy weight individuals that 
adiponectin levels decreased significantly with weight loss. 
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  In a study of Pima Indians, Krafoff  et al. (301) examined the relationship of 
adiponectin to a variety of markers of inflammation and endothelial dysfunction and 
assessed the relationship of these markers to a later incidence of diabetes.  This 
research provided further in vivo evidence that adiponectin concentrations correlated 
with markers of inflammation and endothelial dysfunction (170).  They concluded 
that adiponectin is negatively correlated with markers of inflammation in vivo.  
Moreover, once adiposity is taken into account, these other markers have little or no 
predictive value for the development of diabetes.  Thus, adiponectin may be an 
important link between adiposity and inflammation and type 2 diabetes.   Stejskal et 
al. (302) conducted a study consisting of 109 persons with type 2 diabetes and 
concluded that individuals with type 2 diabetes have lower adiponectin concentrations 
in serum than patients with a high risk of atherosclerotic complications without type 2 
diabetes.  These researchers also concluded that adiponectin may be a novel marker 
of metabolic control in persons with a high risk of cardiovascular complications of 
atherosclerosis. 
  Shetty et al. (175) found that adiponectin’s association with HDL and PAI-1 
was independent of BMI, which suggests adiponectin may mediate some effects of 
adiposity, but whether central obesity or other unrecognized pathways might play a 
regulatory role remains to be seen.  They found that in subjects with diabetes or who 
are at risk of developing diabetes, adiponectin is negatively correlated with BMI, 
triglycerides, CRP, PAI-1 and tPA, suggesting that adiponectin may act as an anti-
inflammatory mediator with respect to CRP, PAI-1 and tPA.  These findings are 
consistent with prior data that adiponectin levels correlate negatively with 
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inflammation and endothelial dysfunction (303).  Shetty et al. (175)were the first to 
find a negative correlation with adiponectin to PAI-1, which is also associated with 
insulin resistance and the metabolic syndrome (304).  This provides another possible 
mode for adiponectin in affecting the metabolic syndrome-induced morbidity and 
mortality. 
  Satoh et al. (305) found that the ratio of leptin-to-adiponectin may be a 
potential atherogenic index in obese type 2 diabetic patients.  These researchers 
compared 98 non-obese individuals with type 2 diabetes to 60 obese individuals with 
type 2 diabetes to see if there were differences in predicting atherosclerosis between 
the groups.  These researchers found that obese individuals with type 2 diabetes have 
significantly higher leptin-to-adiponectin ratios then the non-obese type 2 diabetic 
subjects.  In the present study no significant difference was found in leptin-to-
adiponectin ratios between the obese women with or without type 2 diabetes at any 
time point; however, ratios of leptin-to-adiponectin significantly decreased for both 
groups with weight loss.  An interesting finding is that of the 30 obese females Satoh 
et al.(305) analyzed, in individuals with a BMI of 27.4 kg/m2 + 0.35, the leptin-to-
adiponectin ratio was 2.59 + 0.20.  This is very close to the results in both the non-
diabetic and diabetic subjects in the present study after 16 week of weight loss.  Non-
diabetics had a BMI of 30.1 kg/m2 and had a leptin-to-adiponectin ratio of 2.6 + 0.6, 
while diabetic subjects with a BMI of 33.0 kg/m2 had a ratio 4.0 + 0.5. 
Effects of Weight Loss in Lipid Levels and Blood Pressure 
  The fact that total cholesterol, LDL-cholesterol and triglycerides decrease 
with weight loss is established and systematically reduces an individual’s risk for 
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coronary heart disease (224;306;307).  Anderson and Konz (25) concluded that for 
every 1 kg reduction in body weight, serum total cholesterol will decrease by 0.99% 
or 2.28 mg/dl, LDL-cholesterol will decrease by approximately 0.68% or 0.91 mg/dl, 
and triglycerides will decrease by 1.93% or 1.54 mg/dl.  Weight loss also often 
decreases HDL-cholesterol levels in women (308).  In the present study reductions in 
serum total cholesterol and triglyceride values were seen in both non-diabetic and 
diabetic subjects.  LDL-cholesterol values decreased in the non-diabetic subjects but 
increased in the diabetic subjects.  This occurrence is explained by reporting that in 
several individuals, LDL-cholesterol raised dramatically.  This was most likely due to 
release of fatty acids from adipose tissue and lack of LDL-receptors on the liver to 
clear the excess fatty acids from the blood stream.   
  It is recognized that in approximately 85 percent of individuals with 
hypertension, blood pressure decreases in a linear fashion with weight loss (306).  
The present study did not find any changes in systolic or diastolic blood pressure 
measurements.  This is due to both non-diabetic and diabetic individuals being 
excluded if they had uncontrolled hypertension.  Some subjects were on medications 
to control hypertension but after weight loss the medications were either lowered or 
discontinued. 
Follicle-Stimulating Hormone Analysis 
  Female sex steroid hormone concentrations regulate adipose tissue mass 
(309).  Menopausal status can be a determinant of body composition changes in 
women, predominantly in an increase in visceral fat mass, particularly in the abdomen 
(310).  It has also been postulated that changes in sex hormones may also be caused 
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by an indirect mechanism related to insulin resistance (310).  To eliminate 
menopausal and sex hormone concentrations as confounding variable in the present 
study, follicle-stimulating hormone levels were measured. 
  The population in the present study consisted predominantly of post-
menopausal women.  Normal FSH levels are considered to be within the range of 3 to 
10 mIU/ml.  Basal FSH levels generally rise in the third decade of life through the 
first few years after menopause due to physiologic and biochemical changes that 
reduce negative feedback controls on FSH production.  Menopause is associated with 
substantially increased FSH levels, usually greater than 40 mIU/ml (311).  However, 
in perimenopausal women the absolute value cannot be relied upon to establish the 
true onset of menopause (312;313).  In the present study, non-diabetic subjects at 
baseline had FSH levels of 42.9 mIU/ml and diabetic subjects had levels of 26.4 
mIU/ml, indicating that the majority of the subjects were either perimenopausal or 
menopausal.  After analysis of the present FSH levels there was no significant 
difference between non-diabetic and diabetic subjects at any point throughout the 
study, indicating that FSH levels could not explain body composition differences 
between the two groups.  FSH levels increased in both groups with weight loss.  One 
could suppose that FSH levels would decrease with weight loss indicating improved 
fertility status.  A possible explanation for FSH levels increasing in the present study 
could be due to metabolic and biochemical changes that occur with menopause; 
additional changes in their body composition were not able to compensate for their 
age and natural progression of menopause.   
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Study Limitations 
  It is recognized that there are several limitations to this study that could be 
addressed in future.  The first and primary limitation is the sample size.  The sample 
size was calculated to include 25 subjects with type 2 diabetes and 25 subjects 
without type 2 diabetes to allow a 20% attrition rate.  This means that 20 subjects in 
both groups needed to complete the study to meet the sample size calculations.  Some 
of the results were approaching significance and may have become significant if 
enough subjects were recruited for the study.  The sample size was not met due to 
financial and resource limitations on the part of HMR®. 
  The second limitation is controlling study subjects medication use.  The 
primary importance of this was a subject’s use of non-steroidal anti-inflammatory 
drugs (NSAIDs).  During the phone screen and during the initial screening visit, it 
was stressed to potential study participants that chronic use of anti-inflammatory 
medications was not allowed during the study.  However, approximately half of the 
study participants reported use of NSAIDs to the nurses at the HMR® program.  For 
any clinical study dealing with individuals on an outpatient basis, it is understood to 
contain variables that are uncontrollable by the principal investigator and research 
team.  The results of the study would have been stronger if the study subjects’ use of 
anti-inflammatory, hypertension and hyperlipidemia medications were better 
controlled.   
  The third limitation to the study regards determining if individuals with type 2 
diabetes have a more difficult time losing weight than individuals without type 2 
diabetes; a weight loss protocol in which more individuals in the general population 
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could participate would have been beneficial.  This study was able to find that 
medically-supervised programs were safe and effective for individuals with type 2 
diabetes but does not explain why under “normal” dieting experiences individuals 
often do not lose much weight.  A study consisting of a reduced-calorie diet and meal 
replacements along with encouraged physical activity and record keeping would be 
better suited to determine this hypothesis.  Many individuals are not able to 
participate in medically-supervised weight loss programs due to location or cost.  
Instead, providing a reduced-calorie diet with meal replacements could be 
implemented so that issues of cost or location of a diet program is not a deterring 
factor for individuals to partake in a weight loss program.  
  Another limitation is that many of the outcome measurements were 
significantly different between the groups from the outset.  Subjects were matched for 
BMI and age, but there were significant differences in initial body weight and 
amounts of abdominal fat.  In a flawless study there would not have been any 
variations in the groups prior to weight loss.  However, with the limits of time and 
financial resources it was not feasible to recruit individuals and match every outcome 
parameter. 
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CHAPTER SIX 
Overall Summary and Conclusion 
   
  With the increasing prevalence of obesity throughout the world, type 2 
diabetes mellitus is dramatically rising as well.  Type 2 diabetes is a leading 
contributor to the risk of coronary heart disease, kidney disease, blindness, stroke, 
peripheral vascular disease and neuropathy (8).  It is of utmost importance in our 
society to decrease morbidity and mortality in these individuals and to increase their 
quality of life. 
  The purpose of this study was to evaluate adherence to a medically-supervised 
LED weight loss program and changes in body composition and metabolic 
parameters after weight loss in women with and without type 2 diabetes.  Previous 
studies have investigated the effects of weight loss on changes in body composition, 
adipose tissue hormones, and cytokines in obese individuals, but none has directly 
compared differences in non-diabetic and diabetic subjects undergoing a medically-
supervised low-energy diet weight loss program (HMR®).   It is known that 
individuals with type 2 diabetes often have a more difficult time losing weight.  The 
important question is if individuals with type 2 diabetes have a greater difficulty in 
behavioral and environmental cues to lose weight or if metabolic and biochemical 
adaptations occur in these individuals, making them metabolically dysfunctional to 
lose weight. 
  Vijan et al. (314) surveyed and conducted focus groups in suburban and urban 
individuals with type 2 diabetes to evaluate barriers against adherence to following 
dietary recommendations in this patient population.  Overall, these patients seemed 
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more likely to cooperate with pharmaceutical diabetes management than with self-
care behaviors such as dietary modification or home glucose monitoring. The patients 
stated that even moderate dietary modifications were more cumbersome than taking 
anti-diabetic oral agents.  An even stricter diet that promotes weight loss and thus 
likely to lead to more substantial benefits was seen as having a burden similar to that 
of twice-daily insulin injections. The cost of a diabetes diet was also barrier 
mentioned in these focus groups.  In the present study, both non-diabetic and diabetic 
women who completed the 16-week medically-supervised LED weight loss program 
successfully lost weight.  Non-diabetics subject lost 15.4 kg resulting in a 16% 
decrease in body weight and diabetic subjects lost 12.2 kg resulting in an 11.7% 
decrease in body weight.  However, diabetic women in the study were more likely to 
drop from the weight loss program and once these women were included in the 
analysis (intention-to-treat analysis), diabetic subjects overall did not lose as much 
weight as non-diabetic subjects.  There are several possible reasons for these results.  
It is known that in individuals with type 2 diabetes adherence rates to diet and 
exercise are low (315-318).  Many factors that may influence dietary adherence 
include personal motivation (319), holidays and other social gatherings (177;319), 
scheduling issues (319), cravings to eat inappropriate foods (177), lack of family 
support (177), perceived high cost of the diet (320), and displeasure at eating the 
recommended foods (320).  The subjects in the present study underwent a highly 
rigorous medically-supervised LED weight loss program and thus the women with 
type 2 diabetes may have had a more difficult time following the diet. 
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  The next question related to possible differences in body composition and 
metabolic variations between the diabetic and non-diabetic women, which may 
explain differences in how diabetic and non-diabetic individuals lose weight.  First, 
although the measurements of the DEXA and BOD POD® varied, overall results 
indicated that the diabetic women had more lean tissue than the non-diabetic women.  
The higher levels of lean tissue may be related to the insulin resistant state and 
impaired glucose and fatty acids by skeletal muscle in type 2 diabetes.  The women 
with type 2 diabetes also lost less percent body fat and total body fat mass than the 
women without type 2 diabetes.  More significantly is where, and what type of body 
fat was decreased in these subjects.  It has been well established that abdominal 
obesity increases the risk of type 2 diabetes (1;29;56-58).  In the present study, prior 
to weight loss there was no difference between the diabetic and non-diabetic women 
in waist circumference.  However, non-diabetic women decreased their waist 
circumferences significantly more than diabetic women.  Although there was no 
significant difference in the amount of visceral and subcutaneous fat loss after initial 
adjustment for baseline values it is still important to note that diabetic women had a 
significantly greater amount of absolute abdominal visceral fat mass than the non-
diabetic women before and after equivalent amounts of weight loss.  Visceral fat has 
been shown to be associated with a decrease in insulin sensitivity (252).  The higher 
amounts of insulin may be one of the key initial stimuli for the metabolic disruptions 
found in obesity causing the increased risk for the other co-morbid diseases 
associated with obesity and type 2 diabetes mellitus. 
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  Although the changes in insulin and insulin sensitivity (determined by 
HOMA-IR) overtime were not significantly different between the two groups in the 
present study, diabetic individuals still had higher insulin levels and higher insulin 
resistance than their obese counterparts, despite losing weight.  Insulin is thought to 
increase several stomach and adipose tissue hormones and cytokines causing 
increased inflammation and thrombotic events in this population, as was in the 
present study.  The production of the adipose tissue derived hormone leptin increases 
in the presence of higher serum insulin levels.  After weight loss leptin levels were 
still consistently higher in the diabetic subjects than in the non-diabetic subjects.  The 
stomach derived hormone, ghrelin, is also inversely related to insulin resistance and 
visceral adipose tissue accumulation is believed to down-regulate ghrelin (254).  The 
excess of visceral adipose tissue in the diabetic women even after weight loss would 
explain why ghrelin levels were lower after weight loss in these women than in the 
non-diabetic women. 
  The risk of coronary heart disease is increased by proinflammatory and 
prothrombotic cytokines such as TNF-α, IL-6, CRP, and PAI-1.  Although there were 
no significant changes in the present study, the proinflammatory cytokines, TNF-α, 
IL-6 and CRP increase with greater serum insulin levels.  These cytokines are known 
to up-regulate and down-regulate each other and most likely play an additional role in 
this complex system of body fat accumulation and mobilization.  The prothrombotic 
protein PAI-1 plays a key role in the pathogenesis of myocardial infarction, stroke, 
and other vascular events (137-140) and is increased with insulin resistance and type 
2 diabetes.  In the present study, PAI-1 levels decreased in both diabetic and non-
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diabetic women.  Although not statistically significant, PAI-1 levels were higher in 
diabetic women than non-diabetic women after weight loss.  These results indicate 
that even though diabetic subjects decreased PAI-1 levels with weight loss, they were 
still at a greater risk of cardiovascular disease than the non-diabetic women. 
  Resistin and adiponectin are recently studied adipose tissue derived hormones, 
believed to play a role in insulin resistance and either promote cardiovascular risk 
factors, as in the case of resistin, or have anti-inflammatory properties and reduce the 
risk of cardiovascular disease, as with adiponectin.  Adiponectin levels were 
significantly lower in the diabetic subjects at baseline and increased with weight loss, 
demonstrating an improvement in cardiovascular disease risk.  These results were 
consistent with findings of Monzillo et al.(182).  There was non-significant reduction 
in adiponectin levels in the non-diabetic women after weight loss.   Although these 
results were non-significant, Wolfe et al.(181) also found that in normal, healthy 
weight individuals’ adiponectin levels decreased significantly with weight loss.  In 
the present study, we may have seen this as well with a larger study population.  
These results may be due to a decrease in adiposity and not reflect an increase in 
cardiovascular disease risk.  It has been proposed that resistin increases in individuals 
with type 2 diabetes and is a potential link between obesity and insulin resistance.  In 
the present study resistin levels were significantly greater in diabetic women than 
non-diabetic women.  However, resistin levels did not decrease in either group with 
weight loss.  This data are consistent with Steppan and colleagues (178), but this 
theory is still controversial. 
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  Overall, the results of the present study found that medically-supervised LED 
weight loss programs are safe and effective for treating obesity in individuals with 
type 2 diabetes.  Lipid profiles and cardiovascular risk factors improved in both non-
diabetic and diabetic subjects with weight loss.  The findings also suggest that insulin 
may play a critical role in the complex axis affecting changes in body composition 
and inflammation in individuals with type 2 diabetes.  Further research should focus 
on the effects of body composition, adipose tissue hormones, and inflammatory 
cytokines in levels of insulin control of individuals with type 2 diabetes mellitus. 
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Patient Screening Information 
 
Subject 
Number Category Enrolled Randomized Age BMI Screen Date Comments
001 NonDM Yes HMR 55 38.5 1/21/2003
002 DM No No 46 33 1/28/2003 Couldn't follow diet
003 DM Yes HMR 55 44.5 1/28/2003
004 DM Yes HMR 43 44.6 2/21/2003
005 NonDM Yes HMR 50 30.6 3/4/2003
006 DM No No 46 48 3/11/2003 >BMI
006 DM No No 54 43 3/18/2003 Graves Disease
007 DM Yes HMR 52 39 4/4/2003
008 DM Yes HMR 54 32.5 4/24/2003
009 DM Yes HMR 61 41.5 5/6/2003
010 DM Yes HMR 54 35.5 5/8/2003
011 DM No No 41 36.5 5/9/2003 Type 1.5 Diabetes
012 DM Yes HMR 48 34.5 5/12/2003
013 NonDM Yes HMR 51 36 6/6/2003
014 DM Yes HMR 58 38 6/11/2003
015 DM Yes HMR 52 33.5 6/12/2003
016 NonDM Yes No 43 44.5 6/13/2003
017 DM Yes HMR 54 32 7/7/2003
018 DM Yes HMR 53 35 7/18/2003
019 NonDM No No 49 38 7/21/2003 Metabolic Syndrome
020 DM Yes HMR 58 45 7/28/2003
021 DM Yes No 54 41 7/25/2003
022 DM No No 53 36 8/1/2003 Need to increase HbA1c
023 DM Yes HMR 41 38.5 8/6/2003
024 NonDM Yes HMR 53 32 9/3/2003
025 DM Yes HMR 64 36 9/4/2003
026 NonDM Yes HMR 52 31.7 10/17/2003
027 NonDM No HMR 40 43 11/20/2003 Hypothyroidism
028 NonDM Yes HMR 40 42 12/15/2003
029 NonDM Yes HMR 55 39.5 12/16/2003
030 DM Yes HMR 57 42.5 2/25/2004
031 DM Yes HMR 48 36 3/2/2004
032 NonDM Yes HMR 52 39 3/25/2004
033 NonDM Yes HMR 57 38.6 3/30/2004
034 DM Yes HMR 60 43.8 3/31/2004
035 NonDM No No 59 40 4/1/2004 Prediabetic
036 DM Yes HMR 51 37.2 4/14/2004
037 NonDM Yes HMR 51 32.2 4/28/2004
038 DM Yes HMR 44 34.7 5/10/2004
039 DM Yes HMR 57 39.1 5/18/2004
040 NonDM Yes HMR 40 36.6 5/19/2004
041 DM Yes HMR 41 40.5 5/20/2004  
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Non-Diabetic Subjects weight in kg 
 
 
Non-Diabetic Subjects
Pt. # Screen Wk1 Wk2 Wk3 Wk4 Wk5 Wk6 Wk7 Wk8 Wk9 Wk10 Wk11 Wk12 Wk13 Wk14 Wk15 Wk16
001 103.2 101.8 100.9 100.5 99.8 99.3 98.0 98.9 95.7 95.5 94.5 93.2 92.7 91.8 91.8 89.8 90.7
005 73.5 71.6 70.7 69.8 69.1 68.9 68.0 68.0 66.4 65.7 65.5 64.8 63.9 63.6 63.4 62.7 62.5
013 95.0 92.7 91.8 91.1 90.0 89.8 88.6 88.4 87.3 86.4 85.5 84.8 84.1 83.4 82.7 82.0 81.6
024 98.5 95.9 94.1 92.7 91.4 90.0 88.6 87.5 85.9 85.9 82.3 80.7 79.5 78.6 78.2 76.6 74.5
026 78.7 84.3 83.2 81.6 80.5 79.8 77.7 76.8 75.0 75.5 73.0 72.3 71.4 70.5 69.5 69.1 68.0
028 117.5 118.9 115.9 115.0 113.4 111.8 110.5 108.0 107.0 106.4 103.9 103.2 100.9 100.9 98.9 96.8 95.9
029 101.1 99.8 99.1 97.3 97.0 94.8 94.5 92.3 92.7 91.1 90.2 89.1 88.0 86.8 86.6 86.4 85.2
032 103.5 105.2 103.6 102.7 101.4 100.7 99.3 98.0 97.3 94.8 95.2 94.5 93.2 93.6 93.0 92.3 91.4
033 105.1 101.8 100.2 98.4 97.5 96.1 94.8 93.9 93.2 91.8 90.7 90.5 88.9 88.9 88.0 87.0 86.4
037 81.1 80.2 78.4 77.0 75.7 74.5 72.7 71.8 71.6 70.9 69.8 69.1 68.4 67.7 67.5 65.9 65.5
040 102.7 98.9 97.5 95.2 93.9 92.3 91.1 90.5 88.6 87.3 86.1 85.5 84.1 84.1 83.0 80.5 80.7
Average 96.4 95.6 94.1 92.9 91.8 90.7 89.4 88.5 87.3 86.5 85.1 84.3 83.2 82.7 82.0 80.8 80.2
Count 11.0 11.0 11.0 11.0 11.0 11.0 11.0 11.0 11.0 11.0 11.0 11.0 11.0 11.0 11.0 11.0 11.0
SD 13.3 13.0 12.7 12.7 12.6 12.4 12.4 12.1 12.1 11.8 11.7 11.7 11.4 11.6 11.3 11.2 11.2
SE 4.0 3.9 3.8 3.8 3.8 3.7 3.8 3.6 3.6 3.6 3.5 3.5 3.4 3.5 3.4 3.4 3.4
95% LCI 88.5 87.9 86.6 85.3 84.3 83.4 82.1 81.4 80.2 79.5 78.2 77.4 76.4 75.9 75.3 74.2 73.6
95% UCI 104.2 103.2 101.6 100.4 99.2 98.0 96.8 95.7 94.5 93.4 92.1 91.2 89.9 89.6 88.7 87.4 86.8
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Diabetic subjects weight in kg (WD = withdrew) 
 
Diabetic Subjects
Pt. # Screen Wk1 Wk2 Wk3 Wk4 Wk5 Wk6 Wk7 Wk8 Wk9 Wk10 Wk11 Wk12 Wk13 Wk14 Wk15 Wk16
003 122.2 120.7 121.1 118.4 116.8 115.9 113.9 113.2 112.3 111.6 110.5 110.0 108.9 108.0 108.0 107.3 108.0
004 110.7 110.7 109.1 108.4 107.5 107.1 105.5 104.6 102.1 103.0 102.3 WD
007 115.5 111.8 110.2 109.3 107.7 106.4 104.8 103.4 100.9 99.1 98.6 97.0 96.4 94.5 93.4 93.0 91.8
008 95.7 101.1 100.0 100.7 98.0 96.1 95.7 95.7 94.1 93.6 93.2 93.2 93.0 92.7 92.7 93.4 93.4
009 112.1 108.0 107.7 105.7 105.5 103.4 103.2 103.4 102.7 102.0 100.2 100.0 99.1 100.0 97.7 96.8 99.1
010 100.6 97.7 96.6 95.9 95.9 94.8 93.6 93.2 92.1 92.1 90.7 90.7 91.1 WD
012 76.6 74.3 73.6 73.2 71.8 71.4 71.4 71.1 70.0 69.3 69.8 68.6 69.1 69.1 69.8 70.0 70.0
014 103.2 101.8 101.4 100.2 98.9 97.3 96.1 94.5 93.9 93.2 92.3 92.0 90.7 90.7 90.0 89.1 88.6
015 82.9 81.6 80.0 80.5 78.6 78.6 77.5 78.2 WD
017 88.6 84.1 83.6 84.1 81.6 83.0 80.5 79.1 77.0 78.0 77.0 75.9 75.0 73.9 73.0 73.0 71.8
018 97.1 96.4 95.2 94.3 93.0 91.8 90.5 88.0 87.3 86.1 84.3 83.6 83.2 82.5 80.2 78.6 77.3
020 98.9 95.2 95.2 93.4 94.1 93.6 92.3 92.6 93.0 93.0 93.5 93.9 93.3 92.7 92.7 92.7 92.7
023 111.1 111.4 109.5 108.9 108.2 106.4 106.8 105.2 103.4 103.4 102.7 102.0 101.1 101.1 101.1 100.7 100.0
025 98.2 95.0 95.0 92.5 93.0 91.6 89.3 89.1 88.0 88.0 87.5 85.7 86.1 85.9 86.6 87.3 85.5
030 122.9 119.8 118.2 116.6 116.1 115.2 114.1 113.9 111.4 110.9 110.7 110.7 108.9 108.6 107.3 106.6 106.8
031 114.1 113.4 112.3 112.0 114.5 112.0 112.5 111.6 110.5 109.8 111.6 109.8 109.5 110.5 108.9 110.0 109.1
034 115.6 112.7 110.7 108.9 107.5 106.1 105.2 103.0 101.8 100.2 99.1 97.7 95.7 95.7 93.6 93.2 92.3
036 98.1 96.6 95.2 94.1 92.0 91.1 90.2 89.5 90.2 89.3 88.4 88.6 88.2 87.5 87.3 87.0 87.3
038 101.9 98.9 98.0 96.6 95.0 93.4 93.2 91.6 90.9 89.8 88.6 88.0 86.6 86.6 84.8 85.7 84.1
039 106.8 105.7 103.4 102.7 101.6 99.8 98.6 97.0 95.5 94.8 93.4 92.5 91.4 90.9 89.1 87.7 86.8
041 122.5 119.1 116.1 115.5 113.9 113.9 112.0 108.2 108.2 105.7 103.9 103.0 101.6 101.6 101.6 101.6 101.6
Average 104.5 102.7 101.5 100.6 99.6 98.5 97.5 96.5 96.3 95.6 94.9 93.8 93.1 92.9 92.1 91.9 91.5
Count 21 21 21 21 21 21 21 21 20 20 20 19 19 18 18 18 18
SD 12.7 12.6 12.4 12.0 12.4 12.0 12.0 11.7 11.1 10.8 10.9 11.1 10.8 11.2 11.1 11.1 11.5
SE 2.8 2.8 2.7 2.6 2.7 2.6 2.6 2.6 2.5 2.4 2.4 2.5 2.5 2.7 2.6 2.6 2.7
95% LCI 97.2 96.1 95.3 94.4 93.2 92.3 91.3 91.3 90.8 90.2 89.1 88.1 88.1 86.9 86.7 86.3 -5.3
95% UCI 110.0 108.1 106.8 105.7 104.9 103.6 102.6 101.5 101.1 100.4 99.7 98.8 97.9 98.1 97.2 97.0 96.8
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Percent Weight Loss and Change in kg for Non-Diabetic and Diabetic Completed and 
ITT Subjects.  ITT (Intention-To-Treat) Indicates Last Weight Change Carried 
Forward for All Study Participants. (WD = withdrew) 
Non-Diabetic Subjects
Pt. #
Scrn 
Wt Wk 1 Wk 4 Chg
% 
Chg Wk 8 Chg
% 
Chg Wk 12 Chg % Chg Wk 16 Chg
ITT 
Chg % Chg
ITT    
% Chg
001 103.2 101.8 99.8 -2.0 -2.0 95.7 -6.1 -6.0 92.7 -9.1 -8.9 90.7 -11.1 -11.1 -10.9 -10.9
005 73.5 71.6 69.1 -2.5 -3.5 66.4 -5.2 -7.3 63.9 -7.7 -10.8 62.5 -9.1 -9.1 -12.7 -12.7
013 95.0 92.7 90.0 -2.7 -2.9 87.3 -5.5 -5.9 84.1 -8.6 -9.3 81.6 -11.1 -11.1 -12.0 -12.0
024 98.5 95.9 91.4 -4.5 -4.7 85.9 -10.0 -10.4 79.5 -16.4 -17.1 74.5 -21.4 -21.4 -22.3 -22.3
026 78.7 84.3 80.5 -3.9 -4.6 75.0 -9.3 -11.1 71.4 -13.0 -15.4 68.0 -16.4 -16.4 -19.4 -19.4
028 117.5 118.9 113.4 -5.5 -4.6 107.0 -11.8 -9.9 100.9 -18.0 -15.1 95.9 -23.0 -23.0 -19.3 -19.3
029 101.1 99.8 97.0 -2.7 -2.7 92.7 -7.0 -7.1 88.0 -11.8 -11.8 85.2 -14.5 -14.5 -14.6 -14.6
032 103.5 105.2 101.4 -3.9 -3.7 97.3 -8.0 -7.6 93.2 -12.0 -11.4 91.4 -13.9 -13.9 -13.2 -13.2
033 105.1 101.8 97.5 -4.3 -4.2 93.2 -8.6 -8.5 88.9 -13.0 -12.7 86.4 -15.5 -15.5 -15.2 -15.2
037 81.1 80.2 75.7 -4.5 -5.7 71.6 -8.6 -10.8 68.4 -11.8 -14.7 65.5 -14.8 -14.8 -18.4 -18.4
040 102.7 98.9 93.9 -5.0 -5.1 88.6 -10.2 -10.3 84.1 -14.8 -14.9 80.7 -18.2 -18.2 -18.4 -18.4
Average 96.4 95.6 91.8 -3.8 -4.0 87.3 -8.2 -8.6 83.2 -12.4 -12.9 80.2 -15.4 -15.4 -16.0 -16.0
Count 11.0 11.0 11.0 11.0 11.0 11.0 11.0 11.0 11.0 11.0 11.0 11.0 11.0 11.0 11.0 11.0
SD 13.3 13.0 12.6 1.1 1.1 12.1 2.1 2.0 11.4 3.2 2.7 11.2 4.3 4.3 3.7 3.7
SE 4.0 3.9 3.8 0.3 0.3 3.6 0.6 0.6 3.4 1.0 0.8 3.4 1.3 1.3 1.1 1.1
95% LCI 88.5 87.9 84.3 -4.4 -4.6 80.2 -9.5 -9.8 76.4 -14.2 -14.5 73.6 -17.9 -17.9 -18.2 -18.2
95% UCI 104.2 103.2 99.2 -3.1 -3.3 94.5 -7.0 -7.5 89.9 -10.5 -11.3 86.8 -12.8 -12.8 -13.8 -13.8
Diabetic Subjects
003 122.2 120.7 116.8 -3.9 -3.2 112.3 -8.4 -7.0 108.9 -11.8 -9.8 108.0 -12.7 -12.7 -10.5 -10.5
004 110.7 110.7 107.5 -3.2 -2.9 102.1 -8.6 -7.8 102.3 -8.4 -7.6 WD -8.4 -7.6
007 115.5 111.8 107.7 -4.1 -3.7 100.9 -10.9 -9.8 96.4 -15.5 -13.8 91.8 -20.0 -20.0 -17.9 -17.9
008 95.7 101.1 98.0 -3.2 -3.1 94.1 -7.0 -7.0 93.0 -8.2 -8.1 93.4 -7.7 -7.7 -7.6 -7.6
009 112.1 108.0 105.5 -2.5 -2.3 102.7 -5.2 -4.8 99.1 -8.9 -8.2 99.1 -8.9 -8.9 -8.2 -8.2
010 100.6 97.7 95.9 -1.8 -1.8 92.1 -5.6 -5.7 91.1 -6.6 -6.8 WD -6.6 -6.8
012 76.6 74.3 71.8 -2.5 -3.4 70.0 -4.3 -5.8 69.1 -5.2 -7.0 70.0 -4.3 -4.3 -5.8 -5.8
014 103.2 101.8 98.9 -3.0 -2.9 93.9 -8.0 -7.8 90.7 -11.1 -10.9 88.6 -13.2 -13.2 -12.9 -12.9
015 82.9 81.6 78.6 -3.0 -3.7 78.2 -3.4 -4.2 WD -3.4 -4.2
017 88.6 84.1 81.6 -2.5 -3.0 77.0 -7.0 -8.4 75.0 -9.1 -10.8 71.8 -12.3 -12.3 -14.6 -14.6
018 97.1 96.4 93.0 -3.4 -3.5 87.3 -9.1 -9.4 83.2 -13.2 -13.7 77.3 -19.1 -19.1 -19.8 -19.8
020 98.9 95.2 94.1 -1.1 -1.2 93.0 -2.3 -2.4 93.3 -1.9 -2.0 92.7 -2.5 -2.5 -2.6 -2.6
023 111.1 111.4 108.2 -3.2 -2.9 103.4 -8.0 -7.1 101.1 -10.2 -9.2 100.0 -11.4 -11.4 -10.2 -10.2
025 98.2 95.0 93.0 -2.0 -2.2 88.0 -7.0 -7.4 86.1 -8.9 -9.3 85.5 -9.5 -9.5 -10.0 -10.0
030 122.9 119.8 116.1 -3.6 -3.0 111.4 -8.4 -7.0 108.9 -10.9 -9.1 106.8 -13.0 -13.0 -10.8 -10.8
031 114.1 113.4 114.5 1.1 1.0 110.5 -3.0 -2.6 109.5 -3.9 -3.4 109.1 -4.3 -4.3 -3.8 -3.8
034 115.6 112.7 107.5 -5.2 -4.6 101.8 -10.9 -9.7 95.7 -17.0 -15.1 92.3 -20.5 -20.5 -18.1 -18.1
036 98.1 96.6 92.0 -4.5 -4.7 90.2 -6.4 -6.6 88.2 -8.4 -8.7 87.3 -9.3 -9.3 -9.6 -9.6
038 101.9 98.9 95.0 -3.9 -3.9 90.9 -8.0 -8.0 86.6 -12.3 -12.4 84.1 -14.8 -14.8 -14.9 -14.9
039 106.8 105.7 101.6 -4.1 -3.9 95.5 -10.2 -9.7 91.4 -14.3 -13.5 86.8 -18.9 -18.9 -17.8 -17.8
041 122.5 119.1 113.9 -5.2 -4.4 108.2 -10.9 -9.2 101.6 -17.5 -14.7 101.6 -17.5 -17.5 -14.7 -14.7
Average 104.5 102.7 99.6 -3.1 -3.0 95.4 -7.3 -7.0 93.6 -10.2 -9.7 91.5 -12.2 -11.3 -11.7 -10.9
Count 21.0 21.0 21.0 21.0 21.0 21.0 21.0 21.0 20.0 20.0 20.0 18.0 18.0 21.0 18.0 21.0
SD 12.7 12.6 12.4 1.4 1.3 11.5 2.6 2.2 10.7 4.1 3.5 11.5 5.5 5.6 5.0 5.1
SE 2.8 2.8 2.7 0.3 0.3 2.5 0.6 0.5 2.4 0.9 0.8 2.7 1.3 1.2 1.2 1.1
95% LCI 97.2 94.2 -8.4 -3.6 94.9 -12.2 -8.1 92.6 -14.8 -11.5 89.9 -17.5 -14.2 -13.3 -13.2 -2.2
95% UCI 110.0 108.1 104.9 -2.5 -2.5 100.3 -6.2 -6.1 98.2 -8.4 -8.2 96.8 -9.6 -8.9 -9.4 -8.7
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Change and Percent Change in BMI (kg/m2) for Non-Diabetic and Diabetic Subjects. 
(WD = withdrew) 
Non-Diabetic Subjects
Pt. #
Screen 
BMI Final BMI Chg BMI %Chg
001 39.0 34.3 4.7 -12.1
005 30.6 26.0 4.6 -14.9
013 35.9 30.9 5.1 -14.1
024 31.2 23.6 7.6 -24.4
026 31.7 27.4 4.3 -13.7
028 43.1 35.2 7.9 -18.4
029 39.5 33.3 6.2 -15.7
032 39.2 34.6 4.6 -11.8
033 38.6 31.7 6.9 -17.8
037 32.2 26.0 6.2 -19.3
040 36.6 28.7 7.8 -21.5
Average 36.1 30.1 6.0 -16.7
Count 11.0 11.0 11.0 11.0
SD 4.2 4.0 1.4 4.0
SE 1.3 1.2 0.4 1.2
95% LCI 33.7 27.8 5.2 -19.0
95% UCI 38.6 32.5 6.8 -14.4
Diabetic Subjects
003 44.8 39.6 5.2 -11.6
004 44.6 WD
007 41.1 32.7 8.4 -20.5
008 31.6 30.9 0.8 -2.4
009 39.9 35.3 4.6 -11.6
010 35.5 WD
012 33.0 30.1 2.8 -8.6
014 39.0 33.5 5.5 -14.1
015 33.5 WD
017 32.0 25.9 6.1 -19.0
018 34.5 27.5 7.1 -20.4
020 41.2 38.6 2.6 -6.2
023 38.4 34.5 3.8 -10.0
025 36.0 31.4 4.7 -13.0
030 42.4 36.9 5.6 -13.1
031 36.1 34.5 1.6 -4.4
034 43.8 34.9 8.8 -20.2
036 37.1 33.0 4.1 -11.0
038 34.7 28.6 6.1 -17.5
039 39.2 31.9 7.3 -18.7
041 40.5 33.6 6.9 -17.1
Average 38.0 33.0 5.1 -13.3
Count 21.0 18.0 18.0 18.0
SD 4.1 3.6 2.2 5.6
SE 0.9 0.8 0.5 1.3
95% LCI 36.3 31.3 4.1 -15.9
95% UCI 38.1 33.0 5.1 -13.3  
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Total Percent Body Fat Determined by DEXA. 
 
Non-Diabetic Subjects
Pt #
DEXA % Total 
Fat Wk0 Wk8 Chg Wk16 Chg
001 50.8 47.1 -3.7 45.2 -5.6
005 47.1 44.2 -2.9 39.9 -7.2
013 49.5 45.9 -3.6 44.8 -4.7
024 48.1 42.1 -6.0 32.3 -15.8
026 48.9 48.8 -0.1 41.4 -7.5
028 54.2 48.3 -5.9 45.9 -8.3
029 47.5 44.6 -2.9 41.2 -6.3
032 53.4 49.6 -3.8 46.6 -6.8
033 51.0 49.3 -1.7 46.9 -4.1
037 52.3 49.0 -3.3 42.3 -10.0
040 46.5 44.7 -1.8 41.6 -4.9
Average 49.9 46.7 -3.2 42.6 -7.4
Count 11.0 11.0 11.0 11.0 11.0
SD 2.6 2.5 1.7 4.2 3.3
SE 0.8 0.8 0.5 1.3 1.0
95% LCI 48.4 45.2 -4.3 40.1 -9.3
95% UCI 51.5 48.2 -2.2 45.0 -5.4
Diabetic Subjects
003 46.8 53.7 6.9 53.1 6.3
004 56.1 53.2 -2.9 WD
007 38.2 41.5 3.3 38.5 0.3
008 47.1 50.1 3.0 48.0 0.9
009 49.6 44.9 -4.7 44.9 -4.7
012 49.5 49.4 -0.1 49.3 -0.2
014 46.2 45.8 -0.4 40.4 -5.8
017 39.0 37.3 -1.7 32.6 -6.4
018 42.1 34.3 -7.8 28.1 -14.0
020 45.5 43.8 -1.7 41.8 -3.7
023 54.6 53.1 -1.5 51.0 -3.6
025 51.1 48.9 -2.2 47.0 -4.1
030 49.7 47.1 -2.6 44.1 -5.6
031 44.0 43.6 -0.4 40.3 -3.7
034 43.4 47.7 4.3 44.6 1.2
036 48.4 46.6 -1.8 44.1 -4.3
038 43.6 36.5 -7.1 31.8 -11.8
039 44.6 41.2 -3.4 36.6 -8.0
041 42.9 39.4 -3.5 34.8 -8.1
Average 46.4 45.2 -1.3 41.7 -4.2
Count 19.0 19.0 19.0 18.0 18.0
SD 4.7 5.7 3.7 7.0 4.8
SE 1.1 1.3 0.8 1.6 1.1
95% LCI 44.3 42.6 -2.9 38.5 -6.4
95%UCI 48.6 47.7 0.4 44.9 -2.0  
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Percent Trunk Fat Determined by DEXA. 
 
Non-Diabetic Subjects
Pt #
DEXA %Trunk Fat 
Wk0 Wk8 Chg Wk16 Chg
001 46.7 48.6 1.9 47.5 0.8
005 51.3 48.7 -2.6 42.6 -8.7
013 51.4 46.0 -5.4 45.4 -6.0
024 51.3 43.3 -8.0 31.0 -20.3
026 48.9 49.5 0.6 39.9 -9.0
028 56.3 50.0 -6.3 47.8 -8.5
029 47.2 42.4 -4.8 39.9 -7.3
032 54.7 50.5 -4.2 46.7 -8.0
033 52.6 49.8 -2.8 47.4 -5.2
037 54.8 51.8 -3.0 42.7 -12.1
040 48.0 46.6 -1.4 43.8 -4.2
Average 51.2 47.9 -3.3 43.2 -8.0
Count 11 11 11 11 11
SD 3.2 3.0 2.9 5.0 5.2
SE 1.0 0.9 0.9 1.5 1.6
95% LCI 49.3 46.2 -5.0 40.2 -11.1
95% UCI 53.1 49.7 -1.5 46.1 -5.0
Diabetic Subjects
003 43.1 54.9 11.8 55.0 11.9
004 56.9 52.2 -4.7 WD
007 38.8 44.9 6.1 42.2 3.4
008 47.8 52.4 4.6 50.0 2.2
009 49.9 43.9 -6.0 43.7 -6.2
012 52.8 52.6 -0.2 52.3 -0.5
014 48.5 49.1 0.6 42.5 -6.0
017 43.8 43.1 -0.7 37.9 -5.9
018 46.4 35.9 -10.5 29.0 -17.4
020 46.6 45.3 -1.3 43.4 -3.2
023 57.9 55.3 -2.6 52.6 -5.3
025 52.5 51.1 -1.4 47.8 -4.7
030 51.2 48.4 -2.8 45.3 -5.9
031 44.4 45.0 0.6 39.8 -4.6
034 40.2 49.0 8.8 46.2 6.0
036 50.8 49.3 -1.5 46.6 -4.2
038 45.1 35.2 -9.9 30.2 -14.9
039 46.3 43.1 -3.2 37.4 -8.9
041 45.0 42.3 -2.7 36.1 -8.9
Average 47.8 47.0 -0.8 43.2 -4.1
Count 19 19 19 18 18
SD 5.1 5.7 5.6 7.3 7.0
SE 1.2 1.3 1.3 1.7 1.6
95% LCI 45.5 44.4 -3.3 39.9 -7.3
95% UCI 50.1 49.6 1.7 46.6 -0.8  
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Total Body Fat in kg Determined by DEXA. 
 
Non-Diabetic Subjects
Pt # Wk0 Wk8 Chg %Chg Wk16 Chg %Chg
001 50.8 44.4 -6.5 -12.7 40.4 -10.4 -20.5
005 33.4 28.5 -4.9 -14.7 24.5 -9.0 -26.9
013 46.1 39.4 -6.7 -14.4 36.4 -9.7 -21.1
024 45.6 35.3 -10.4 -22.7 23.6 -22.0 -48.2
026 40.8 35.6 -5.2 -12.7 27.2 -13.6 -33.3
028 62.4 49.2 -13.2 -21.1 43.1 -19.4 -31.0
029 47.7 40.6 -7.1 -14.9 34.6 -13.1 -27.4
032 53.7 46.9 -6.8 -12.7 41.1 -12.6 -23.5
033 52.6 45.1 -7.5 -14.3 39.5 -13.2 -25.0
037 41.9 34.7 -7.2 -17.3 26.9 -15.0 -35.8
040 46.2 38.3 -7.8 -17.0 32.7 -13.5 -29.2
Average 47.4 39.8 -7.6 -15.9 33.6 -13.8 -29.3
Count 11 11 11 11 11 11 11
SD 7.6 6.2 2.3 3.4 7.1 3.9 7.9
SE 2.3 1.9 0.7 1.0 2.1 1.2 2.4
95% LCI 42.9 36.2 -9.0 -17.9 29.4 -16.1 -34.0
95% UCI 51.9 43.5 -6.2 -13.9 37.8 -11.5 -24.6
Diabetic Subjects
003 55.6 58.9 3.3 6.0 56.4 0.8 1.5
004 55.8 52.4 -3.4 -6.1 WD
007 41.1 34.7 -6.4 -15.6 34.7 -6.4 -15.6
008 44.6 46.1 1.5 3.5 43.8 -0.8 -1.7
009 53.0 45.1 -8.0 -15.0 43.5 -9.6 -18.0
012 36.8 33.6 -3.2 -8.7 33.0 -3.8 -10.2
014 47.7 42.3 -5.4 -11.3 35.0 -12.7 -26.6
017 33.5 28.7 -4.8 -14.3 23.2 -10.3 -30.7
018 40.3 29.4 -10.8 -26.9 21.4 -18.9 -46.9
020 44.0 39.0 -5.0 -11.4 38.7 -5.3 -12.1
023 59.3 54.0 -5.3 -8.9 50.1 -9.3 -15.6
025 49.0 42.8 -6.2 -12.6 39.8 -9.1 -18.6
030 59.8 51.8 -7.9 -13.3 46.7 -13.1 -21.9
031 49.4 46.9 -2.5 -5.1 43.6 -5.8 -11.7
034 48.6 47.9 -0.7 -1.4 39.8 -8.7 -18.0
036 47.0 40.7 -6.3 -13.4 37.5 -9.5 -20.2
038 43.6 32.6 -11.0 -25.3 26.4 -17.2 -39.5
039 46.8 38.4 -8.4 -18.0 31.5 -15.3 -32.7
041 51.0 42.2 -8.7 -17.1 34.8 -16.1 -31.7
Average 47.7 42.5 -5.2 -11.3 37.8 -9.5 -20.6
Count 19 19 19 19 18 18 18
SD 7.1 8.5 3.8 8.4 9.0 5.5 12.4
SE 1.6 1.9 0.9 1.9 2.1 1.3 2.9
95% LCI 44.5 38.7 -6.9 -15.1 33.6 -12.0 -26.3
95% UCI 50.9 46.3 -3.5 -7.5 42.0 -7.0 -14.8  
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Trunk Fat in kg Determined by DEXA. 
 
Non-Diabetic Subjects
Pt # Wk0 Wk8 Chg %Chg Wk16 Chg %Chg
001 21.6 22.0 0.4 1.9 20.6 -1.0 -4.5
005 19.0 16.0 -3.0 -15.8 13.0 -6.0 -31.4
013 25.0 19.8 -5.2 -20.8 17.8 -7.2 -28.9
024 24.7 17.9 -6.9 -27.7 10.9 -13.8 -55.8
026 20.4 17.8 -2.6 -12.7 11.6 -8.9 -43.4
028 36.9 28.2 -8.8 -23.7 23.0 -13.9 -37.7
029 23.6 18.9 -4.7 -19.9 17.3 -6.4 -26.9
032 27.0 22.8 -4.2 -15.4 19.9 -7.1 -26.1
033 26.7 22.9 -3.7 -13.9 19.5 -7.2 -26.8
037 23.4 19.1 -4.3 -18.3 13.6 -9.8 -41.9
040 23.6 18.7 -4.9 -20.6 16.5 -7.1 -30.0
Average 24.7 20.4 -4.3 -17.0 16.7 -8.0 -32.1
Count 11 11 11 11 11 11 11
SD 4.7 3.4 2.3 7.7 4.0 3.6 13.0
SE 1.4 1.0 0.7 2.3 1.2 1.1 3.9
95% LCI 21.9 18.4 -5.7 -21.5 14.4 -10.2 -39.8
95% UCI 27.5 22.4 -3.0 -12.5 19.1 -5.9 -24.5
Diabetic Subjects
003 27.5 30.3 2.8 10.1 31.3 3.8 13.9
004 27.9 24.5 -3.4 -12.2 WD
007 25.6 24.4 -1.1 -4.4 21.6 -3.9 -15.4
008 23.2 25.5 2.2 9.7 23.8 0.6 2.7
009 24.8 21.7 -3.1 -12.4 19.4 -5.4 -21.9
012 21.6 19.7 -1.9 -8.8 19.1 -2.5 -11.6
014 26.3 23.7 -2.6 -9.9 19.1 -7.2 -27.3
017 21.4 18.3 -3.1 -14.5 15.4 -6.0 -28.1
018 25.4 16.3 -9.0 -35.7 11.6 -13.8 -54.3
020 24.1 22.2 -1.8 -7.6 21.7 -2.4 -9.8
023 31.5 29.4 -2.0 -6.4 30.3 -1.2 -3.8
025 27.2 23.6 -3.6 -13.2 21.2 -6.0 -22.1
030 34.6 27.8 -6.7 -19.5 24.5 -10.1 -29.3
031 26.2 25.6 -0.6 -2.3 21.8 -4.4 -16.8
034 25.7 24.6 -1.1 -4.2 20.2 -5.5 -21.3
036 25.7 22.4 -3.4 -13.1 21.0 -4.7 -18.4
038 23.4 15.4 -8.0 -34.3 12.4 -11.0 -46.9
039 23.5 19.5 -3.9 -16.8 15.8 -7.6 -32.5
041 27.7 22.9 -4.7 -17.1 18.9 -8.7 -31.6
Average 26.0 23.0 -2.9 -11.2 20.5 -5.3 -20.8
Count 19 19 19 19 18 18 18
SD 3.2 4.0 3.0 11.5 5.1 4.2 16.3
SE 0.7 0.9 0.7 2.6 1.2 1.0 3.8
95% LCI 24.5 21.2 -4.2 -16.4 18.1 -7.3 -28.3
95% UCI 27.4 24.9 -1.6 -6.0 22.9 -3.4 -13.3  
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Total Lean Tissue in kg Determined by DEXA. 
 
Non-Diabetic Subjects
Pt # Wk0 Wk8 Chg %Chg Wk16 Chg %Chg
001 46.5 47.2 0.7 1.4 46.2 -0.2 -0.5
005 35.3 33.7 -1.6 -4.5 34.7 -0.6 -1.6
013 44.4 43.9 -0.5 -1.2 42.1 -2.4 -5.3
024 46.3 45.5 -0.8 -1.8 46.7 0.4 0.8
026 40.2 34.7 -5.5 -13.7 35.9 -4.3 -10.7
028 49.9 50.2 0.2 0.5 47.9 -2.0 -4.1
029 50.0 47.5 -2.5 -4.9 46.4 -3.5 -7.1
032 43.8 44.5 0.6 1.5 44.0 0.1 0.3
033 48.2 43.6 -4.6 -9.5 42.0 -6.2 -12.8
037 35.8 33.7 -2.1 -5.9 34.4 -1.4 -3.9
040 50.4 44.5 -5.9 -11.7 43.0 -7.3 -14.6
Average 44.6 42.6 -2.0 -4.5 42.1 -2.5 -5.4
Count 11.0 11.0 11.0 11.0 11.0 11.0 11.0
SD 5.4 5.8 2.4 5.3 5.0 2.6 5.3
SE 1.6 1.8 0.7 1.6 1.5 0.8 1.6
95% LCI 41.4 39.2 -3.4 -7.7 39.2 -4.0 -8.6
95% UCI 47.8 46.1 -0.6 -1.4 45.1 -1.0 -2.3
Diabetic Subjects
003 61.4 48.1 -13.2 -21.6 47.1 -14.2 -23.2
004 41.5 44.1 2.6 6.3 WD
007 66.9 55.4 -11.6 -17.3 52.8 -14.1 -21.1
008 46.9 42.5 -4.3 -9.3 44.3 -2.6 -5.6
009 50.5 52.1 1.6 3.1 49.6 -0.9 -1.8
012 35.7 32.6 -3.1 -8.8 31.9 -3.8 -10.7
014 53.0 47.3 -5.7 -10.8 48.9 -4.2 -7.9
017 50.0 45.6 -4.4 -8.7 45.3 -4.7 -9.3
018 52.4 53.6 1.1 2.2 51.9 -0.5 -0.9
020 50.5 47.6 -2.9 -5.7 51.5 1.0 1.9
023 46.3 44.6 -1.7 -3.6 44.9 -1.4 -2.9
025 44.3 42.0 -2.2 -5.0 42.3 -2.0 -4.5
030 57.6 55.1 -2.5 -4.3 56.2 -1.4 -2.5
031 59.6 57.2 -2.4 -4.1 61.6 1.9 3.3
034 61.5 50.0 -11.6 -18.8 47.0 -14.6 -23.7
036 47.5 44.1 -3.5 -7.3 44.9 -2.7 -5.6
038 53.8 54.3 0.5 1.0 54.1 0.3 0.5
039 55.2 51.7 -3.5 -6.4 51.5 -3.8 -6.8
041 64.5 61.4 -3.1 -4.8 61.7 -2.8 -4.3
Average 52.6 48.9 -3.7 -6.5 49.3 -3.9 -6.9
Count 19.0 19.0 19.0 19.0 18.0 18.0 18.0
SD 8.1 6.7 4.3 7.2 7.1 5.1 8.1
SE 1.9 1.5 1.0 1.7 1.7 1.2 1.9
95% LCI 49.0 45.9 -5.6 -9.8 46.0 -6.3 -10.7
95% UCI 56.2 51.9 -1.7 -3.3 52.6 -1.6 -3.2  
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Trunk Lean Tissue in kg Determined by DEXA. 
 
Non-Diabetic Subjects
Pt # Wk0 Wk8 Chg %Chg Wk16 Chg %Chg
001 23.6 22.5 -1.2 -4.9 21.9 -1.7 -7.2
005 17.2 16.0 -1.2 -6.7 16.8 -0.3 -2.0
013 22.8 22.5 -0.4 -1.6 20.6 -2.3 -10.0
024 22.4 22.5 0.0 0.1 23.4 1.0 4.5
026 20.7 17.2 -3.5 -16.8 17.6 -3.1 -14.8
028 27.8 27.4 -0.4 -1.4 24.1 -3.7 -13.2
029 25.6 24.9 -0.7 -2.8 25.1 -0.6 -2.2
032 21.6 21.6 -0.1 -0.3 21.9 0.3 1.2
033 23.5 22.4 -1.0 -4.4 20.8 -2.6 -11.3
037 18.4 17.0 -1.5 -7.9 17.6 -0.8 -4.6
040 24.8 20.5 -4.3 -17.2 20.2 -4.6 -18.4
Average 22.6 21.3 -1.3 -5.8 20.9 -1.7 -7.1
Count 11 11 11 11 11 11 11
SD 3.1 3.5 1.4 6.1 2.7 1.7 7.1
SE 0.9 1.0 0.4 1.8 0.8 0.5 2.2
95% LCI 20.8 19.3 -2.1 -9.4 19.3 -2.7 -11.3
95% UCI 24.4 23.4 -0.5 -2.2 22.5 -0.6 -2.9
Diabetic Subjects
003 36.2 24.1 -12.1 -33.4 24.7 -11.5 -31.6
004 20.4 0.9 -19.5 -95.6 WD
007 40.1 29.3 -10.7 -26.8 28.7 -11.3 -28.3
008 24.3 22.0 -2.3 -9.4 22.7 -1.6 -6.6
009 23.9 26.8 2.9 12.0 23.9 0.0 -0.2
012 18.8 17.2 -1.6 -8.5 16.8 -2.0 -10.8
014 27.3 23.8 -3.5 -13.0 25.0 -2.3 -8.3
017 26.8 23.3 -3.5 -13.2 24.3 -2.5 -9.4
018 28.5 28.5 0.0 0.0 27.7 -0.8 -3.0
020 27.1 26.2 -0.9 -3.3 27.8 0.7 2.6
023 22.0 22.8 0.9 3.9 26.2 4.3 19.4
025 23.8 21.7 -2.1 -9.0 22.4 -1.5 -6.1
030 32.2 28.8 -3.4 -10.5 28.6 -3.6 -11.1
031 31.9 30.3 -1.6 -5.0 32.1 0.2 0.7
034 38.1 25.0 -13.1 -34.5 22.8 -15.3 -40.2
036 24.2 22.1 -2.1 -8.7 23.1 -1.0 -4.2
038 27.7 27.6 -0.1 -0.4 28.2 0.4 1.5
039 26.5 24.9 -1.6 -6.0 25.6 -0.9 -3.3
041 33.0 30.1 -2.8 -8.5 32.4 -0.5 -1.6
Average 28.0 24.0 -4.1 -14.2 25.7 -2.7 -7.8
Count 19 19 19 19 18 18 18
SD 5.9 6.5 5.7 22.9 3.8 4.9 13.8
SE 1.3 1.5 1.3 5.2 0.9 1.2 3.2
95% LCI 25.4 21.0 -6.6 -24.5 24.0 -5.0 -14.2
95% UCI 30.7 26.9 -1.5 -3.9 27.5 -0.5 -1.4  
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Total Trunk Tissue in kg Determined by DEXA. 
 
Non-Diabetic Subjects
Pt # Wk0 Wk8 Chg %Chg Wk16 Chg %Chg
001 45.2 44.5 -0.8 -1.7 42.6 -2.7 -5.9
005 36.1 32.0 -4.2 -11.5 29.8 -6.3 -17.4
013 47.9 42.3 -5.6 -11.7 38.3 -9.5 -19.9
024 47.2 40.3 -6.8 -14.5 34.4 -12.8 -27.1
026 41.1 35.0 -6.1 -14.8 29.9 -11.2 -27.3
028 64.7 55.5 -9.2 -14.3 47.1 -17.6 -27.2
029 49.3 43.8 -5.4 -11.0 42.4 -6.9 -14.0
032 48.6 44.4 -4.2 -8.7 41.8 -6.8 -14.0
033 50.1 45.4 -4.8 -9.5 40.3 -9.8 -19.6
037 41.8 68.4 26.6 63.5 31.2 -10.6 -25.4
040 48.4 39.3 -9.1 -18.9 36.8 -11.6 -24.0
Average 47.3 44.6 -2.7 -4.8 37.7 -9.6 -20.2
Count 11 11 11 11 11 11 11
SD 7.2 9.9 10.0 23.1 5.8 3.9 6.9
SE 2.2 3.0 3.0 7.0 1.7 1.2 2.1
95% LCI 43.1 38.7 -8.6 -18.5 34.3 -12.0 -24.3
95% UCI 51.6 50.5 3.2 8.8 41.1 -7.3 -16.1
Diabetic Subjects
003 63.7 54.4 -9.3 -14.6 56.1 -7.6 -12.0
004 48.3 46.4 -1.9 -3.9 WD
007 65.6 53.8 -11.9 -18.1 50.4 -15.3 -23.3
008 47.5 47.5 0.0 -0.1 46.6 -1.0 -2.0
009 48.7 48.5 -0.2 -0.4 43.3 -5.5 -11.2
012 40.4 36.9 -3.5 -8.7 35.9 -4.5 -11.2
014 53.7 47.5 -6.2 -11.6 44.2 -9.6 -17.8
017 48.2 41.6 -6.7 -13.8 39.7 -8.5 -17.7
018 53.9 44.8 -9.1 -16.8 39.2 -14.6 -27.1
020 51.2 48.4 -2.7 -5.3 49.5 -1.7 -3.2
023 53.4 52.3 -1.2 -2.2 56.5 3.1 5.7
025 51.0 45.3 -5.7 -11.2 43.5 -7.5 -14.6
030 66.8 56.7 -10.1 -15.1 53.1 -13.7 -20.5
031 58.1 55.9 -2.2 -3.8 53.9 -4.2 -7.2
034 63.8 49.6 -14.2 -22.3 43.0 -20.8 -32.6
036 94.6 44.4 -50.1 -53.0 44.1 -50.4 -53.3
038 51.1 43.0 -8.1 -15.9 40.6 -10.6 -20.6
039 49.9 44.4 -5.5 -11.1 41.4 -8.5 -17.0
041 60.6 53.1 -7.5 -12.4 51.3 -9.3 -15.3
Average 56.3 48.1 -8.2 -12.7 46.2 -10.6 -16.7
count 19 19 19 19 18 18 18
SD 11.7 5.2 10.9 11.6 6.2 11.5 13.0
SE 2.7 1.2 2.5 2.7 1.5 2.7 3.1
95% LCI 51.1 45.8 -13.1 -17.9 43.4 -15.8 -22.7
95% UCI 61.6 50.5 -3.3 -7.4 49.1 -5.3 -10.7  
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 Percent Body Fat Determined by BOD POD®. 
 
Non-Diabetic Subjects
Pt # Wk0 Wk8 Chg Wk16 Chg
001 64.9 48.4 -16.5 50.1 -14.8
005 49.3 43.6 -5.7 38.7 -10.6
013 52.3 46.7 -5.6 31.4 -20.9
024 49.3 41.4 -8.0 31.2 -18.2
026 52.0 46.7 -5.3 36.3 -15.7
028 55.4 52.3 -3.1 45.6 -9.8
029 49.8 47.0 -2.9 41.4 -8.4
032 51.1 46.8 -4.3 45.5 -5.6
033 54.5 49.2 -5.3 44.2 -10.3
037 51.6 48.8 -2.7 38.7 -12.8
040 49.0 42.2 -6.8 39.0 -10.0
Average 52.7 46.6 -6.0 40.2 -12.5
Count 11.0 11.0 11.0 11.0 11.0
SD 4.6 3.2 3.8 5.9 4.5
SE 1.4 1.0 1.2 1.8 1.4
95% LCI 50.0 44.7 -8.3 36.7 -15.1
95% UCI 55.4 48.5 -3.8 43.7 -9.8
Diabetic Subjects
003 56.5 53.0 -3.5 54.2 -2.3
004 58.9 57.0 -1.9 WD
007 55.8 48.0 -7.8 44.7 -11.1
008 46.3 48.6 2.3 49.0 2.7
009 48.1 47.4 -0.6 44.0 -4.1
012 50.9 52.8 1.9 50.9 0.0
014 52.4 46.4 -6.0 45.8 -6.6
017 45.3 41.1 -4.2 34.5 -10.7
018 46.2 38.6 -7.6 31.3 -14.9
020 47.8 46.8 -1.0 44.6 -3.2
023 55.1 52.3 -2.8 50.1 -5.0
025 53.8 48.2 -5.7 49.8 -4.0
031 46.3 45.3 -1.0 42.9 -3.4
034 54.7 47.9 -6.9 45.7 -9.0
036 49.6 46.7 -2.9 45.9 -3.7
038 45.4 40.5 -4.9 36.7 -8.8
039 45.8 41.3 -4.5 41.3 -4.5
041 43.7 38.6 -5.1 35.0 -8.7
Average 50.1 46.7 -3.5 43.9 -5.7
Count 18.0 18.0 18.0 17.0 17.0
SD 4.7 5.2 3.0 6.4 4.4
SE 1.1 1.2 0.7 1.5 1.1
95% LCI 48.0 44.3 -4.8 40.9 -7.8
95% UCI 52.3 49.1 -2.1 46.9 -3.6  
 
 162 
 
Total Fat in kg Determined by BOD POD®. 
 
Non-Diabetic Subjects
Pt # Wk0 Wk8 Chg Wk16 Chg
001 56.1 46.0 -10.1 45.1 -11.0
005 35.2 28.3 -6.9 24.0 -11.2
013 48.8 40.3 -8.5 25.5 -23.3
024 47.1 34.9 -12.1 22.7 -24.3
026 43.6 34.3 -9.3 23.9 -19.8
028 65.5 54.1 -11.3 43.1 -22.4
029 50.2 42.9 -7.3 34.8 -15.3
032 52.4 44.7 -7.7 40.6 -11.8
033 56.8 45.3 -11.5 37.4 -19.3
037 41.7 34.8 -6.8 25.0 -16.7
040 49.7 36.6 -13.0 30.9 -18.8
Average 49.7 40.2 -9.5 32.1 -17.6
Count 11.0 11.0 11.0 11.0 11.0
SD 8.2 7.3 2.2 8.4 4.8
SE 2.5 2.2 0.7 2.5 1.5
95% LCI 44.9 35.9 -10.8 27.1 -20.5
95% UCI 54.5 44.5 -8.2 37.1 -14.8
Diabetic Subjects
003 56.5 58.9 2.4 58.4 1.9
004 65.1 58.6 -6.5 57.4 -7.7
007 55.8 47.8 -8.0 40.2 -15.6
008 44.0 44.8 0.8 45.1 1.2
009 52.2 48.0 -4.2 42.6 -9.6
010 54.1 WD
012 38.4 36.6 -1.8 34.4 -4.0
014 54.1 43.0 -11.1 39.8 -14.3
015 38.6 WD
017 39.2 31.7 -7.6 24.3 -14.9
018 44.2 33.1 -11.1 23.8 -20.4
020 46.4 41.8 -4.6 41.2 -5.2
023 60.6 53.5 -7.2 49.4 -11.2
025 51.9 42.2 -9.6 42.2 -9.7
031 52.6 49.3 -3.3 46.6 -6.0
034 62.3 48.3 -13.9 41.1 -21.2
036 48.5 41.3 -7.2 39.3 -9.2
038 45.6 36.3 -9.2 30.6 -15.0
039 48.3 38.8 -9.5 32.0 -16.3
041 50.9 41.6 -9.3 35.2 -15.7
Average 50.5 44.2 -6.7 40.2 -10.7
Count 20.0 18.0 18.0 18.0 18.0
SD 7.6 7.8 4.3 9.5 6.6
SE 1.7 1.8 1.0 2.2 1.6
95% LCI 47.1 40.6 -8.7 35.8 -13.8
95% UCI 53.8 47.8 -4.7 44.6 -7.7  
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Total Lean Tissue Determined by BOD POD®. 
 
Non-Diabetic Subjects
Pt # Wk0 Wk8 Chg Wk16 Chg
001 46.1 49.0 2.9 44.8 -1.3
005 36.2 36.6 0.4 38.0 1.8
013 44.5 46.0 1.5 55.6 11.1
024 48.3 49.5 1.2 50.2 1.9
026 40.2 39.2 -1.0 41.8 1.6
028 52.7 49.5 -3.2 51.4 -1.3
029 50.5 48.4 -2.1 49.4 -1.1
032 50.2 50.9 0.6 48.6 -1.6
033 47.4 46.8 -0.6 47.3 -0.1
037 39.2 36.5 -2.6 39.5 0.3
040 51.7 50.1 -1.6 48.3 -3.4
Average 46.1 45.7 -0.4 46.8 0.7
Count 11.0 11.0 11.0 11.0 11.0
SD 5.5 5.5 1.9 5.3 3.8
SE 1.7 1.7 0.6 1.6 1.1
95% LCI 42.8 42.4 -1.5 43.7 -1.5
95% UCI 49.3 48.9 0.7 50.0 3.0
Diabetic Subjects
003 52.6 52.2 -0.4 49.4 -3.2
004 45.5 43.3 -2.2 43.3 -2.2
007 55.8 51.8 -3.9 49.8 -6.0
008 51.1 47.4 -3.7 47.0 -4.1
009 56.3 53.2 -3.2 54.1 -2.2
010 44.8 WD
012 37.0 32.8 -4.2 33.2 -3.8
014 49.2 49.7 0.5 47.1 -2.1
015 44.5 WD
017 47.4 45.4 -2.0 46.1 -1.4
018 51.5 52.7 1.2 52.2 0.8
020 50.6 47.5 -3.1 51.1 0.5
023 49.4 48.7 -0.7 49.2 -0.3
025 44.5 45.5 1.0 42.5 -2.0
031 61.0 59.5 -1.5 62.1 1.1
034 51.5 52.7 1.1 48.8 -2.7
036 49.3 47.2 -2.1 40.4 -8.9
038 54.8 53.4 -1.4 52.8 -1.9
039 57.2 55.2 -2.0 53.7 -3.5
041 66.8 66.2 -0.6 65.3 -1.5
Average 51.0 50.2 -1.5 49.3 -2.4
Count 20.0 18.0 18.0 18.0 18.0
SD 6.6 7.0 1.7 7.4 2.4
SE 1.5 1.6 0.4 1.7 0.6
95% LCI 48.2 47.0 -2.3 45.9 -3.5
95% UCI 53.9 53.5 -0.7 52.8 -1.3
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 Change in Subcutaneous and Visceral Adipose Tissue Stores for Non-Diabetic and 
Diabetic Subjects. 
 
Non-Diabetic Subjects
Pt #
Subcut-
aneous 
Fat 1    
(sq cm)
Subcut-
aneous 
Fat 2    
(sq cm) %Chg
Chg     
(sq cm)
Visceral 
Fat 1    
(sq cm)
Visceral 
Fat 2    
(sq cm) %Chg
Chg    
(sq cm)
Total 
Abdominal  
Fat Loss    
(sq cm)
001 655.1 538.8 -17.8 -116.3 122.9 98.9 -19.5 -24.0 -140.3
005 411.2 320.1 -22.2 -91.1 144.9 90.6 -37.5 -54.3 -145.4
013 638.2 516.9 -19.0 -121.3 84.2 74.8 -11.1 -9.4 -130.7
024 539.3 224.5 -58.4 -314.8 63.5 25.6 -59.7 -37.9 -352.8
026 613.8 361.9 -41.0 -252.0 62.4 35.5 -43.2 -26.9 -278.9
028 767.6 595.7 -22.4 -171.9 111.3 63.6 -42.8 -47.7 -219.6
029 507.8 429.3 -15.4 -78.4 167.4 104.5 -37.6 -62.9 -141.3
032 716.3 577.3 -19.4 -139.0 176.2 123.9 -29.7 -52.3 -191.3
033 697.6 504.6 -27.7 -193.0 141.4 103.4 -26.8 -37.9 -230.9
037 521.5 317.7 -39.1 -203.8 103.8 91.6 -11.8 -12.2 -216.0
040 534.5 336.1 -37.1 -198.4 113.8 60.8 -46.6 -53.0 -251.4
Average 600.3 429.3 -29.0 -170.9 117.4 79.4 -33.3 -38.0 -208.9
Count 11 11.0 11.0 11.0 11.0 11.0 11.0 11.0 11.0
SD 106.8 124.3 13.3 71.4 38.2 30.5 15.2 17.9 69.1
SE 32.2 37.5 4.0 21.5 11.5 9.2 4.6 5.4 20.8
95% LCI 537.1 355.9 -36.9 -213.1 94.9 61.4 -42.2 -48.6 -249.8
95% UCI 663.4 502.799 -21.2 -128.7 140.0 97.4 -24.3 -27.4 -168.1
Diabetic Subjects
003 603.0 530.1 -12.1 -72.9 326.1 228.9 -29.8 -97.1 -170.0
007 552.2 435.5 -21.1 -116.8 304.2 152.0 -50.0 -152.2 -269.0
008 491.9 462.7 -6.0 -29.3 84.7 90.1 6.4 5.5 -23.8
009 590.3 511.0 -13.4 -79.3 185.1 133.2 -28.0 -51.9 -131.2
012 393.6 336.0 -14.6 -57.6 179.0 136.1 -24.0 -43.0 -100.6
014 644.1 482.7 -25.1 -161.4 188.8 116.9 -38.1 -71.9 -233.3
017 376.3 277.6 -26.2 -98.8 232.7 113.0 -51.4 -119.7 -218.4
018 490.0 329.4 -32.8 -160.6 167.0 73.4 -56.1 -93.6 -254.2
020 545.1 504.7 -7.4 -40.4 160.8 139.8 -13.1 -21.1 -61.4
023 699.0 549.0 -21.5 -150.0 174.8 132.0 -24.5 -42.8 -192.9
025 536.8 436.3 -18.7 -100.5 121.3 81.6 -32.7 -39.7 -140.2
030 412.4 300.6 -27.1 -111.9 322.4 249.7 -22.6 -72.7 -184.6
031 347.5 374.0 7.6 26.5 228.1 183.4 -19.6 -44.7 -18.3
034 745.3 554.7 -25.6 -190.6 254.8 111.6 -56.2 -143.2 -333.8
036 563.3 432.1 -23.3 -131.2 154.7 108.5 -29.9 -46.2 -177.4
038 414.9 352.6 -15.0 -62.2 203.7 105.3 -48.3 -98.4 -160.6
039 636.9 431.2 -32.3 -205.7 124.0 66.1 -46.7 -58.0 -263.6
041 354.6 306.3 -13.6 -48.3 337.8 161.9 -52.1 -175.9 -224.2
Average 522.1 422.6 -18.2 -99.5 208.3 132.4 -34.3 -75.9 -175.4
Count 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0
SD 120.2 90.1 8.3 46.5 75.0 49.5 17.0 48.2 85.9
SE 28.3 21.2 1.9 11.0 17.7 11.7 4.0 11.4 20.3
95% LCI 466.5 380.9 -22.1 -121.0 173.7 109.6 -42.1 -98.2 -215.1
95% UCI 577.6 464.2 -14.4 -78.0 243.0 155.3 -26.4 -53.7 -135.7  
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Change and Percent Change in Waist Circumference (cm) for Non-Diabetic and 
Diabetic Subjects. 
Non-Diabetic Subjects
Pt #  Wk0 Wk16 Total Change %Chg
001 100.3 99.1 -1.3 -1.3
005 90.2 76.2 -14.0 -15.5
013 104.1 91.4 -12.7 -12.2
024 104.1 82.6 -21.6 -20.7
026 86.4 77.5 -8.9 -10.3
028 132.1 95.3 -36.8 -27.9
029 114.3 101.6 -12.7 -11.1
032 121.9 101.6 -20.3 -16.7
033 139.7 91.4 -48.3 -34.5
037 116.8 96.5 -20.3 -17.4
040 105.4 91.4 -14.0 -13.3
Average 110.5 91.3 -19.2 -16.4
Count 11.0 11.0 11.0 11.0
SD 16.5 9.0 13.2 9.0
SE 5.0 2.7 4.0 2.7
95% LCI 100.8 86.0 -26.9 -21.7
95% UCI 120.2 96.6 -11.4 -11.1
Diabetic Subjects
003 128.3 124.5 -3.8 -3.0
004 134.6 WD
007 137.2 114.3 -22.9 -16.7
008 101.6 102.9 1.3 1.3
009 102.9 99.1 -3.8 -3.7
010 111.8 WD
012 101.6 95.3 -6.3 -6.2
014 123.2 114.3 -8.9 -7.2
015 104.1 WD
017 106.7 96.5 -10.2 -9.5
018 118.1 95.3 -22.9 -19.4
020 118.1 116.8 -1.3 -1.1
023 121.9 109.2 -12.7 -10.4
025 104.1 96.5 -7.6 -7.3
030 127.0 124.5 -2.5 -7.6
031 120.7 119.4 -1.3 -8.0
034 139.7 104.1 -35.6 -7.2
036 104.1 94.0 -10.2 -8.0
038 121.9 99.1 -22.9 -8.4
039 125.7 105.4 -20.3 -8.5
041 121.9 99.1 -22.9 -8.7
Average 117.9 106.1 -11.9 -7.8
Count 21.0 18.0 18.0 18.0
SD 12.1 10.4 10.3 4.8
SE 2.7 2.5 2.4 1.1
95% LCI 112.7 101.3 -16.7 -10.0
95% UCI 123.1 110.9 -7.2 -5.5  
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Insulin (µU/ml) and HOMA-IR. 
 
026 9.8 6.6 6.8 -3.0 -30.6 4.9 5.0 5.6 0.7 14.3
028 17.1 11.7 27.6 10.5 61.4 4.9 4.5 5.4 0.5 10.2
029 27.8 12.5 6.9 -20.9 -75.2 5.7 5.2 5.5 -0.2 -3.5
032 15.7 13.2 8.6 -7.1 -45.2 5.5 5.5 5.7 0.2 3.6
033 9.1 13.8 8.6 -0.5 -5.5 6.0 5.6 6.1 0.1 1.7
037 7.2 7.9 3.9 -3.3 -45.8 5.5 5.5 5.4 -0.1 -1.8
040 34.7 11.3 8.6 -26.1 -75.2 5.6 5.9 5.4 -0.2 -3.6
Average 14.4 21.1 8.9 -5.5 -30.1 5.3 5.2 5.4 0.1 1.8
Count 11 11 11 11 11 11 11 11 11 11
SD 9.4 35.9 6.6 10.0 39.0 0.4 0.5 0.5 0.3 6.5
SE 2.8 10.8 2.0 3.0 11.8 0.1 0.2 0.1 0.1 1.9
95% LCI 8.8 -0.1 4.9 -11.4 -53.2 5.0 4.9 5.1 -0.1 -2.0
95% UCI 19.9 42.3 12.8 0.4 -7.0 5.6 5.5 5.7 0.3 5.6
Diabetic Subjects
003 33.3 22.8 12.3 -21.0 -63.1 8.6 8.8 8.0 -0.6 -7.6
004 14.0 19.4 WD 5.5 7.6 WD
007 27.8 26.2 20.5 -7.3 -26.3 11.5 11.4 7.3 -4.2 -36.5
008 22.1 22.1 18.6 -3.5 -15.8 6.0 5.8 6.4 0.4 6.7
009 11.5 9.9 7.5 -4.0 -34.8 6.8 7.5 6.3 -0.5 -7.4
010 14.9 13.9 WD 3.2 3.7 WD
012 11.8 10.2 10.8 -1.0 -8.5 9.5 9.3 8.7 -0.8 -8.4
014 11.3 6.0 6.3 -5.0 -44.2 8.6 7.9 7.7 -0.9 -10.5
017 4.8 7.1 5.0 0.2 4.2 8.6 10.1 8.7 0.1 1.2
018 7.3 7.6 8.6 1.3 17.8 9.5 9.4 7.9 -1.6 -16.8
020 18.2 20.5 26.3 8.1 44.5 9.6 9.8 7.8 -1.8 -18.8
023 13.9 15.5 9.4 -4.5 -32.4 5.1 5.8 5.0 -0.1 -2.0
025 15.9 11.3 12.0 -3.9 -24.5 5.8 6.2 5.5 -0.3 -5.2
030 41.4 29.4 20.5 -20.9 -50.5 6.3 6.5 5.7 -0.6 -9.5
031 31.9 22.1 15.0 -16.9 -53.0 8.9 9.2 9.0 0.1 1.1
034 34.9 28.6 10.0 -24.9 -71.3 6.4 6.0 6.1 -0.3 -4.7
036 22.5 21.6 21.8 -0.7 -3.1 6.5 6.5 6.2 -0.3 -4.6
038 23.7 12.1 11.0 -12.7 -53.6 9.6 10.4 7.2 -2.4 -25.0
039 17.0 11.7 9.3 -7.7 -45.3 7.3 7.0 5.9 -1.4 -19.2
041 28.2 9.2 12.2 -16.0 -56.7 8.3 8.8 6.9 -1.4 -16.9
Average 20.3 16.4 13.2 -7.8 -28.7 7.6 7.9 7.0 -0.9 -10.2
Count 20 20 18 18 18 20 20 18 18 18
SD 10.0 7.4 6.0 9.0 30.6 2.0 2.0 1.2 1.1 10.5
SE 2.2 1.7 1.4 2.1 7.2 0.4 0.4 0.3 0.3 2.5
95% LCI 16.0 13.1 10.4 -12.0 -42.8 6.7 7.0 6.5 -1.4 -15.1
95% UCI 24.7 19.6 15.9 -3.6 -14.6 8.5 8.7 7.6 -0.4 -5.4
*Italized numbers are taken from baseline or are interpolated
*Baseline Insulin was never taken
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Glucose (mg/dl) and HbA1c (%). 
024 87 88 84 86 -2 -2.3 5.2 5.2 4.9 5 -0.2 -3.8
026 102 97 94 91 -6 -6.2 4.9 5 5.6 5.5 0.5 10.0
028 89 92 88 90 -2 -2.2 4.9 4.5 5.4 5.1 0.6 13.3
029 98 121 107 101 -20 -16.5 5.7 5.2 5.5 5.5 0.3 5.8
032 88 101 95 93 -8 -7.9 5.5 5.5 5.7 5.5 0 0.0
033 91 101 100 99 -2 -2.0 6 5.6 6.1 5.8 0.2 3.6
037 95 102 104 91 -11 -10.8 5.5 5.5 5.4 5.4 -0.1 -1.8
040 95 104 94 98 -6 -5.8 5.6 5.9 5.4 5.5 -0.4 -6.8
Average 90.5 98.8 96.5 92.9 -5.9 -5.5 5.3 5.2 5.4 5.3 0.1 2.9
Count 11 11 11 11 11 11 11 11 11 11 11 11.0
SD 6.9 10.0 6.9 5.3 6.3 5.7 0.4 0.5 0.5 0.4 0.4 8.1
SE 2.1 3.0 2.1 1.6 1.9 1.7 0.1 0.2 0.1 0.1 0.1 2.5
95% LCI 86.4 92.9 92.4 89.8 -9.6 -8.9 5.0 4.9 5.1 5.1 -0.1 -1.9
95% UCI 94.7 104.7 100.5 96.0 -2.2 -2.2 5.6 5.5 5.7 5.5 0.4 7.7
Diabetic Subjects
003 194 186 194 150 -36 -19.4 8.6 8.8 8.0 7.1 -1.7 -19.3
004 158 159 123 WD 6.9 6.8 6.6 WD
007 278 251 129 129 -122 -48.6 11.5 11.4 7.3 6.3 -5.1 -44.7
008 106 118 144 127 9 7.6 6 5.8 6.4 5.8 0 0.0
009 148 148 123 120 -28 -18.9 6.8 7.5 6.3 6.3 -1.2 -16.0
010 86 104 112 WD 5.9 5.8 5 WD
012 192 228 209 221 -7 -3.1 9.5 9.3 8.7 9.1 -0.2 -2.2
014 129 118 125 117 -1 -0.8 8.6 7.9 7.7 6.9 -1 -12.7
015 116 229 203 WD 7.8 7.8 7.8 WD
017 239 213 215 171 -42 -19.7 8.6 10.1 8.7 8.3 -1.8 -17.8
018 270 257 177 141 -116 -45.1 9.5 9.4 7.9 5.9 -3.5 -37.2
020 256 253 176 199 -54 -21.3 9.6 9.8 7.8 6.5 -3.3 -33.7
023 92 106 96 93 -13 -12.3 5.1 5.8 5 5.6 -0.2 -3.4
025 107 103 101 104 1 1.0 5.8 6.2 5.5 5.5 -0.7 -11.3
030 113 113 118 108 -5 -4.4 6.3 6.5 5.7 5.9 -0.6 -9.2
031 299 254 260 173 -81 -31.9 8.9 9.2 9 8.2 -1 -10.9
034 126 137 134 111 -26 -19.0 6.4 6 6.1 5.8 -0.2 -3.3
036 134 155 128 131 -24 -15.5 6.5 6.5 6.2 6.2 -0.3 -4.6
038 207 299 142 129 -170 -56.9 9.6 10.4 7.2 6.1 -4.3 -41.3
039 145 156 103 95 -61 -39.1 7.3 7 5.9 5.8 -1.2 -17.1
041 154 274 113 139 -135 -49.3 8.3 8.8 6.9 6.4 -2.4 -27.3
Average 169.0 183.9 148.8 136.6 -50.6 -22.0 7.8 7.9 6.9 6.5 -1.6 -17.3
Count 21 21 21 18 18 18 21 21 21 18 18 18.0
SD 65.8 64.9 45.1 35.0 53.1 19.2 1.7 1.7 1.2 1.0 1.5 14.0
SE 14.4 14.2 9.8 8.2 12.5 4.5 0.4 0.4 0.3 0.2 0.4 3.3
95% LCI 140.8 156.1 129.5 120.4 -75.2 -30.9 7.1 7.2 6.4 6.1 -2.3 -23.8
95% UCI 197.2 211.6 168.1 152.7 -26.1 -13.2 8.5 8.7 7.5 7.0 -0.9 -10.9
*Italized numbers are taken from baseline or are interpolated
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Leptin (pg/ml). 
 
Non-Diabetic Subjects
Pt # Wk0 Wk8 Chg %Chg Wk16 Chg %Chg
001 76857.0 35942.0 -40915.0 -53.2 31043.0 -45814.0 -59.6
005 24193.0 11439.0 -12754.0 -52.7 11829.0 -12364.0 -51.1
013 70440.0 42643.0 -27797.0 -39.5 28810.0 -41630.0 -59.1
024 21333.0 4854.9 -16478.1 -77.2 3600.4 -17732.6 -83.1
026 61113.0 14550.0 -46563.0 -76.2 7948.0 -53165.0 -87.0
028 70044.0 38438.0 -31606.0 -45.1 20491.0 -49553.0 -70.7
029 83162.0 27309.0 -55853.0 -67.2 20336.0 -62826.0 -75.5
032 44642.0 40347.0 -4295.0 -9.6 36394.0 -8248.0 -18.5
033 97736.0 43021.0 -54715.0 -56.0 28139.0 -69597.0 -71.2
037 79602.0 28989.0 -50613.0 -63.6 15360.0 -64242.0 -80.7
040 75309.0 25931.0 -49378.0 -65.6 15652.0 -59657.0 -79.2
Average 64039.2 28496.7 -35542.5 -55.1 19963.9 -44075.3 -66.9
Count 11 11 11 11 11 11 11
SD 24306.5 13260.5 18120.8 19.2 10277.7 21811.0 19.6
SE 7328.7 3998.2 5463.6 5.8 3098.8 6576.3 5.9
95% LCI 49675.0 20660.3 -46251.1 -66.4 13890.1 -56964.8 -78.5
95% UCI 78403.4 36333.2 -24833.8 -43.7 26037.6 -31185.8 -55.3
Diabetic Subjects
003 99158.0 59641.0 -39517.0 -39.9 65975.0 -33183.0 -33.5
007 77182.0 28778.0 -48404.0 -62.7 21360.0 -55822.0 -72.3
008 65464.0 66748.0 1284.0 2.0 49138.0 -16326.0 -24.9
009 43165.0 31262.0 -11903.0 -27.6 27345.0 -15820.0 -36.7
012 37725.0 32710.0 -5015.0 -13.3 30725.0 -7000.0 -18.6
014 49215.0 21045.0 -28170.0 -57.2 18771.0 -30444.0 -61.9
017 19062.0 11843.0 -7219.0 -37.9 9753.2 -9308.8 -48.8
018 22560.0 8340.3 -14219.7 -63.0 4971.7 -17588.3 -78.0
020 34362.0 31749.0 -2613.0 -7.6 35767.0 1405.0 4.1
023 80411.0 44664.0 -35747.0 -44.5 39618.0 -40793.0 -50.7
025 47855.0 16929.0 -30926.0 -64.6 20158.0 -27697.0 -57.9
030 49427.0 25866.0 -23561.0 -47.7 25230.0 -24197.0 -49.0
031 62561.0 45601.0 -16960.0 -27.1 57793.0 -4768.0 -7.6
034 65451.0 31922.0 -33529.0 -51.2 21178.0 -44273.0 -67.6
036 50571.0 36567.0 -14004.0 -27.7 37836.0 -12735.0 -25.2
038 30331.0 16147.0 -14184.0 -46.8 11388.0 -18943.0 -62.5
039 39519.0 18614.0 -20905.0 -52.9 9089.0 -30430.0 -77.0
041 34216.0 12488.0 -21728.0 -63.5 12922.0 -21294.0 -62.2
Average 50457.5 30050.8 -20406.7 -40.7 27723.2 -22734.3 -46.1
Count 18 18 18 18 18 18 18
SD 21165.8 16166.2 13589.7 20.2 17225.5 14761.9 24.2
SE 4988.8 3810.4 3203.1 4.8 4060.1 3479.4 5.7
95% LCI 40679.4 22582.4 -26684.8 -50.0 19765.4 -29553.9 -57.3
95% UCI 60235.6 37519.2 -14128.6 -31.4 35681.0 -15914.6 -34.9  
 
 196 
 
Ghrelin (pg/ml). 
 
Non-Diabetic Subjects
Pt # Wk0 Wk8 Chg %Chg Wk16 Chg %Chg
001 1089.0 814.0 -275.0 -25.3 855.0 -234.0 -21.5
005 1159.0 1136.0 -23.0 -2.0 1057.0 -102.0 -8.8
013 614.0 487.0 -127.0 -20.7 1363.0 749.0 122.0
024 1411.0 1709.0 298.0 21.1 1773.0 362.0 25.7
026 783.0 788.0 5.0 0.6 701.0 -82.0 -10.5
028 766.0 883.0 117.0 15.3 942.0 176.0 23.0
029 605.0 474.0 -131.0 -21.7 531.0 -74.0 -12.2
032 590.0 521.0 -69.0 -11.7 515.0 -75.0 -12.7
033 778.0 814.0 36.0 4.6 954.0 176.0 22.6
037 1016.0 1456.0 440.0 43.3 1900.0 884.0 87.0
040 405.0 475.0 70.0 17.3 537.0 132.0 32.6
Average 837.8 868.8 31.0 1.9 1011.6 173.8 22.5
Count 11.0 11.0 11.0 11.0 11.0 11.0 11.0
SD 298.6 413.8 201.5 21.2 482.3 361.0 45.4
SE 90.0 124.8 60.7 6.4 145.4 108.9 13.7
95% LCI 661.4 624.3 -88.1 -10.6 726.6 -39.5 -4.4
95% UCI 1014.3 1113.4 150.1 14.5 1296.7 387.2 49.3
Diabetic Subjects
003 1196.0 986.0 -210.0 -17.6 1041.0 -155.0 -13.0
007 418.0 641.0 223.0 53.3 564.0 146.0 34.9
008 864.0 786.0 -78.0 -9.0 1253.0 389.0 45.0
009 1226.0 1758.0 532.0 43.4 1698.0 472.0 38.5
012 449.0 567.0 118.0 26.3 497.0 48.0 10.7
014 546.0 777.0 231.0 42.3 724.0 178.0 32.6
017 792.0 1423.0 631.0 79.7 1158.0 366.0 46.2
018 771.0 943.0 172.0 22.3 1148.0 377.0 48.9
020 511.0 578.0 67.0 13.1 537.0 26.0 5.1
023 587.0 631.0 44.0 7.5 650.0 63.0 10.7
025 455.0 598.0 143.0 31.4 618.0 163.0 35.8
030 554.0 586.0 32.0 5.8 647.0 93.0 16.8
031 656.0 739.0 83.0 12.7 707.0 51.0 7.8
034 582.0 766.0 184.0 31.6 881.0 299.0 51.4
036 535.0 656.0 121.0 22.6 471.0 -64.0 -12.0
038 541.0 666.0 125.0 23.1 858.0 317.0 58.6
039 437.0 517.0 80.0 18.3 619.0 182.0 41.6
041 465.0 545.0 80.0 17.2 510.0 45.0 9.7
Average 643.6 786.8 143.2 23.6 810.1 166.4 26.1
Count 18.0 18.0 18.0 18.0 18.0 18.0 18.0
SD 241.9 324.6 191.0 22.4 331.0 171.9 21.9
SE 57.0 76.5 45.0 5.3 78.0 40.5 5.2
95% LCI 531.9 636.9 55.0 13.2 657.2 87.0 16.0
95% UCI 755.4 936.8 231.5 33.9 963.0 245.9 36.2  
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Adiponectin (ng/ml). 
 
Non-Diabetic Subjects
Pt # WK0 WK8 Chg %Chg WK16 Chg %Chg
001 9480.4 9196.3 -284.1 -3.0 11637.0 2156.6 22.7
005 12229.0 10637.0 -1592.0 -13.0 12708.0 479.0 3.9
013 7701.8 6987.2 -714.6 -9.3 5586.5 -2115.3 -27.5
024 25779.0 23125.0 -2654.0 -10.3 26121.0 342.0 1.3
026 18372.0 11072.0 -7300.0 -39.7 13382.0 -4990.0 -27.2
028 5245.0 5345.6 100.6 1.9 5060.7 -184.3 -3.5
029 8831.0 9290.2 459.2 5.2 11969.0 3138.0 35.5
032 6340.7 6323.9 -16.8 -0.3 5843.1 -497.6 -7.8
033 12793.0 11745.0 -1048.0 -8.2 11190.0 -1603.0 -12.5
037 14818.0 11324.0 -3494.0 -23.6 9643.1 -5174.9 -34.9
040 5261.8 4384.8 -877.0 -16.7 5038.3 -223.5 -4.2
Average 11532.0 9948.3 -1583.7 -10.6 10743.5 -788.5 -4.9
count 11 11 11 11 11 11 11
SD 6281.7 5054.9 2239.8 12.8 6053.5 2589.6 21.2
SE 1894.0 1524.1 675.3 3.9 1825.2 780.8 6.4
95% LCI 7819.7 6961.0 -2907.3 -18.2 7166.1 -2318.8 -17.4
95% UCI 15244.2 12935.5 -260.1 -3.1 14320.9 741.9 7.6
Diabetic Subjects
003 7805.6 8977.0 1171.4 15.0 8315.9 510.3 6.5
007 7833.7 6868.3 -965.4 -12.3 6963.8 -869.9 -11.1
008 13429.0 13640.0 211.0 1.6 17796.0 4367.0 32.5
009 7147.8 8007.1 859.3 12.0 9263.5 2115.7 29.6
012 5300.9 5477.5 176.6 3.3 6245.8 944.9 17.8
014 7758.7 7002.7 -756.0 -9.7 8276.0 517.3 6.7
017 6930.1 6188.7 -741.4 -10.7 6665.8 -264.3 -3.8
018 8100.3 8089.9 -10.4 -0.1 14381.0 6280.7 77.5
020 3730.7 5056.9 1326.2 35.5 4932.9 1202.2 32.2
023 10988.0 9312.6 -1675.4 -15.2 10590.0 -398.0 -3.6
025 6924.8 5695.5 -1229.3 -17.8 6525.8 -399.0 -5.8
030 3614.6 3424.9 -189.7 -5.2 4016.4 401.8 11.1
031 7425.9 7397.9 -28.0 -0.4 7733.7 307.8 4.1
034 6944.8 6978.3 33.5 0.5 7453.9 509.1 7.3
036 5312.1 5759.2 447.1 8.4 5854.3 542.2 10.2
038 3640.2 3368.7 -271.5 -7.5 4464.9 824.7 22.7
039 5862.1 4515.7 -1346.4 -23.0 6688.5 826.4 14.1
041 1876.1 2285.7 409.6 21.8 2399.3 523.2 27.9
Average 6701.4 6558.1 -143.3 -0.2 7698.2 996.8 15.3
count 18 18 18 18 18 18 18
SD 2719.2 2618.6 848.5 14.8 3657.9 1741.6 20.5
SE 640.9 617.2 200.0 3.5 862.2 410.5 4.8
95% LCI 5445.2 5348.4 -535.3 -7.0 6008.4 192.2 5.9
95% UCI 7957.6 7767.9 248.7 6.6 9388.0 1801.4 24.8  
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Resistin (ng/ml). 
 
Non-Diabetic Subjects
Pt # WK0 WK8 Chg %Chg WK16 Chg %Chg
001 4.1 3.9 -0.2 -5.1 3.6 -0.5 -11.9
005 5.4 5.6 0.2 4.3 6.6 1.3 23.3
013 5.3 4.6 -0.6 -12.0 5.9 0.6 12.1
024 3.4 3.4 0.0 0.0 3.1 -0.3 -7.4
026 3.0 2.9 -0.1 -3.3 2.7 -0.3 -10.0
028 3.7 3.1 -0.6 -16.2 2.9 -0.8 -21.6
029 5.0 4.4 -0.6 -12.0 5.3 0.3 6.0
032 5.2 5.3 0.1 1.9 5.2 0.0 0.0
033 5.1 5.5 0.4 7.8 4.9 -0.2 -3.9
037 3.9 2.7 -1.2 -30.8 3.2 -0.7 -17.9
040 6.1 7.0 0.9 14.8 7.9 1.8 29.5
Average 4.6 4.4 -0.2 -4.6 4.7 0.1 -0.2
Count 11 11 11 11 11 11 11
SD 1.0 1.4 0.6 12.7 1.7 0.8 16.4
SE 0.3 0.4 0.2 3.8 0.5 0.2 5.0
95% LCI 4.0 3.6 -0.5 -12.1 3.7 -0.4 -9.9
95% UCI 5.1 5.2 0.2 2.9 5.7 0.6 9.5
Diabetic Subjects
003 5.1 5.3 0.2 3.9 4.7 -0.4 -7.8
007 3.5 3.9 0.4 11.4 4.2 0.7 20.0
008 3.5 4.0 0.5 13.1 3.6 0.0 1.4
009 3.8 3.8 0.1 1.6 4.6 0.8 22.4
012 3.8 3.5 -0.3 -7.9 3.4 -0.4 -10.6
014 8.9 6.7 -2.2 -24.7 11.6 2.7 30.0
017 9.2 9.1 -0.1 -1.4 6.8 -2.4 -26.0
018 5.6 8.8 3.3 58.4 5.9 0.3 5.2
020 3.5 2.8 -0.7 -20.0 2.4 -1.1 -31.4
023 10.2 9.0 -1.2 -11.8 9.8 -0.4 -3.9
025 7.0 8.5 1.5 20.7 7.2 0.1 2.0
030 5.1 5.1 0.0 0.0 5.5 0.4 7.8
031 7.1 4.1 -3.0 -42.3 4.6 -2.5 -35.2
034 6.3 5.0 -1.3 -20.6 6.6 0.3 4.8
036 5.4 5.0 -0.4 -7.4 7.7 2.3 42.6
038 4.3 4.7 0.4 9.3 5.3 1.0 23.3
039 5.9 10.4 4.5 76.3 8.5 2.6 44.1
041 3.5 4.6 1.1 31.4 6.7 3.2 91.4
Average 5.6 5.8 0.1 5.0 6.1 0.4 10.0
count 18 18 18 18 18 18 18
SD 2.1 2.3 1.8 28.8 2.3 1.6 30.6
SE 0.5 0.5 0.4 6.8 0.6 0.4 7.2
95% LCI 4.7 4.7 -0.7 -8.3 5.0 -0.3 -4.1
95% UCI 6.6 6.9 1.0 18.3 7.1 1.1 24.1  
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IL-6 (pg/ml). 
 
Non-Diabetic Subjects
Pt # Wk0 Wk8 Chg %Chg Wk16 Chg %Chg
001 6.5 3.0 -3.5 -53.8 2.0 -4.5 -69.2
005 11.0 12.6 1.6 14.5 2.3 -8.7 -79.1
013 7.6 3.5 -4.1 -53.9 5.9 -1.7 -22.4
024 1.2 0.8 -0.4 -33.3 1.2 0.0 0.0
026 0.9 1.6 0.7 86.0 1.1 0.3 30.2
028 2.1 1.3 -0.8 -36.5 1.1 -1.0 -48.8
029 5.2 5.2 -0.1 -1.2 3.4 -1.8 -35.1
032 2.4 3.5 1.1 46.0 5.6 3.3 137.6
033 3.0 2.4 -0.6 -19.5 2.0 -1.0 -31.9
037 1.1 1.2 0.1 9.9 0.9 -0.2 -20.7
040 2.9 2.5 -0.4 -15.2 7.1 4.2 143.1
Average 4.0 3.4 -0.6 -5.2 3.0 -1.0 0.3
Count 11 11 11 11 11 11 11
SD 3.2 3.3 1.8 42.9 2.2 3.5 75.4
SE 1.0 1.0 0.5 12.9 0.7 1.0 22.7
95% LCI 2.1 1.5 -1.6 -30.5 1.6 -3.1 -44.3
95% UCI 5.9 5.4 0.5 20.2 4.3 1.0 44.9
Diabetic Subjects
003 2.5 1.7 -0.8 -32.8 2.4 -0.1 -3.6
007 2.4 1.6 -0.8 -34.3 2.0 -0.4 -16.3
008 0.5 0.9 0.4 80.0 0.6 0.1 20.0
009 2.1 1.4 -0.7 -33.3 1.4 -0.7 -33.3
012 5.3 3.0 -2.3 -43.4 2.6 -2.7 -50.9
014 3.8 6.1 2.3 60.5 4.5 0.7 18.4
017 3.2 1.2 -2.0 -62.5 1.1 -2.1 -65.6
018 2.0 1.9 -0.1 -5.0 2.1 0.1 5.0
020 2.5 3.0 0.5 20.2 0.7 -1.8 -72.3
023 1.7 1.8 0.1 4.1 1.5 -0.2 -12.9
025 2.5 3.6 1.1 44.0 2.8 0.3 12.0
030 0.8 2.4 1.6 194.0 0.8 -0.1 -9.6
031 1.7 1.7 0.0 1.8 1.9 0.2 12.4
034 2.8 3.1 0.3 10.9 2.3 -0.5 -16.7
036 1.7 3.9 2.2 131.0 4.1 2.4 144.0
038 1.8 1.5 -0.3 -16.2 1.5 -0.3 -16.2
039 1.2 1.2 -0.1 -5.7 1.4 0.1 11.5
041 2.1 1.5 -0.6 -26.3 2.0 -0.1 -6.2
Average 2.3 2.3 0.0 15.9 2.0 -0.3 -4.5
Count 18 18 18 18 18 18 18
SD 1.1 1.3 1.2 65.5 1.1 1.1 46.0
SE 0.3 0.3 0.3 15.4 0.3 0.3 10.8
95% LCI 1.7 1.7 -0.5 -14.3 1.5 -0.8 -25.7
95% UCI 2.8 2.9 0.6 46.2 2.5 0.2 16.8  
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TNF-α (pg/ml). 
 
Non-Diabetic Subjects
Pt # Wk0 Wk8 Chg %Chg Wk16 Chg %Chg
001 1.0 1.0 0.0 0.0 0.8 -0.2 -20.0
005 0.6 0.6 0.0 0.0 0.5 -0.1 -16.7
013 1.1 0.9 -0.2 -18.2 3.2 2.1 190.9
024 1.0 0.9 -0.1 -10.0 0.9 -0.1 -10.0
026 1.6 1.8 0.2 12.5 1.8 0.2 12.5
028 1.0 1.4 0.4 40.0 1.2 0.2 20.0
029 0.8 0.8 0.0 0.0 1.1 0.3 37.5
032 1.7 2.5 0.8 47.1 2.4 0.7 41.2
033 2.1 2.2 0.1 4.8 2.1 0.0 0.0
037 1.6 1.8 0.2 12.5 1.5 -0.1 -6.3
040 1.1 1.3 0.2 18.2 1.4 0.3 27.3
Average 1.2 1.4 0.1 9.7 1.5 0.3 25.1
Count 11 11 11 11 11 11 11
SD 0.5 0.6 0.3 19.7 0.8 0.7 58.9
SE 0.1 0.2 0.1 5.9 0.2 0.2 17.8
95% LCI 1.0 1.0 0.0 -1.9 1.1 -0.1 -9.7
95% UCI 1.5 1.7 0.3 21.3 2.0 0.7 60.0
Diabetic Subjects
003 2.7 1.6 -1.1 -40.7 1.6 -1.1 -40.7
007 0.8 2.2 1.4 175.0 2.5 1.7 212.5
008 0.7 0.8 0.1 14.3 0.7 0.0 0.0
009 0.9 0.8 -0.1 -11.1 0.8 -0.1 -11.1
012 1.1 1.2 0.1 9.1 1.1 0.0 0.0
014 1.0 1.1 0.1 10.0 1.1 0.1 10.0
017 1.0 1.2 0.2 20.0 0.8 -0.2 -20.0
018 1.2 2.9 1.7 141.7 1.2 0.0 0.0
020 0.9 1.0 0.1 11.1 0.9 0.0 0.0
023 1.5 1.3 -0.2 -13.3 1.3 -0.2 -13.3
025 1.2 1.3 0.1 8.3 0.9 -0.3 -25.0
030 1.7 1.7 0.0 0.0 1.5 -0.2 -11.8
031 1.4 1.6 0.2 14.3 1.4 0.0 0.0
034 2.1 1.4 -0.7 -33.3 1.8 -0.3 -14.3
036 1.3 1.5 0.2 15.4 1.2 -0.1 -7.7
038 1.5 1.2 -0.3 -20.0 3.0 1.5 100.0
039 1.7 1.7 0.0 0.0 1.4 -0.3 -17.6
041 1.4 1.7 0.3 21.4 1.7 0.3 21.4
Average 1.3 1.5 0.1 17.9 1.4 0.0 10.1
Count 18 18 18 18 18 18 18
SD 0.5 0.5 0.6 54.4 0.6 0.6 58.2
SE 0.1 0.1 0.1 12.8 0.1 0.1 13.7
95% LCI 1.1 1.2 -0.2 -7.2 1.1 -0.2 -16.8
95% UCI 1.6 1.7 0.4 43.0 1.7 0.3 37.0  
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PAI-1 (pg/ml). 
 
Non-Diabetic Subjects
Pt # WK0 WK8 Chg %Chg  WK16 Chg %Chg
001 21192.0 7827.0 -13365.0 -63.1 7661.0 -13531.0 -63.8
005 16080.0 8098.0 -7982.0 -49.6 9977.0 -6103.0 -38.0
013 10022.0 7425.0 -2597.0 -25.9 5972.0 -4050.0 -40.4
024 3218.0 2937.0 -281.0 -8.7 5895.0 2677.0 83.2
026 3719.0 4118.0 399.0 10.7 3022.0 -697.0 -18.7
028 10336.0 5944.0 -4392.0 -42.5 4832.0 -5504.0 -53.3
029 12603.0 6030.0 -6573.0 -52.2 4602.0 -8001.0 -63.5
032 10626.0 6573.0 -4053.0 -38.1 5849.0 -4777.0 -45.0
033 7729.0 7712.0 -17.0 -0.2 5918.0 -1811.0 -23.4
037 5669.0 9759.0 4090.0 72.1 4220.0 -1449.0 -25.6
040 5472.0 4790.0 -682.0 -12.5 5507.0 35.0 0.6
Average 9696.9 6473.9 -3223.0 -19.1 5768.6 -3928.3 -26.2
Count 11.0 11.0 11.0 11.0 11.0 11.0 11.0
SD 5462.3 1976.9 4808.0 38.3 1833.8 4440.2 41.2
SE 1646.9 596.1 1449.7 11.5 552.9 1338.8 12.4
95% LCI 6468.9 5305.6 -6064.3 -41.7 4685.0 -6552.3 -50.5
95% UCI 12924.9 7642.2 -381.7 3.5 6852.3 -1304.3 -1.8
Diabetic Subjects
003 27176.0 9939.0 -17237.0 -63.4 7348.0 -19828.0 -73.0
007 13191.0 7025.0 -6166.0 -46.7 6703.0 -6488.0 -49.2
008 8644.0 15782.0 7138.0 82.6 8785.0 141.0 1.6
009 13658.0 8239.0 -5419.0 -39.7 5878.0 -7780.0 -57.0
012 14005.0 10869.0 -3136.0 -22.4 13471.0 -534.0 -3.8
014 11542.0 10878.0 -664.0 -5.8 10481.0 -1061.0 -9.2
017 10914.0 5415.0 -5499.0 -50.4 5047.0 -5867.0 -53.8
018 14837.0 3073.0 -11764.0 -79.3 2527.0 -12310.0 -83.0
020 8496.0 8552.0 56.0 0.7 5864.0 -2632.0 -31.0
023 3939.0 6090.0 2151.0 54.6 8733.0 4794.0 121.7
025 8776.0 9780.0 1004.0 11.4 7521.0 -1255.0 -14.3
030 12986.0 18662.0 5676.0 43.7 9615.0 -3371.0 -26.0
031 14014.0 13739.0 -275.0 -2.0 8212.0 -5802.0 -41.4
034 9419.0 9984.0 565.0 6.0 7363.0 -2056.0 -21.8
036 10011.0 11778.0 1767.0 17.7 8716.0 -1295.0 -12.9
038 18391.0 12643.0 -5748.0 -31.3 7154.0 -11237.0 -61.1
039 7812.0 5080.0 -2732.0 -35.0 8102.0 290.0 3.7
041 12138.0 6575.0 -5563.0 -45.8 6410.0 -5728.0 -47.2
Average 12219.4 9672.4 -2547.0 -11.4 7662.8 -4556.6 -25.4
Count 18.0 18.0 18.0 18.0 18.0 18.0 18.0
SD 4970.7 3959.5 5893.2 42.9 2327.5 5693.2 44.9
SE 1171.6 933.3 1389.0 10.1 548.6 1341.9 10.6
95% LCI 9923.0 7843.2 -5269.5 -31.2 6587.5 -7186.7 -46.1
95% UCI 14515.7 11501.6 175.5 8.4 8738.0 -1926.5 -4.7  
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CRP (ng/ml). 
 
Non-Diabetic Subjects
Pt # Wk0 Wk8 Chg %Chg Wk16 Chg %Chg
001 2147.9 1017.1 -1130.8 -52.6 608.6 -1539.3 -71.7
005 14358.0 8260.6 -6097.4 -42.5 7383.5 -6974.5 -48.6
013 2964.0 1121.0 -1843.0 -62.2 1563.0 -1401.0 -47.3
024 1212.0 1197.7 -14.3 -1.2 441.5 -770.5 -63.6
026 1964.2 3106.3 1142.1 58.1 1371.3 -592.9 -30.2
028 11892.0 11293.0 -599.0 -5.0 5375.3 -6516.7 -54.8
029 1082.5 887.7 -194.8 -18.0 689.8 -392.7 -36.3
032 10030.0 10766.0 736.0 7.3 11131.0 1101.0 11.0
033 12359.0 8616.3 -3742.7 -30.3 10110.0 -2249.0 -18.2
037 14165.0 11203.0 -2962.0 -20.9 14207.0 42.0 0.3
040 6612.1 5830.4 -781.7 -11.8 6272.2 -339.9 -5.1
Average 7162.4 5754.5 -1408.0 -16.3 5377.6 -1784.9 -33.1
Count 11 11 11 11 11 11 11
SD 5485.2 4419.6 2137.4 32.9 4878.2 2605.5 27.2
SE 1653.9 1332.6 644.4 9.9 1470.8 785.6 8.2
95% LCI 3920.9 3142.7 -2671.1 -35.7 2494.8 -3324.6 -49.2
95% UCI 10404.0 8366.3 -144.9 3.2 8260.4 -245.1 -17.0
Diabetic Subjects
003 10609.0 7786.4 -2822.6 -26.6 10797.0 188.0 1.8
007 8146.9 5569.1 -2577.8 -31.6 5091.2 -3055.7 -37.5
008 596.7 379.0 -217.7 -36.5 625.6 28.9 4.8
009 4276.5 1402.2 -2874.3 -67.2 1815.7 -2460.8 -57.5
012 3287.0 944.5 -2342.5 -71.3 642.7 -2644.3 -80.4
014 7992.1 8748.4 756.3 9.5 11408.0 3415.9 42.7
017 2519.6 2437.5 -82.1 -3.3 1395.9 -1123.7 -44.6
018 5047.3 4446.4 -600.9 -11.9 2509.4 -2537.9 -50.3
020 16671.0 8128.6 -8542.4 -51.2 6101.9 -10569.1 -63.4
023 11248.0 10267.0 -981.0 -8.7 8016.4 -3231.6 -28.7
025 1408.8 3420.2 2011.4 142.8 1672.5 263.7 18.7
030 1042.8 5332.1 4289.3 411.3 1854.2 811.4 77.8
031 10144.0 9065.7 -1078.3 -10.6 5914.5 -4229.5 -41.7
034 12299.0 8895.8 -3403.2 -27.7 10251.0 -2048.0 -16.7
036 1497.3 9023.7 7526.4 502.7 803.5 -693.8 -46.3
038 8112.9 2573.5 -5539.4 -68.3 7736.7 -376.2 -4.6
039 4335.7 3011.1 -1324.6 -30.6 3918.8 -416.9 -9.6
041 5001.3 2653.7 -2347.6 -46.9 2716.1 -2285.2 -45.7
Average 6346.4 5226.9 -1119.5 31.9 4626.2 -1720.3 -21.2
Count 18 18 18 18 18 18 18
SD 4554.4 3273.9 3518.9 162.4 3684.5 2864.6 39.9
SE 1073.5 771.7 829.4 38.3 868.5 675.2 9.4
95% LCI 4242.4 3714.5 -2745.2 -43.1 2924.0 -3043.7 -39.6
95% UCI 8450.5 6739.4 506.2 106.9 6328.3 -396.9 -2.7  
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FSH (mIU/ml). 
 
Non-Diabetic Subjects
Pt # Wk0 Wk8 Chg %Chg Wk16 Chg %Chg
001 28.1 30.7 2.6 9.3 35.6 7.5 26.7
005 53.6 59.3 5.7 10.6 50.6 -3.0 -5.6
013 19.1 18.6 -0.5 -2.6 21.5 2.4 12.6
024 88.5 96.4 7.9 8.9 93.5 5.0 5.6
026 76.7 108.1 31.4 40.9 103.6 26.9 35.1
028 8.1 7.0 -1.1 -13.6 8.2 0.1 1.2
029 56.8 72.3 15.5 27.3 81.2 24.4 43.0
032 46.8 97.9 51.1 109.2 41.7 -5.1 -10.9
033 63.8 84.3 20.5 32.1 64.3 0.5 0.8
037 23.0 48.8 25.8 112.2 46.1 23.1 100.4
040 7.4 7.7 0.3 4.1 7.8 0.4 5.4
Average 42.9 57.4 14.5 30.8 50.4 7.5 19.5
Count 11 11 11 11 11 11 11
SD 27.6 37.4 16.5 42.5 32.5 11.7 31.7
SE 8.3 11.3 5.0 12.8 9.8 3.5 9.6
95% LCI 26.6 35.3 4.7 5.7 31.2 0.6 0.7
95% UCI 59.2 79.5 24.2 55.9 69.6 14.4 38.2
Diabetic Subjects
003 37.4 36.7 -0.7 -1.9 37.2 -0.2 -0.5
007 15.5 21.2 5.7 36.8 22.1 6.6 42.6
008 103.6 112.4 8.8 8.5 100.5 -3.1 -3.0
009 40.2 40.0 -0.2 -0.5 41.9 1.7 4.2
012 10.1 30.6 20.5 203.0 31.4 21.3 210.9
014 35.8 42.5 6.7 18.7 37.4 1.6 4.5
017 9.1 17.9 8.8 96.7 22.2 13.1 144.0
018 23.1 28.9 5.8 25.1 26.9 3.8 16.5
020 12.2 16.4 4.2 34.4 14.8 2.6 21.3
023 6.1 6.4 0.3 4.9 6.0 -0.1 -1.6
025 57.4 55.7 -1.7 -3.0 56.8 -0.6 -1.0
030 40.0 47.9 7.9 19.8 59.8 19.8 49.5
031 8.8 18.7 9.9 112.5 9.5 0.7 8.0
034 28.4 42.2 13.8 48.6 50.5 22.1 77.8
036 12.2 16.6 4.4 36.1 12.6 0.4 3.3
038 8.9 7.8 -1.1 -12.4 7.6 -1.3 -14.6
039 16.9 21.9 5.0 29.6 20.7 3.8 22.5
041 9.7 9.7 0.0 0.0 9.7 0.0 0.0
Average 26.4 31.9 5.5 36.5 31.5 5.1 32.5
Count 18 18 18 18 18 18 18
SD 24.3 24.7 5.8 53.1 24.1 8.2 58.5
SE 5.7 5.8 1.4 12.5 5.7 1.9 13.8
95% LCI 15.2 20.4 2.8 12.0 20.4 1.4 5.4
95% UCI 37.6 43.3 8.1 61.0 42.7 8.9 59.5  
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Total Cholesterol (mg/dl) and LDL-cholesterol (mg/dl). 
Non-Diabetic Subjects
Pt #
Screen 
Chol Wk0 Wk8 Wk16 Chg % Chg
Screen 
LDL Wk0 Wk8 Wk16 Chg % Chg
001 208 191 139 221 30 15.7 120 120 75 132 12 10.0
005 266 257 220 255 -2 -0.8 175 185 154 159 -26 -14.1
013 230 248 149 149 -99 -39.9 121 81 65 88 7 8.6
024 231 228 142 162 -66 -28.9 146 159 83 93 -66 -41.5
026 163 227 144 156 -71 -31.3 95 156 94 101 -55 -35.3
028 244 216 159 177 -39 -18.1 143 134 88 118 -16 -11.9
029 141 197 141 134 -63 -32.0 68 127 89 78 -49 -38.6
032 177 177 131 143 -34 -19.2 103 103 75 87 -16 -15.5
033 267 238 113 175 -63 -26.5 179 175 55 116 -59 -33.7
037 224 230 184 170 -60 -26.1 105 104 98 74 -30 -28.8
040 185 145 147 159 14 9.7 111 71 95 107 36 50.7
Average 212.4 214.0 151.7 172.8 -41.2 -17.9 124.2 128.6 88.3 104.8 -23.8 -13.6
Count 11 11 11 11 11 11 11 11 11 11 11 11
SD 41.5 33.4 28.5 35.6 39.8 18.2 33.8 37.4 25.5 25.3 32.6 27.8
SE 12.5 10.1 8.6 10.7 12.0 5.5 10.2 11.3 7.7 7.6 9.8 8.4
95% LCI 187.9 194.3 134.9 151.8 -64.7 -28.7 104.2 106.6 73.2 89.9 -43.1 -30.0
95% UCI 236.9 233.7 168.6 193.8 -17.6 -7.2 144.2 150.7 103.4 119.8 -4.6 2.8
Diabetic Subjects
003 171 161 141 137 -24 -14.0 66 66 66 44 -22 -33.3
004 211 217 224 WD 123 144 157 WD
007 209 209 171 169 -40 -19.1 99 99 157 97 -2 -2.0
008 223 189 153 295 106 47.5 105 105 70 176 71 67.6
009 250 257 222 241 -16 -6.4 140 140 147 171 31 22.1
010 217 201 214 WD 151 151 75 WD
012 185 187 157 172 -15 -8.1 125 125 75 120 -5 -4.0
014 261 228 188 191 -37 -14.2 161 161 121 140 -21 -13.0
015 225 192 225 WD 133 118 119 WD
017 183 157 196 184 27 14.8 50 54 119 111 57 105.6
018 253 252 188 193 -59 -23.3 180 184 137 141 -43 -23.4
020 221 195 175 174 -21 -9.5 96 96 90 110 14 14.6
023 232 214 195 194 -20 -8.6 145 142 128 131 -11 -7.7
025 252 236 217 202 -34 -13.5 169 161 158 138 -23 -14.3
030 191 177 174 203 26 13.6 99 101 113 131 30 29.7
031 191 188 188 179 -9 -4.7 97 79 125 97 18 22.8
034 187 176 142 143 -33 -17.6 198 113 89 90 -23 -20.4
036 157 143 187 134 -9 -5.7 87 77 124 77 0 0.0
038 223 194 168 204 10 4.5 150 119 108 141 22 18.5
039 226 213 176 182 -31 -13.7 156 144 122 132 -12 -8.3
041 150 259 122 178 -81 -54.0 83 176 73 123 -53 -30.1
Average 210.4 202.1 182.0 187.5 -14.4 -7.3 124.4 121.7 113.0 120.6 1.6 6.9
Count 21 21 21 18 18 18 21 21 21 18 18 18
SD 31.5 32.0 29.0 37.2 40.0 20.2 38.9 36.1 30.0 32.1 32.6 35.0
SE 3.7 3.7 3.9 2.9 2.8 4.0 3.4 3.5 3.8 3.2 3.2 3.0
95% LCI 203.0 194.9 174.4 181.7 -20.0 -15.2 117.8 114.8 105.5 114.3 -4.6 0.9
95% UCI 217.7 209.4 189.7 193.3 -8.9 0.5 131.0 128.5 120.5 126.8 7.7 12.9
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Triglyceride (mg/dl) and HDL-cholesterol (mg/dl). 
Non-Diabetic Subjects
Pt #
Screen 
Trigly-
cerides Wk0 Wk8 Wk16 Chg % Chg
Screen 
HDL Wk0 Wk8 Wk16 Chg % Chg
001 158 158 139 110 -48 -30.4 56 42 36 38 -4 -9.5
005 127 117 236 182 65 55.6 66 49 41 41 -8 -16.3
013 311 132 177 101 -31 -23.5 47 46 42 41 -5 -10.9
024 59 47 39 46 -1 -2.1 73 60 51 60 0 0.0
026 107 76 68 71 -5 -6.6 46 56 36 41 -15 -26.8
028 161 159 156 89 -70 -44.0 68 50 40 41 -9 -18.0
029 103 82 52 43 -39 -47.6 52 54 42 47 -7 -13.0
032 75 75 89 89 14 18.7 59 59 38 38 -21 -35.6
033 152 125 110 120 -5 -4.0 58 38 36 35 -3 -7.9
037 183 294 154 150 -144 -49.0 82 67 55 66 -1 -1.5
040 141 111 94 99 -12 -10.8 46 52 33 32 -20 -38.5
Average 143.4 125.1 119.5 100.0 -25.1 -13.1 59.4 52.1 40.9 43.6 -8.5 -16.2
Count 11 11 11 11 11 11 11 11 11 11 11 11
SD 67.3 66.3 59.3 41.2 53.0 31.3 11.8 8.4 6.7 10.4 7.2 12.7
SE 20.3 20.0 17.9 12.4 16.0 9.4 3.6 2.5 2.0 3.1 2.2 3.8
95% LCI 103.6 85.9 84.4 75.7 -56.4 -31.6 52.4 47.1 37.0 37.5 -12.7 -23.7
95% UCI 183.1 164.3 154.5 124.3 6.2 5.4 66.3 57.0 44.9 49.8 -4.2 -8.7
Diabetic Subjects
003 296 296 467 308 12 4.1 46 27 26 31 4 14.8
004 228 228 210 WD 42 37 29 WD
007 362 362 173 230 -132 -36.5 38 30 23 26 -4 -13.3
008 224 224 152 267 43 19.2 73 71 53 66 -5 -7.0
009 339 339 277 185 -154 -45.4 42 30 28 33 3 10.0
010 106 106 167 WD 45 34 30 WD
012 119 119 213 92 -27 -22.7 36 32 25 34 2 6.3
014 280 280 169 108 -172 -61.4 44 33 33 29 -4 -12.1
015 241 203 385 ED 45 34 30 WD
017 342 276 194 119 -157 -56.9 65 48 38 49 1 2.1
018 176 193 112 78 -115 -59.6 38 29 29 36 7 24.1
020 505 368 294 173 -195 -53.0 31 25 26 29 4 16.0
023 145 152 122 106 -46 -30.3 58 42 43 42 0 0.0
025 135 159 128 98 -61 -38.4 56 43 33 44 1 2.3
030 195 168 138 196 28 16.7 53 42 33 33 -9 -21.4
031 215 350 156 212 -138 -39.4 51 39 32 40 1 2.6
034 159 152 134 98 -54 -35.5 47 33 26 33 0 0.0
036 130 148 161 126 -22 -14.9 44 36 31 32 -4 -11.1
038 120 183 83 92 -91 -49.7 49 38 43 45 7 18.4
039 125 142 91 56 -86 -60.6 45 41 36 39 -2 -4.9
041 137 208 68 90 -118 -56.7 40 41 35 37 -4 -9.8
Average 218.0 221.7 185.4 146.3 -82.5 -34.5 47.2 37.2 32.6 37.7 -0.1 0.9
Count 21 21 21 18 18 18 20 21 20 18 18 18
SD 104.1 83.2 98.7 71.8 70.9 25.8 10.1 9.8 7.3 9.4 4.3 12.4
SE 22.7 18.1 21.5 16.9 16.7 6.1 2.2 2.1 1.6 2.2 1.0 2.9
95% LCI 173.5 186.1 143.2 113.2 -115.3 -46.4 42.7 33.0 29.4 33.3 -2.1 -4.8
95% UCI 262.6 257.3 227.6 179.5 -49.7 -22.6 51.6 41.4 35.8 42.0 1.9 6.7
*Italized numbers are interpolated or taken from baseline week
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 Systolic and Diastolic Blood Pressure Measurements (mmHg). 
Non-Diabetic Subjects
Pt #
Screen 
Systolic
Screen 
Diastolic
Wk0 
S
Wk0 
D
Wk4  
S
Wk4  
D
Wk8 
S
Wk8 
D
Wk12 
S
Wk12 
D
Wk16 
S
Wk16 
D
001 128 68 122 74 100 70 110 72 102 60 112 66
005 120 64 134 80 142 74 120 80 128 84 130 90
013 122 74 108 78 110 74 98 64 100 70 116 66
024 126 72 108 70 108 66 102 70 102 58 114 66
026 122 76 130 80 122 70 110 84 112 70 130 84
028 118 72 110 70 104 74 100 70 118 60 102 74
029 130 78 120 70 100 80 100 60 120 70 140 70
032 114 78 120 70 100 70 110 70 112 70 110 68
033 132 82 110 74 120 80 124 66 152 90 108 72
037 122 78 120 72 130 72 128 70 104 70 130 76
040 122 80 112 70 110 70 112 76 122 84 110 80
Average 123.3 74.7 117.6 73.5 113.3 72.7 110.4 71.1 115.6 71.5 118.4 73.8
Count 11 11 11 11 11 11 11 11 11 11 11 11
SD 5.3 5.4 8.9 4.1 13.7 4.3 10.2 6.9 15.2 10.5 12.1 8.0
SE 1.6 1.6 2.7 1.2 4.1 1.3 3.1 2.1 4.6 3.2 3.6 2.4
95% LCI 120.1 71.5 112.4 71.0 105.1 70.2 104.4 67.0 106.6 65.2 111.2 69.1
95% UCI 126.4 77.9 122.9 75.9 121.4 75.3 116.4 75.2 124.6 77.7 125.5 78.6
Diabetic Subjects
003 130 78 100 68 120 78 130 80 112 80 140 86
004 145 105 140 80 132 90 120 80 WD
007 122 78 142 88 130 84 118 74 100 70 108 68
008 132 78 130 80 150 86 146 82 120 74 132 80
009 145 90 124 82 132 76 140 80 140 90 150 94
010 138 72 140 84 118 66 120 76 136 74 WD
012 140 82 138 90 100 76 120 80 134 82 130 70
014 148 72 134 74 110 68 120 60 116 60 122 76
015 158 90 144 88 130 84 78 100 WD
017 136 78 110 70 120 64 130 70 120 72 126 66
018 136 88 144 86 138 74 130 90 120 80 140 82
020 122 78 110 70 120 70 130 70 126 72 100 80
023 112 72 110 74 110 74 106 70 104 70 110 70
025 132 78 118 78 90 56 100 58 100 60 118 82
030 132 72 138 90 110 80 116 80 124 72 120 70
031 116 68 110 80 112 80 116 72 108 74 120 60
034 118 78 110 74 102 62 110 70 100 62 100 54
036 118 78 124 70 140 90 110 70 140 78 124 74
038 118 76 120 86 108 60 118 74 110 74 118 74
039 124 78 124 80 116 74 128 80 114 78 122 88
041 122 78 120 60 106 70 100 60 110 60 118 80
Average 130.7 79.4 125.2 78.7 118.8 74.4 118.4 75.0 117.6 72.7 122.1 75.2
Count 21 21 21 21 21 21 21 21 19 19 18 18
SD 12.2 8.2 13.7 8.2 14.9 9.6 15.0 9.8 13.1 8.1 13.2 10.0
SE 2.7 1.8 3.0 1.8 3.2 2.1 3.3 2.1 3.0 1.8 3.1 2.4
95% LCI 125.4 75.9 119.4 75.2 112.4 70.3 112.0 70.9 111.7 69.1 116.0 70.6
95% UCI 135.9 82.9 131.1 82.2 125.1 78.5 124.8 79.2 123.5 76.4 128.2 79.8
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Correlation Analyses 
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Diabetic Subjects 
 
                                  Pearson Correlation Coefficients, N = 18 
                                    
 
                             Weight         Leptin         Resistin         Insulin         HOMA-IR 
 
        Weight         1.00000        0.58332       -0.06395       0.31957        0.15609 
                                                  0.0110          0.8010          0.1961          0.5363 
 
        Leptin          0.58332        1.00000       -0.32905        0.38868        0.41457 
                             0.0110                               0.1824           0.1109          0.0872 
 
        Resistin      -0.06395       -0.32905        1.00000       -0.50912       -0.64540 
                             0.8010          0.1824                                0.0309          0.0038 
 
        Insulin         0.31957        0.38868        -0.50912       1.00000         0.88828 
                             0.1961          0.1109           0.0309                               <.0001 
 
        HOMA-IR   0.15609        0.41457       -0.64540         0.88828        1.00000 
                             0.5363          0.0872          0.0038           <.0001 
 
Non-Diabetic Subjects 
 
                            Pearson Correlation Coefficients, N = 11 
                                    
 
                            Weight         Leptin         Resistin         Insulin         HOMA-IR 
 
        Weight         1.00000       0.71257       0.43343        0.58066         0.60139 
                                                 0.0139         0.1829          0.0611           0.0503 
 
        Leptin           0.71257      1.00000       0.41352        0.22670          0.24788 
                              0.0139                            0.2062          0.5026            0.4624 
 
        Resistin        0.43343       0.41352       1.00000       -0.13450        -0.11060 
                              0.1829         0.2062                              0.6934            0.7461 
 
        Insulin          0.58066      0.22670      -0.13450        1.00000          0.99801 
                              0.0611        0.5026         0.6934                                 <.0001 
 
        HOMA-IR    0.60139      0.24788      -0.11060        0.99801         1.00000 
                              0.0503        0.4624         0.7461           <.0001 
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Diabetic Subjects 
 
                            Pearson Correlation Coefficients, N = 18 
                                     
 
                             BMI          Leptin          Resistin          Insulin          HOMA-IR 
 
        BMI             1.00000     0.59797       -0.13450         0.44322        0.40553 
                                               0.0088           0.5947           0.0654          0.0950 
 
        Leptin          0.59797     1.00000       -0.32905         0.38868        0.41457 
                             0.0088                             0.1824           0.1109          0.0872 
 
        Resistin      -0.13450    -0.32905        1.00000        -0.50912      -0.64540 
                             0.5947       0.1824                                 0.0309          0.0038 
 
        Insulin         0.44322     0.38868       -0.50912         1.00000        0.88828 
                             0.0654       0.1109           0.0309                               <.0001 
 
        HOMA-IR   0.40553     0.41457      -0.64540          0.88828       1.00000 
                             0.0950       0.0872          0.0038            <.0001 
 
Non-Diabetic Subjects 
 
                            Pearson Correlation Coefficients, N = 11 
                                     
 
                              BMI          Leptin          Resistin          Insulin          HOMA-IR 
 
        BMI             1.00000      0.82402        0.31312          0.60938        0.63385 
                                                0.0018          0.3485            0.0466          0.0362 
 
        Leptin          0.82402      1.00000        0.41352          0.22670        0.24788 
                             0.0018                             0.2062             0.5026          0.4624 
 
        Resistin       0.31312      0.41352        1.00000         -0.13450      -0.11060 
                             0.3485       0.2062                                  0.6934          0.7461 
 
        Insulin         0.60938     0.22670       -0.13450           1.00000       0.99801 
                             0.0466       0.5026          0.6934                                 <.0001 
 
        HOMA-IR   0.63385    0.24788        -0.11060           0.99801       1.00000 
                            0.0362       0.4624            0.7461            <.0001 
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Diabetic Subjects 
                            Pearson Correlation Coefficients, N = 18 
                                   
 
            Leptin      Resistin      Insulin      HOMA-IR      Ghrelin      Adiponectin 
 
 Leptin            1.00000   -0.32905     0.38868     0.41457          0.03533       0.24760 
                                         0.1824        0.1109       0.0872            0.8893         0.3219 
 
 Resistin        -0.32905    1.00000    -0.50912    -0.64540        -0.18873      -0.04695 
                        0.1824                        0.0309        0.0038           0.4533         0.8532 
 
 Insulin           0.38868  -0.50912      1.00000      0.88828       -0.41806      -0.14652 
                        0.110       0.0309                           <.0001           0.0843         0.5618 
 
 HOMA-IR     0.41457  -0.64540      0.88828      1.00000      -0.38697      -0.18609 
                        0.0872      0.0038        <.0001                            0.1126          0.4597 
 
 Ghrelin          0.03533  -0.18873     -0.41806    -0.38697       1.00000        0.57527 
                        0.8893      0.4533        0.0843        0.1126                              0.0125 
 
 Adiponectin  0.24760  -0.04695     -0.14652    -0.18609        0.57527       1.00000 
                        0.3219     0.8532         0.5618        0.4597          0.0125 
Non-Diabetic Subjects 
                            Pearson Correlation Coefficients, N = 11 
                                    
 
                       Leptin      Resistin      Insulin       HOMA-IR      Ghrelin      Adiponectin 
 
 Leptin           1.00000    0.41352      0.22670     0.24788         -0.37545    -0.61844 
                                        0.2062        0.5026        0.4624            0.2552       0.0425 
 
 Resistin        0.41352    1.00000     -0.13450   -0.11060         -0.38078     -0.45637 
                       0.2062                         0.6934       0.7461            0.2480         0.1583 
 
 Insulin          0.22670  -0.13450      1.00000     0.99801         -0.31998     -0.49174 
                       0.5026      0.6934                         <.0001            0.3374         0.1245 
 
 HOMA-IR   0.24788  -0.11060       0.99801     1.00000         -0.35775     -0.49922 
                      0.4624      0.7461        <.0001                               0.2800         0.1180 
 
 Ghrelin      -0.37545  -0.38078      -0.31998    -0.35775          1.00000       0.44422 
                     0.2552       0.2480         0.3374       0.2800                                0.1711 
 
 Adiponectin -0.61844  -0.45637   -0.49174    -0.49922          0.44422      1.00000 
                        0.0425      0.1583      0.1245        0.1180            0.1711 
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Diabetic Subjects 
 
                            Pearson Correlation Coefficients, N = 18 
                                     
 
    BMI             CRP             IL-6             TNF-α             Insulin 
 
        BMI            1.00000       0.43709      -0.01402       -0.02011           0.44322 
                                                0.0697         0.9560           0.9369             0.0654 
 
        CRP            0.43709      1.00000        0.25831         0.40949         -0.18633 
                             0.0697                             0.3007           0.0915            0.4591 
 
        IL-6           -0.01402      0.25831        1.00000         0.00698         -0.19369 
                             0.9560        0.3007                                0.9781            0.4412 
 
        TNF-α       -0.02011      0.40949        0.00698         1.00000          0.07350 
                             0.9369         0.0915         0.9781                                   0.7719 
 
        Insulin        0.44322     -0.18633      -0.19369          0.07350        1.00000 
                             0.0654        0.4591         0.4412             0.7719 
 
Non-Diabetic Subjects 
 
                                Pearson Correlation Coefficients, N = 11 
                                   
 
                               BMI             CRP             IL-6              TNF-α             Insulin 
 
        BMI               1.00000      -0.10754        0.25181        0.24618            0.60938 
                                                     0.7675         0.4551          0.4656              0.0466 
 
        CRP             -0.10754       1.00000       -0.05715        0.20543            0.00026 
                               0.7675                               0.8754          0.5691              0.9994 
 
        IL-6               0.25181     -0.05715        1.00000         0.49414          -0.13721 
                                0.4551        0.8754                                0.1224             0.6875 
 
        TNF-α           0.24618      0.20543         0.49414        1.00000          -0.12708 
                               0.4656         0.5691           0.1224                                  0.7096 
 
        Insulin           0.60938      0.00026       -0.13721        -0.12708           1.00000 
                               0.0466        0.9994           0.6875           0.7096 
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Diabetic Subjects 
 
                            Pearson Correlation Coefficients, N = 18 
                                   
 
                           Weight          Leptin          Resistin          Insulin          HOMA-IR 
 
        Weight        1.00000        0.58332       -0.06395         0.31957         0.15609 
                                                  0.0110          0.8010           0.1961           0.5363 
 
        Leptin         0.58332        1.00000      -0.32905          0.38868         0.41457 
                             0.0110                              0.1824            0.1109           0.0872 
 
        Resistin     -0.06395      -0.32905        1.00000         -0.50912       -0.64540 
                            0.8010          0.1824                                  0.0309          0.0038 
 
        Insulin        0.31957        0.38868      -0.50912          1.00000        0.88828 
                             0.1961          0.1109         0.0309                                <.0001 
 
        HOMA-IR  0.15609       0.41457      -0.64540           0.88828       1.00000 
                             0.5363         0.0872         0.0038            <.0001 
 
Non-Diabetic Subjects 
 
                            Pearson Correlation Coefficients, N = 11 
                                    
 
                           Weight          Leptin          Resistin          Insulin          HOMA-IR 
 
        Weight       1.00000         0.71257        0.43343         0.58066         0.60139 
                                                  0.0139          0.1829           0.0611           0.0503 
 
        Leptin        0.71257        1.00000         0.41352         0.22670         0.24788 
                            0.0139                                0.2062           0.5026           0.4624 
 
        Resistin     0.43343         0.41352        1.00000        -0.13450       -0.11060 
                           0.1829           0.2062                                 0.6934          0.7461 
 
        Insulin       0.58066        0.22670       -0.13450         1.00000         0.99801 
                           0.0611          0.5026           0.6934                                <.0001 
 
        HOMA-IR 0.60139        0.24788       -0.11060         0.99801        1.00000 
                            0.0503          0.4624           0.7461         <.0001 
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Diabetic Subjects 
                            Pearson Correlation Coefficients, N = 18 
                                     
 
                  SAT          VAT          Insulin          HOMA-IR          Resistin          Ghrelin 
 
 SAT         1.00000    -0.07844     0.06746        0.03148               0.13456         0.14492 
                                     0.7570        0.7903         0.9013                 0.5945           0.5661 
 
 VAT       -0.07844     1.00000     0.32018        0.28711              -0.28494       -0.12384 
                   0.7570                         0.1952          0.2480                 0.2518          0.6244 
 
 Insulin      0.06746     0.32018    1.00000         0.88828             -0.50912       -0.41806 
                    0.7903         0.1952                         <.0001                 0.0309          0.0843 
 
 HOMA-IR 0.03148   0.28711     0.88828        1.00000              -0.64540       -0.38697 
                     0.9013     0.2480      <.0001                                        0.0038          0.1126 
 
 Resistin     0.13456  -0.28494   -0.50912       -0.64540               1.00000        -0.18873 
                     0.5945      0.2518      0.0309          0.0038                                       0.4533 
 
 Ghrelin      0.14492  -0.12384   -0.41806       -0.38697              -0.18873        1.00000 
                     0.5661      0.6244      0.0843          0.1126                 0.4533 
 
Non-Diabetic Subjects 
                            Pearson Correlation Coefficients, N = 11 
                                     
                 SAT          VAT          Insulin          HOMA-IR          Resistin          Ghrelin 
 
 SAT        1.00000     0.54467     0.61906         0.62963              0.20826         -0.45145 
                                    0.0832        0.0423          0.0379                0.5389           0.1634 
 
 VAT        0.54467    1.00000     0.03378         0.06491              0.17620         -0.31443 
                   0.0832                        0.9214          0.8496                 0.6043            0.3463 
 
 Insulin     0.61906    0.03378     1.00000         0.99801            -0.13450         -0.31998 
                   0.0423      0.9214                            <.0001                0.6934            0.3374 
 
 HOMA-IR 0.62963  0.06491     0.99801        1.00000             -0.11060         -0.35775 
                     0.0379    0.8496      <.0001                                      0.7461            0.2800 
 
 Resistin     0.20826   0.17620   -0.13450       -0.11060              1.00000         -0.38078 
                     0.5389      0.6043     0.6934           0.7461                                       0.2480 
 
 Ghrelin    -0.45145  -0.31443   -0.31998      -0.35775             -0.38078           1.00000 
                    0.1634       0.3463      0.3374        0.2800                 0.2480 
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Diabetic Subjects 
                                Pearson Correlation Coefficients, N = 18 
                                    
               BMI              %BF              SAT              VAT              Fat              Lean 
 
BMI       1.00000        0.56699         0.58108          0.65818         0.81721       0.23290 
                                     0.0176           0.0114            0.0030          <.0001          0.3523 
 
%BF       0.56699       1.00000         0.66674          0.37650         0.80252      -0.56366 
                 0.0176                               0.0035            0.1363           0.0001         0.0185 
 
SAT        0.58108       0.66674        1.00000         -0.07844         0.59476      -0.23720 
                  0.0114         0.0035                                 0.7570           0.0092         0.3433 
 
VAT       0.65818       0.37650       -0.07844          1.00000         0.60538        0.33578 
                  0.0030         0.1363         0.7570                                   0.0078         0.1731 
 
Fat          0.81721       0.80252        0.59476           0.60538        1.00000        -0.02126 
                <.0001          0.0001          0.0092             0.0078                                0.9333 
 
Lean          0.23290       -0.56366       -0.23720        0.33578      -0.02126       1.00000 
                    0.3523          0.0185           0.3433          0.1731         0.9333 
  
Non-Diabetic Subjects 
                            Pearson Correlation Coefficients, N = 11 
                                    
               BMI              %BF              SAT              VAT              Fat              Lean 
 
BMI       1.00000         0.74983         0.94085         0.58185         0.95563       0.58038 
                                      0.0079          <.0001            0.0604          <.0001         0.0612 
 
%BF      0.74983         1.00000         0.65655         0.63711         0.70635        0.30799 
                0.0079                                 0.0282           0.0350           0.0151          0.3568 
 
SAT       0.94085         0.65655         1.00000         0.54467         0.95345        0.44314 
               <.0001           0.0282                                  0.0832          <.0001          0.1722 
 
VAT      0.58185         0.63711          0.54467        1.00000         0.51832        0.00809 
                0.0604           0.0350            0.0832                                0.1024           0.9812 
 
Fat         0.95563         0.70635          0.95345         0.51832        1.00000        0.60202 
               <.0001            0.0151           <.0001            0.1024                               0.0500 
 
Lean      0.58038         0.30799          0.44314          0.00809        0.60202       1.00000 
                0.0612           0.3568            0.1722            0.9812          0.0500 
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Diabetic Subjects 
 
 
                            Pearson Correlation Coefficients, N = 18 
                                     
 
                            Insulin             Weight             BMI 
 
Insulin                 1.00000            0.31957           0.44322 
                                                       0.1961             0.0654 
 
Weight                 0.31957           1.00000           0.79522 
                               0.1961                                    <.0001 
 
BMI                     0.44322            0.79522          1.00000 
0.654 <.0001 
 
Non-Diabetic Subjects 
 
                            Pearson Correlation Coefficients, N = 11 
                                   
 
                            Insulin             Weight             BMI 
 
Insulin                 1.00000            0.58066           0.60938 
                                                       0.0611             0.0466 
 
Weight                 0.58066           1.00000           0.89177 
                               0.0611                                    0.0002 
 
BMI                     0.60938           0.89177           1.00000 
                               0.0466            0.0002 
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Diabetic Subjects 
                                Pearson Correlation Coefficients, N = 18 
                                    
                  Insulin            %BF            SAT             VAT            Fat            Lean 
 
 Insulin      1.00000          0.26757       0.06746        0.32018       0.29263     0.17826 
                                           0.2992         0.7903          0.1952         0.2386       0.4791 
 
 %BF         0.26757          1.00000       0.66674        0.37650       0.80252   -0.56366 
                    0.2992                                0.0035          0.1363         0.0001       0.0185 
 
 SAT          0.06746          0.66674       1.00000      -0.07844       0.59476   -0.23720 
                    0.7903            0.0035                             0.7570          0.0092      0.3433 
 
 VAT         0.32018          0.37650      -0.07844       1.00000        0.60538    0.33578 
                    0.1952            0.1363         0.7570                               0.0078      0.1731 
 
 Fat            0.29263          0.80252       0.59476        0.60538       1.00000   -0.02126 
                    0.2386            0.0001         0.0092          0.0078                           0.9333 
 
 Lean         0.17826        -0.56366      -0.23720        0.33578      -0.02126    1.00000 
                    0.4791           0.0185          0.3433          0.1731         0.9333 
 
Non-Diabetic Subjects 
                            Pearson Correlation Coefficients, N = 11 
                                     
                  Insulin            %BF            SAT            VAT            Fat             Lean 
 
 Insulin      1.00000          0.53063       0.61906       0.03378       0.61609     0.38407 
                                           0.0931         0.0423         0.9214         0.0436        0.2436 
 
 %BF        0.53063          1.00000        0.65655       0.63711       0.70635     0.30799 
                   0.0931                                 0.0282         0.0350         0.0151        0.3568 
 
 SAT         0.61906          0.65655        1.00000       0.54467      0.95345      0.44314 
                   0.0423            0.0282                               0.0832      <.0001         0.1722 
 
 VAT        0.03378          0.63711        0.54467       1.00000      0.51832      0.00809 
                   0.9214            0.0350          0.0832                             0.1024       0.9812 
 
 Fat           0.61609          0.70635        0.95345       0.51832      1.00000      0.60202 
                   0.0436            0.0151         <.0001          0.1024                          0.0500 
 
 Lean        0.38407          0.30799        0.44314       0.00809      0.60202      1.00000 
                   0.2436            0.3568          0.1722          0.9812        0.0500 
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Diabetic Subjects 
 
                            Pearson Correlation Coefficients, N = 18 
                                  
 
                    Insulin          Leptin          Resistin          Ghrelin          HOMA-IR 
 
Insulin        1.00000        0.38868       -0.50912        -0.41806          0.88828 
                                          0.1109          0.0309            0.0843           <.0001 
 
Leptin        0.38868        1.00000       -0.32905          0.03533          0.41457 
                     0.1109                               0.1824            0.8893            0.0872 
 
Resistin    -0.50912      -0.32905         1.00000        -0.18873         -0.64540 
                     0.0309         0.1824                                 0.4533            0.0038 
 
Ghrelin     -0.41806       0.03533        -0.18873         1.00000         -0.38697 
                     0.0843         0.8893           0.4533                                   0.1126 
 
HOMA-IR 0.88828       0.41457        -0.64540        -0.38697          1.00000 
                   <.0001          0.0872           0.0038            0.1126 
 
Non-Diabetic Subjects 
 
                            Pearson Correlation Coefficients, N = 11 
                                  
 
                     Insulin          Leptin          Resistin          Ghrelin          HOMA-IR 
 
Insulin          1.00000        0.22670      -0.13450         -0.31998         0.99801 
                                            0.5026         0.6934             0.3374          <.0001 
 
Leptin          0.22670        1.00000        0.41352         -0.37545         0.24788 
                       0.5026                              0.2062             0.2552           0.4624 
 
Resistin      -0.13450        0.41352        1.00000        -0.38078        -0.11060 
                      0.6934          0.2062                                 0.2480           0.7461 
 
Ghrelin       -0.31998      -0.37545       -0.38078        1.00000         -0.35775 
                      0.3374          0.2552          0.2480                                  0.2800 
 
HOMA-IR   0.99801        0.24788      -0.11060       -0.35775          1.00000 
                     <.0001           0.4624         0.7461           0.2800 
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Diabetic Subjects 
 
                            Pearson Correlation Coefficients, N = 18 
                                    
 
                      Insulin            CRP            IL-6            TNF-α            Adiponectin 
 
Insulin           1.00000         -0.18633    -0.19369       0.07350        -0.14652 
                                                0.4591       0.4412         0.7719           0.5618 
 
CRP             -0.18633          1.00000      0.25831       0.40949        -0.07220 
                        0.4591                               0.3007         0.0915           0.7759 
 
IL-6              -0.19369          0.25831     1.00000        0.00698        -0.12576 
                         0.4412           0.3007                             0.9781            0.6190 
 
TNF-α           0.07350          0.40949      0.00698       1.00000        -0.38637 
                        0.7719            0.0915        0.9781                               0.1132 
 
Adiponectin -0.14652        -0.07220     -0.12576      -0.38637        1.00000 
                        0.5618           0.7759         0.6190          0.1132 
 
Non-Diabetic Subjects 
 
                                Pearson Correlation Coefficients, N = 11 
                                    
 
                      Insulin            CRP            IL-6            TNF-α            Adiponectin 
 
Insulin           1.00000          0.00026     -0.13721     -0.12708        -0.49174 
                                               0.9994         0.6875         0.7096          0.1245 
 
CRP              0.00026          1.00000     -0.05715       0.20543        -0.36323 
                       0.9994                                0.8754         0.5691           0.3022 
 
IL-6             -0.13721         -0.05715      1.00000       0.49414        -0.54031 
                       0.6875             0.8754                            0.1224           0.0862 
 
TNF-α         -0.12708          0.20543       0.49414      1.00000        -0.46298 
                        0.7096            0.5691         0.1224                              0.1516 
 
Adiponectin -0.49174        -0.36323     -0.54031     -0.46298         1.00000 
                        0.1245           0.3022         0.0862         0.1516 
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Diabetic Subjects 
 
                                Pearson Correlation Coefficients, N = 18 
                                    
 
                     %BF            Leptin            Resistin            Ghrelin            HOMA-IR 
 
%BF             1.00000       0.72023        -0.09666           -0.12694           0.21251 
                                           0.0011           0.7121               0.6273             0.4128 
 
Leptin           0.72023       1.00000       -0.32905             0.03533           0.41457 
                       0.0011                              0.1824                0.8893             0.0872 
 
Resistin       -0.09666      -0.32905         1.00000          -0.18873          -0.64540 
                       0.7121          0.1824                                   0.4533             0.0038 
 
Ghrelin        -0.12694       0.03533       -0.18873            1.00000          -0.38697 
                        0.6273         0.8893          0.4533                                      0.1126 
 
HOMA-IR    0.21251       0.41457       -0.64540           -0.38697           1.00000 
                       0.4128         0.0872           0.0038              0.1126 
 
Non-Diabetic Subjects 
 
                            Pearson Correlation Coefficients, N = 11 
                                     
 
                      %BF            Leptin            Resistin            Ghrelin            HOMA-IR 
 
%BF              1.00000       0.61181        -0.01212           -0.52210           0.56978 
                                            0.0455           0.9718               0.0995             0.0673 
 
Leptin            0.61181       1.00000         0.41352           -0.37545           0.24788 
                        0.0455                               0.2062               0.2552            0.4624 
 
Resistin        -0.01212       0.41352         1.00000           -0.38078          -0.11060 
                        0.9718         0.2062                                     0.2480             0.7461 
 
Ghrelin        -0.52210      -0.37545        -0.38078            1.00000          -0.35775 
                       0.0995          0.2552           0.2480                                       0.2800 
 
HOMA-IR    0.56978        0.24788        -0.11060           -0.35775          1.00000 
                       0.0673          0.4624            0.7461              0.2800 
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Diabetic Subjects 
 
                                Pearson Correlation Coefficients, N = 18 
                                    
 
                       %BF            CRP            IL-6            TNF-α             Adiponectin 
 
%BF               1.00000       0.23269      0.24746     -0.20420            0.14741 
                                             0.3688        0.3383         0.4318              0.572 
 
CRP                0.23269      1.00000      0.25831       0.40949           -0.07220 
                         0.3688                           0.3007         0.0915               0.7759 
 
IL-6                0.24746      0.25831      1.00000       0.00698           -0.12576 
                         0.3383        0.3007                            0.9781              0.6190 
 
TNF-α          -0.20420      0.40949      0.00698       1.00000            -0.38637 
                        0.4318        0.0915        0.9781                                    0.1132 
 
Adiponectin   0.14741    -0.07220     -0.12576      -0.38637             1.00000 
                        0.5724        0.7759        0.6190          0.1132 
 
Non-Diabetic Subjects 
 
                                Pearson Correlation Coefficients, N = 11 
                                    
 
                       %BF            CRP            IL-6            TNF-α            Adiponectin 
 
%BF               1.00000       0.20583     -0.09351     -0.23333         -0.39723 
                                             0.5683        0.7845         0.4899            0.2264 
 
CRP                0.20583       1.00000    -0.05715       0.20543         -0.36323 
                         0.5683                            0.8754         0.5691            0.3022 
 
IL-6               -0.09351     -0.05715      1.00000       0.49414         -0.54031 
                         0.7845         0.8754                            0.1224             0.0862 
 
TNF-α           -0.23333      0.20543       0.49414      1.00000         -0.46298 
                         0.4899         0.5691        0.1224                                0.1516 
 
Adiponectin  -0.39723     -0.36323     -0.54031     -0.46298          1.00000 
                         0.2264         0.3022        0.0862        0.1516 
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Diabetic Subjects 
 
                            Pearson Correlation Coefficients, N = 18 
                                   
 
                       SAT          Leptin          Resistin          Ghrelin          HOMA-IR 
 
SAT               1.00000     0.44022        0.13456          0.14492         0.03148 
                                          0.0675          0.5945            0.5661           0.9013 
 
Leptin            0.44022     1.00000      -0.32905          0.03533         0.41457 
                        0.0675                            0.1824            0.8893           0.0872 
 
Resistin          0.13456   -0.32905       1.00000         -0.18873       -0.64540 
                         0.5945      0.1824                                 0.4533          0.0038 
 
Ghrelin           0.14492    0.03533      -0.18873          1.00000       -0.38697 
                         0.5661      0.8893         0.4533                                  0.1126 
 
HOMA-IR      0.03148    0.41457      -0.64540        -0.38697        1.00000 
                         0.9013      0.0872         0.0038            0.1126 
 
Non-Diabetic Subjects 
 
                            Pearson Correlation Coefficients, N = 11 
                                     
 
                       SAT          Leptin          Resistin          Ghrelin          HOMA-IR 
 
SAT               1.00000     0.86803        0.20826        -0.45145         0.62963 
                                          0.0005          0.5389            0.1634           0.0379 
 
Leptin            0.86803     1.00000        0.41352        -0.37545         0.24788 
                        0.0005                            0.2062            0.2552           0.4624 
 
Resistin         0.20826      0.41352       1.00000        -0.38078       -0.11060 
                        0.5389        0.2062                               0.2480           0.7461 
 
Ghrelin        -0.45145     -0.37545      -0.38078         1.00000       -0.35775 
                       0.1634         0.2552         0.2480                                 0.2800 
 
HOMA-IR    0.62963       0.24788     -0.11060         -0.35775       1.00000 
                       0.0379         0.4624         0.7461            0.2800 
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Diabetic Subjects 
 
                            Pearson Correlation Coefficients, N = 18 
                                     
 
                       SAT          CRP          IL-6          TNF-α          Adiponectin 
 
SAT               1.00000     0.56124    0.15238    -0.10988        0.29269 
                                          0.0154      0.5461        0.6643          0.2385 
 
CRP               0.56124    1.00000     0.25831     0.40949      -0.07220 
                        0.0154                        0.3007         0.0915        0.7759 
 
IL-6               0.15238     0.25831     1.00000     0.00698     -0.12576 
                        0.5461       0.3007                         0.9781        0.6190 
 
TNF-α         -0.10988     0.40949      0.00698    1.00000     -0.38637 
                        0.6643      0.0915         0.9781                         0.1132 
 
Adiponectin  0.29269   -0.07220     -0.12576   -0.38637      1.00000 
                       0.2385       0.7759         0.6190      0.1132 
 
Non-Diabetic Subjects 
 
                                Pearson Correlation Coefficients,N = 11 
                                    
 
                       SAT          CRP          IL-6          TNF-α          Adiponectin 
 
SAT               1.00000     0.00821    0.20746     0.42953       -0.64839 
                                          0.9820      0.5405       0.1874           0.0309 
 
CRP               0.00821     1.00000  -0.05715     0.20543       -0.36323 
                        0.9820                        0.8754       0.5691           0.3022 
 
IL-6               0.20746    -0.05715    1.00000     0.49414      -0.54031 
                        0.5405       0.8754                        0.1224          0.0862 
 
TNF-α           0.42953     0.20543     0.49414    1.00000      -0.46298 
                        0.1874       0.5691       0.1224                           0.1516 
 
Adiponectin -0.64839   -0.36323    -0.54031   -0.46298       1.00000 
                        0.0309       0.3022       0.0862      0.1516 
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Diabetic Subjects 
 
                            Pearson Correlation Coefficients, N = 18 
                                     
 
                       VAT          Leptin          Resistin          Ghrelin          HOMA-IR 
 
VAT               1.00000     0.50514      -0.28494         -0.12384         0.28711 
                                           0.0325         0.2518             0.6244           0.2480 
 
Leptin             0.50514     1.00000      -0.32905          0.03533         0.41457 
                         0.0325                           0.1824             0.8893           0.0872 
 
Resistin         -0.28494   -0.32905        1.00000        -0.18873        -0.64540 
                         0.2518       0.1824                                0.4533            0.0038 
 
Ghrelin          -0.12384    0.03533       -0.18873         1.00000        -0.38697 
                          0.6244      0.8893          0.4533                                 0.1126 
 
HOMA-IR      0.28711    0.41457       -0.64540        -0.38697         1.00000 
                         0.2480      0.0872           0.0038           0.1126 
 
Non-Diabetic Subjects 
 
                            Pearson Correlation Coefficients, N = 11 
                                     
 
                       VAT          Leptin          Resistin          Ghrelin          HOMA-IR 
 
VAT              1.00000      0.78083        0.17620         -0.31443        0.06491 
                                           0.0046          0.6043            0.3463          0.8496 
 
Leptin            0.78083      1.00000        0.41352         -0.37545        0.24788 
                        0.0046                             0.2062             0.2552          0.4624 
 
Resistin         0.17620       0.41352       1.00000         -0.38078       -0.11060 
                        0.6043         0.2062                                0.2480           0.7461 
 
Ghrelin        -0.31443     -0.37545      -0.38078          1.00000        -0.35775 
                       0.3463         0.2552          0.2480                                  0.2800 
 
HOMA-IR    0.06491       0.24788      -0.11060         -0.35775        1.00000 
                       0.8496         0.4624          0.7461            0.2800 
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Diabetic Subjects 
 
                            Pearson Correlation Coefficients, N = 18 
                                     
 
                       VAT          CRP          IL-6          TNF-α          Adiponectin 
 
VAT               1.00000     0.20013   -0.14189    0.18429       -0.36219 
                                           0.4259       0.5744      0.4641          0.1397 
 
 CRP               0.20013    1.00000     0.25831    0.40949       -0.07220 
                          0.4259                       0.3007      0.0915           0.7759 
 
 IL-6              -0.14189    0.25831     1.00000    0.00698       -0.12576 
                          0.5744     0.3007                         0.9781          0.6190 
 
TNF-α             0.18429   0.40949      0.00698    1.00000      -0.38637 
                          0.4641     0.0915        0.9781                          0.1132 
 
Adiponectin   -0.36219  -0.07220    -0.12576   -0.38637       1.00000 
                          0.1397      0.7759       0.6190      0.1132 
 
Non-Diabetic Subjects 
 
                                Pearson Correlation Coefficients, N = 11 
                                    
 
                       VAT          CRP          IL-6          TNF-α          Adiponectin 
 
VAT               1.00000     0.42850     0.25319    0.15575      -0.47394 
                                           0.2166       0.4525      0.6475         0.1408 
 
CRP                0.42850    1.00000    -0.05715    0.20543      -0.36323 
                         0.2166                         0.8754      0.5691          0.3022 
 
IL-6                 0.25319  -0.05715      1.00000   0.49414      -0.54031 
                          0.4525     0.8754                        0.1224          0.0862 
 
TNF-α             0.15575    0.20543      0.49414   1.00000     -0.46298 
                          0.6475      0.5691        0.1224                         0.1516 
 
Adiponectin   -0.47394  -0.36323     -0.54031  -0.46298      1.00000 
                          0.1408      0.3022        0.0862      0.1516 
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Diabetic Subjects 
                            Pearson Correlation Coefficients, N = 18 
                                   
 
                           PAI-1            Weight            BMI            Insulin            HOMA-IR 
 
        PAI-1         1.00000         0.01411          0.16867       0.08314           0.06282 
                                                  0.9557            0.5035         0.7429              0.8044 
 
        Weight       0.01411         1.00000         0.79522        0.31957          0.15609 
                            0.9557                                  <.0001         0.1961             0.5363 
 
        BMI           0.16867         0.79522         1.00000        0.44322          0.40553 
                            0.5035           <.0001                                0.0654            0.0950 
 
        Insulin       0.08314        0.31957         0.44322        1.00000          0.88828 
                            0.7429          0.1961           0.0654                                 <.0001 
 
        HOMA-IR 0.06282       0.15609         0.40553         0.88828        1.00000 
                            0.8044         0.5363           0.0950           <.0001 
 
Non-Diabetic Subjects 
 
                            Pearson Correlation Coefficients, N = 11 
                                   
 
                          PAI-1            Weight            BMI            Insulin            HOMA-IR 
 
        PAI-1       1.00000         -0.08505         -0.04758      -0.02725         -0.01544 
                                                  0.8036            0.8895         0.9366             0.9641 
 
        Weight   -0.08505          1.00000           0.89177       0.58066           0.60139 
                          0.8036                                    0.0002         0.0611             0.0503 
 
        BMI       -0.04758          0.89177           1.00000       0.60938           0.63385 
                          0.8895           0.0002                                 0.0466             0.0362 
 
        Insulin    -0.02725         0.58066           0.60938       1.00000           0.99801 
                          0.9366           0.0611             0.0466                                 <.0001 
 
        HOMA-IR-0.01544      0.60139           0.63385       0.99801           1.00000 
                             0.9641        0.0503            0.0362         <.0001 
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Diabetic Subjects 
                                Pearson Correlation Coefficients, N = 18 
                                    
                 PAI-1            SAT            VAT            %BF            Fat            Lean 
 
PAI-1       1.00000        0.06766        0.21083       0.62502      0.33136    -0.43940 
                                       0.7897          0.4010          0.0073        0.1792       0.0681 
 
SAT         0.06766        1.00000       -0.07844       0.66674      0.59476   -0.23720 
                  0.7897                               0.7570          0.0035        0.0092      0.3433 
 
VAT        0.21083       -0.07844        1.00000       0.37650      0.60538    0.33578 
                  0.4010          0.7570                              0.1363        0.0078       0.1731 
 
%BF        0.62502        0.66674        0.37650       1.00000      0.80252   -0.56366 
                  0.0073          0.0035          0.1363                            0.0001      0.0185 
 
Fat           0.33136        0.59476        0.60538       0.80252      1.00000   -0.02126 
                  0.1792          0.0092          0.0078         0.0001                         0.9333 
 
Lean      -0.43940       -0.23720        0.33578      -0.56366     -0.02126    1.00000 
                  0.0681          0.3433         0.1731          0.0185        0.9333 
 
Non-Diabetic Subjects 
                            Pearson Correlation Coefficients, N = 11 
                                    
                 PAI-1            SAT            VAT            %BF            Fat             Lean 
 
PAI-1      1.00000        -0.00484       0.31444        0.15938     -0.05084    -0.04601 
                                       0.9887          0.3463          0.6397        0.8820        0.8931 
 
SAT       -0.00484         1.00000       0.54467       0.65655       0.95345      0.44314 
                  0.9887                              0.0832         0.0282         <.0001        0.1722 
 
VAT       0.31444         0.54467        1.00000       0.63711      0.51832      0.00809 
                 0.3463          0.0832                               0.0350        0.1024        0.9812 
 
%BF       0.15938         0.65655        0.63711      1.00000       0.70635      0.30799 
                 0.6397           0.0282          0.0350                            0.0151        0.3568 
 
Fat        -0.05084         0.95345         0.51832      0.70635      1.00000      0.60202 
                0.8820           <.0001           0.1024        0.0151                           0.0500 
 
Lean     -0.04601         0.44314         0.00809      0.30799      0.60202     1.00000 
                0.8931           0.1722           0.9812        0.3568        0.0500 
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Diabetic Subjects 
 
                            Pearson Correlation Coefficients, N = 18 
                                  
 
                   PAI-1            Leptin            Ghrelin            Resistin 
 
PAI-1        1.00000         0.31852         -0.44054           0.12748 
                                          0.1977           0.0673             0.6142 
 
Leptin        0.31852        1.00000          0.03533          -0.32905 
                    0.1977                                 0.8893             0.1824 
 
Ghrelin    -0.44054         0.03533         1.00000          -0.18873 
                   0.0673           0.8893                                   0.4533 
 
Resistin    0.12748        -0.32905       -0.18873            1.00000 
                  0.6142            0.1824          0.4533 
 
Non-Diabetic Subjects 
 
                            Pearson Correlation Coefficients, N = 11 
                                    
 
                   PAI-1            Leptin            Ghrelin            Resistin 
 
PAI-1        1.00000         0.15566          0.02727          -0.24821 
                                         0.6476            0.9366             0.4618 
 
Leptin       0.15566         1.00000        -0.37545            0.41352 
                   0.6476                                 0.2552              0.2062 
 
Ghrelin     0.02727       -0.37545         1.00000           -0.38078 
                   0.9366          0.2552                                    0.2480 
 
Resistin   -0.24821        0.41352        -0.38078           1.00000 
                   0.4618          0.2062           0.2480 
 
 
 
 
 
 
 
 
 
 228 
 
 
Diabetic Subjects 
 
                            Pearson Correlation Coefficients, N = 18 
                                     
 
                       PAI-1            CRP            TNF-α             IL-6            Adiponectin 
 
PAI-1            1.00000         0.03367      -0.05453           0.31014     -0.15436 
                                             0.8945          0.8298            0.2104         0.5408 
 
CRP              0.03367        1.00000        0.40949           0.25831     -0.07220 
                       0.8945                               0.0915             0.3007        0.7759 
 
TNF-α         -0.05453        0.40949        1.00000           0.00698     -0.38637 
                       0.8298          0.0915                                  0.9781        0.1132 
 
IL-6             0.31014         0.25831        0.00698          1.00000     -0.12576 
                      0.2104           0.3007          0.9781                               0.6190 
 
Adiponectin-0.15436      -0.07220       -0.38637         -0.12576      1.00000 
                       0.5408         0.7759          0.1132             0.6190 
 
Non-Diabetic Subjects 
 
                                Pearson Correlation Coefficients, N = 11 
                                   
 
                       PAI-1            CRP            TNF-α             IL-6            Adiponectin 
 
PAI-1            1.00000        -0.13854      -0.35547          0.10648       0.09340 
                                             0.7027          0.2834            0.7554         0.7847 
 
CRP            -0.13854         1.00000        0.20543         -0.05715      -0.36323 
                       0.7027                               0.5691            0.8754          0.3022 
 
TNF-α        -0.35547         0.20543        1.00000          0.49414      -0.46298 
                      0.2834           0.5691                                 0.1224         0.1516 
 
IL-6            0.10648        -0.05715        0.49414          1.00000      -0.54031 
                     0.7554           0.8754          0.1224                                0.0862 
 
Adiponectin0.09340      -0.36323       -0.46298          -0.54031       1.00000 
                      0.7847         0.3022          0.1516             0.0862 
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APPENDIX F 
 
Patient at a Glance Summary 
 
 
 
Non-Diabetic Subjects
Pt #
S E B MR PA A P Box TI S E B MR PA A P Box TI S E B MR PA A P Box TI
001 12.0 12.0 0.0 24.0 850.0 1.0 1.0 5.0 0.0 21.0 14.0 3.7 38.7 2336.7 1.0 1.0 6.0 1.0 20.0 12.3 4.0 36.3 2700.0 1.0 1.0 4.0 1.0
005 20.0 12.0 8.5 30.5 1233.0 1.0 1.0 6.0 0.0 29.7 14.7 5.0 49.3 2145.0 1.0 1.0 6.0 1.0 31.0 15.3 8.8 55.2 1872.7 1.0 1.0 6.3 0.7
013 18.0 12.0 4.0 34.0 2012.0 1.0 1.0 6.0 1.0 21.7 14.3 4.3 40.3 2133.7 1.0 1.0 7.0 0.7 21.7 14.0 8.0 43.7 2282.0 1.0 1.0 7.0 1.0
024 18.0 12.0 0.0 31.0 3110.0 1.0 1.0 6.0 1.0 22.7 14.0 1.0 37.3 4571.3 1.0 1.0 7.0 1.0 22.0 14.3 0.0 36.3 5189.0 1.0 1.0 7.0 1.0
026 32.0 0.0 3.0 35.0 540.0 1.0 1.0 6.0 0.0 36.7 1.0 0.0 37.3 2000.0 1.0 1.0 7.0 0.7 37.0 6.7 2.0 45.7 2641.7 1.0 1.0 7.0 1.0
028 39.0 0.0 10.0 49.0 630.0 1.0 1.0 6.0 0.0 35.0 7.3 2.3 44.7 1343.3 1.0 1.0 7.0 0.0 35.0 8.3 9.0 52.3 1739.0 1.0 1.0 7.0 0.7
029 17.0 12.0 3.0 32.0 245.0 1.0 1.0 6.0 0.0 22.8 14.3 4.3 41.5 2041.7 1.0 1.0 7.0 0.7 24.0 15.0 7.3 46.7 2851.7 1.0 1.0 7.0 1.0
032 20.5 12.0 4.0 36.5 494.0 1.0 1.0 6.0 0.0 23.0 15.7 11.5 45.8 2081.0 1.0 1.0 6.7 1.0 26.3 14.7 12.7 54.0 1841.7 1.0 1.0 7.0 0.3
033 20.0 12.0 6.0 38.0 1989.0 1.0 1.0 6.0 0.0 21.3 14.0 15.0 50.3 3028.3 1.0 1.0 7.0 1.0 21.0 16.0 13.0 53.3 3746.7 1.0 1.0 7.0 1.0
037 21.0 12.0 0.0 33.0 1435.0 1.0 1.0 6.0 0.0 23.0 14.3 3.0 40.3 3420.0 1.0 1.0 7.0 1.0 24.0 15.7 11.0 50.7 4480.0 1.0 1.0 7.0 1.0
040 17.0 12.0 4.0 33.0 2355.0 1.0 1.0 6.0 0.0 21.3 14.3 6.7 42.3 2433.3 1.0 1.0 6.3 1.0 20.7 13.7 6.3 40.3 2449.7 1.0 1.0 6.7 1.0
Average 21.3 9.8 3.9 34.2 1353.9 1.0 1.0 5.9 0.2 25.3 12.5 5.2 42.5 2503.1 1.0 1.0 6.7 0.8 25.7 13.3 7.5 46.8 2890.4 1.0 1.0 6.6 0.9
Count 11.0 11.0 11.0 11.0 11.0 11.0 11.0 11.0 11.0 11.0 11.0 11.0 11.0 11.0 11.0 11.0 11.0 11.0 11.0 11.0 11.0 11.0 11.0 11.0 11.0 11.0 11.0
SD 7.6 4.9 3.3 6.1 914.0 0.0 0.0 0.3 0.4 5.7 4.4 4.5 4.5 876.4 0.0 0.0 0.4 0.3 6.0 3.1 4.2 6.9 1125.6 0.0 0.0 0.9 0.2
SE 2.3 1.5 1.0 1.8 275.6 0.0 0.0 0.1 0.1 1.7 1.3 1.3 1.4 264.2 0.0 0.0 0.1 0.1 1.8 0.9 1.3 2.1 339.4 0.0 0.0 0.3 0.1
95% LCI 16.8 6.9 1.9 30.6 813.8 1.0 1.0 5.7 -0.1 21.9 9.9 2.5 39.9 1985.2 1.0 1.0 6.5 0.6 22.2 11.5 5.0 42.7 2225.2 1.0 1.0 6.1 0.7
95% UCI 25.8 12.7 5.8 37.8 1894.0 1.0 1.0 6.1 0.4 28.7 15.1 7.8 45.2 3021.0 1.0 1.0 7.0 1.0 29.2 15.1 9.9 50.9 3555.5 1.0 1.0 7.2 1.0
S=Shakes, E=Entrees, B=Bars, MR=Total Meal Replacements, PA=Physical Activity, A=Attendance
P=Midweek phone call, Box=Number of days in the box, TI=Triple Imperative
Wk 1 Wk8 Average Wk16 Average
Diabetic Subjects
Pt #
S E B MR PA A P Box TI S E B MR PA A P Box TI S E B MR PA A P Box TI
003 21.0 14.0 7.0 42.0 2000.0 1.0 1.0 6.0 1.0 21.0 14.3 6.5 39.7 2676.7 1.0 1.0 7.0 1.0 21.0 14.0 4.0 39.0 2358.3 1.0 0.7 6.7 1.0
007 3.0 3.0 2.0 8.0 45.0 1.0 1.0 5.0 0.0 22.3 15.0 12.3 49.7 1591.7 1.0 1.0 6.7 0.0 23.3 16.3 7.0 46.7 1927.7 1.0 1.0 7.0 0.7
008 30.0 4.0 5.0 39.0 350.0 1.0 1.0 5.0 0.0 30.0 14.7 4.0 44.7 1813.3 1.0 1.0 7.0 0.3 21.0 14.0 0.0 35.0 1813.3 0.7 1.0 5.0 0.0
009 18.0 13.0 2.0 33.0 1152.0 1.0 1.0 6.0 0.0 21.3 19.3 6.0 46.7 2647.0 1.0 1.0 6.0 1.0 21.7 18.3 11.0 51.0 2370.0 1.0 1.0 6.3 1.0
012 19.0 12.0 2.0 33.0 885.0 1.0 1.0 6.0 0.0 10.0 8.0 2.5 20.5 885.0 0.3 0.3 2.3 0.0 21.0 23.0 9.0 53.0 2130.0 1.0 0.0 5.0 1.0
014 47.0 4.0 9.0 60.0 980.0 1.0 1.0 6.0 0.0 24.3 21.0 7.0 52.0 2363.3 1.0 1.0 7.0 0.7 29.3 22.0 5.0 56.0 2021.7 1.0 1.0 7.0 0.3
017 18.0 12.0 6.0 36.0 6380.0 1.0 1.0 6.0 1.0 30.0 13.7 12.3 52.3 4366.7 1.0 1.0 7.0 1.0 21.7 16.0 14.3 54.0 3800.0 1.0 1.0 7.0 1.0
018 14.0 10.0 2.0 26.0 1527.0 1.0 1.0 5.0 0.0 21.0 14.3 2.7 38.0 3504.0 1.0 1.0 7.0 1.0 22.3 10.7 5.3 38.3 3020.3 1.0 1.0 6.7 1.0
020 28.0 0.0 0.0 28.0 40.0 1.0 1.0 6.0 0.0 37.3 2.5 1.0 39.3 76.7 0.7 1.0 6.3 0.0 39.3 8.3 1.0 48.3 70.0 0.0 0.7 6.0 0.0
023 32.0 0.0 0.0 32.0 320.0 1.0 1.0 6.0 0.0 42.5 9.7 12.3 64.5 1527.3 1.0 1.0 7.0 0.0 44.0 12.7 15.3 72.0 1516.7 1.0 1.0 7.0 0.7
025 36.5 0.0 7.0 43.5 1835.0 1.0 1.0 6.0 0.0 36.0 1.0 8.7 45.3 3376.3 1.0 1.0 7.0 1.0 36.5 3.0 4.0 42.0 2717.5 1.0 1.0 7.0 1.0
030 20.0 12.0 1.0 33.0 540.0 1.0 1.0 6.0 0.0 26.0 14.3 6.3 46.7 2671.7 1.0 1.0 7.0 1.0 29.0 19.3 12.7 61.0 2855.3 1.0 1.0 7.0 1.0
031 17.0 12.0 7.0 36.0 280.0 1.0 1.0 5.0 0.0 21.0 19.0 2.3 42.3 2266.7 0.7 0.7 6.0 0.3 39.0 18.0 10.0 63.0 2066.7 1.0 1.0 7.0 1.0
034 26.0 10.0 0.0 36.0 540.0 1.0 1.0 6.0 0.0 21.0 14.3 4.3 40.0 4110.0 1.0 1.0 7.0 1.0 24.0 11.0 3.3 38.3 3178.3 1.0 1.0 7.0 1.0
036 20.0 12.0 0.0 22.0 945.0 1.0 1.0 6.0 0.0 21.7 15.3 3.7 40.7 1850.0 1.0 1.0 7.0 0.7 26.0 15.3 8.3 49.7 3478.3 1.0 1.0 7.0 1.0
038 18.0 13.0 7.0 38.0 1890.0 1.0 1.0 6.0 0.0 22.7 15.3 6.7 44.7 2592.3 1.0 1.0 7.0 1.0 25.3 19.3 13.7 58.3 2974.3 1.0 1.0 7.0 1.0
039 26.0 12.0 4.0 40.0 1320.0 1.0 1.0 6.0 0.0 24.3 14.3 7.0 48.3 3533.3 1.0 1.0 7.0 1.0 27.8 14.5 8.0 46.3 3650.0 1.0 1.0 7.0 1.0
041 31.0 11.0 15.0 57.0 2013.0 1.0 1.0 6.0 1.0 42.7 11.3 6.3 59.0 3359.3 1.0 1.0 6.7 1.0 36.7 5.5 2.0 41.0 2022.7 0.7 1.0 7.0 1.0
Average 23.6 8.6 4.2 35.7 1280.1 1.0 1.0 5.8 0.2 26.4 13.2 6.2 45.2 2511.7 0.9 0.9 6.6 0.7 28.3 14.5 7.4 49.6 2442.8 0.9 0.9 6.6 0.8
Count 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0 18.0
SD 9.8 5.1 4.0 11.7 1437.5 0.0 0.0 0.4 0.4 8.5 5.2 3.5 9.3 1110.5 0.2 0.2 1.1 0.4 7.5 5.4 4.7 10.0 892.1 0.3 0.3 0.7 0.3
SE 2.3 1.2 0.9 2.8 338.8 0.0 0.0 0.1 0.1 2.0 1.2 0.8 2.2 261.8 0.0 0.0 0.3 0.1 1.8 1.3 1.1 2.4 210.3 0.1 0.1 0.2 0.1
95% LCI 19.1 6.2 2.4 30.3 616.0 1.0 1.0 5.6 0.0 22.5 10.8 4.6 40.9 1998.7 0.8 0.9 6.0 0.5 24.8 12.0 5.3 45.0 2030.7 0.8 0.8 6.3 0.7
95%UCI 28.1 10.9 6.1 41.1 1944.2 1.0 1.0 6.0 0.3 30.3 15.6 7.8 49.5 3024.8 1.0 1.0 7.1 0.9 31.7 17.0 9.6 54.2 2855.0 1.0 1.0 7.0 1.0
S=Shakes, E=Entrees, B=Bars, MR=Total Meal Replacements, PA=Physical Activity, A=Attendance
P=Midweek phone call, Box=Number of days in the box, TI=Triple Imperative
Wk 1 Wk8 Average Wk16 Average
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• Procured $139,454 in extramural grants. 
• Developed and presented health information on obesity, cardiovascular disease, 
and diabetes at health fairs, staff appreciation events, and local community 
groups. 
• Reviewed research and prepared health information for international drug 
companies, medically supervised weight loss programs, and commercial 
nutritional supplement outlet stores. 
• Authored six refereed journal articles and nine other publications. 
• Planned innovative curricula, organized group projects, html online access, and 
discussion boards to enhance coursework, and facilitated undergraduate 
education. Developed and taught the following courses to nutrition, dietetics, and 
pre-med majors: 
o Nutrition and Food Science 510: Advanced Nutrition 
o Nutrition and Food Science 240: Nutrition and Physical Fitness 
• Recruited by Department Chair to assume teaching responsibility for professors 
on leave. 
• Consulted on design and information content and answered general email 
questions for HCF Nutrition Foundation website – www.hcf-nutrition.org 
• Served as the Student Representative on the Student Recruitment Committee to 
encourage US students to attend the Nutritional Sciences Graduate Program at the 
University. Prepared and presented slide shows, posters, and letters throughout 
State to promote program. 
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LEXINGTON COMMUNITY COLLEGE 
Lexington, Kentucky 
Instructor, 2002 to 2004 
Recognized educational opportunity and successfully initiated nutrition coursework at 
local community college. Taught six semesters. Reported to the Biology Coordinator. 
• Identified need, obtained approval, and initiated Nutrition 101: Human Nutrition 
and Wellness, an online course for undergraduate students.  
• Prepared in-class and online lectures using PowerPoint, BlackBoard, and Angel 
programs.  
• Achieved student satisfaction rating of 4.6 for Excellence of Teacher and 
Excellence of Course. 
 
VETERANS ADMINISTRATION MEDICAL CENTER 
Lexington, Kentucky 
Preceptor and Mentor, 1998 to 2002 
Recruited to mentor undergraduate dietetic students and to assist undergraduate students 
in research projects. Reported to the Chief of Endocrinology and Director of the 
Metabolic Research Group. 
• Facilitated and mentored undergraduate dietetic students with research projects to 
help them gain research experience as part of Nutrition and Food Science 591: 
Special Problems in Food and Nutrition coursework. 
• Served as preceptor for clinical practicum experience as part of Nutrition and 
Food Science 580: Pre-professional Practice in Dietetics. 
SPECIAL ACHIEVEMENTS  
 
Recognized for achievement and potential as awarded following stipends, scholarships, 
and fellowships: 
• Oxidative Stress in Nutrition Training Grant • National Institutes of Health 
DK07778-02 • 2001 to 2004 
• TORA Tuition Scholarship • University of Kentucky • 1998 to 2001 
• Graduate Research Assistant • University of Kentucky Stipend • 1998-2001 and 
2004 to Present 
 
Coordinated Annual Symposia, sponsored by the National Institutes of Health Oxidative 
Stress and Nutrition Training Grant, on cancer, diabetes, obesity, alcoholism, and 
cardiovascular disease • Attended by 150 professional, research, and academic personnel 
• May 6, 2002, April 17, 2003, and May 17, 2004  
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Worked with Roche Pharmaceutical Company to direct consumer and healthcare 
professional information and prepare presentations on Orlistat, the Company’s weight 
loss drug. 
 
Reviewed research and publications on medically-supervised low calorie and SCAN Diet 
Plans for Health Management Resources, a Boston-based weight loss company, and for 
General Nutrition Centers. 
 
Invited to review research grant proposals and to allocate funding awards as part of the 
Proposal Review Committee for the General Clinical Research Center • University of 
Kentucky • 2004 to Present 
 
Prepared public health television advertisement and outreach program to promote milk 
for healthy nutrition • University of Mississippi • 1997  
 
Completed Massage Therapy Coursework • Capri College • Madison, Wisconsin • 1995 
to 1996 
 
Served as Diet Clerk • University of Wisconsin Medical Center • 1994 to 1996 
PROFESSIONAL and COMMUNITY INVOLVEMENT 
 
American College of Nutrition • Member • 1999 to Present 
American Dietetic Association • Member • 1994 to Present 
American Society for Nutritional Sciences • Member • 1999 to Present 
Kentucky Dietetic Association • Member • 1998 to Present 
North American Association for the Study of Obesity • Member • 1999 to Present 
Nutritional Sciences Graduate Student Association • Member • 1998 to Present 
Society for Experimental Biology and Medicine • Member • 1999 to Present 
American Red Cross • CPR & First Aid Instructor • 1994 to 1996 
GRANTS RECEIVED 
 
Clinical Research Feasibility Funds • 2004 to 2005 • $20,000 • General Clinical Research 
Center • University of Kentucky • National Institutes of Health National Center for 
Research Resources (NIH-NCRR) M01-RR02602 
 
Effects of Weight Loss on Visceral Adiposity and Metabolic Adaptations in Diabetic 
versus Non-Diabetic Women • 2002 to 2004 • $71,972 • Principal Investigator • National 
Institutes of Health M01-RR02602 
 
A 16-Week, Randomized, Double-Blind, Controlled, Parallel Group Study to Compare 
the Effects of Revival Soy Shakes and Casein Meal Replacement Shakes as Part of an 
Energy-Restricted Diet for the Treatment of Obesity • 2003 to 2004 • $47482 • Co-
Principal Investigator • National Institutes of Health M01-RR02602 
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PUBLICATIONS – BOOKS or CHAPTERS  
 
Anderson, JW and Konz, EC. Guidelines for Weight Management and Use of Very-low-
calorie Diets and Meal Replacements. Chapter 19 Food, Diet, and Obesity. Ed. David 
Mela. Woodhead Publishing Lte, Cambridge, England. In Press. 
PUBLICATIONS – ARTICLES, ABSTRACTS, REPORTS, or LETTERS TO 
EDITOR 
 
Konz, EC, Anderson, JW, and Reynolds, LR. Low-energy Diet Effects on Percentage 
Weight and Body Fat Changes in Women with and without Type 2 Diabetes Mellitus. 
Obesity Research 12 (Supplement 1): A36, 2004. 
 
Konz, EC and Anderson, JW. Effect of an Intensive Weight Loss Program on Long-term 
Weight Maintenance Journal American College of Nutrition 22(5):468, 2003. 
 
Tharappel, JC, Nalca, A, Owens, A, Ghabrial, L, Konz, E, Glauret, H, and Spear, B. Cell 
Proliferation and Apoptosis are Altered in Mice Deficient in the NF-κB p50 Subunit After 
Treatment with the Peroxisome Proliferator Ciprofibrate. Toxicology Science 75(2):300-
308, 2003. 
 
Reynolds, LR, Konz, EC, Frederich, RC, and Anderson, JW. Rosiglitazone Amplifies the 
Benefits of Lifestyle Intervention Measures in Long-standing Type 2 Diabetes Mellitus. 
Diabetes Obesity Metabolism 4(4):270-275, 2002. 
 
Konz, EC and Anderson JW. Effects of an Intensive Weight Loss Program on Long-term 
Weight Maintenance and Health Behaviors – Final Report. Health Management 
Resource, 2002. 
 
Anderson, JW and Konz, EC. Obesity and Disease Management: Effects of Weight Loss 
on Co-Morbid Conditions.  Obesity Research 9 (Supplement 4):326S-334S, 2001. 
 
Konz, EC and Anderson, JW. Effects of Weight Gain and Loss on Co-Morbid Conditions. 
Obesity Research 9 (Supplement 3):166S, 2001. 
 
Reynolds, LR, Strange, K, Anderson JW, and Konz, EC. Lifestyle Intervention Reduces 
Multiple Risk Factors in Obese Patients with Poorly Controlled Insulin Requiring Type 2 
Diabetes Mellitus. Proceedings of the 83rd Annual Endocrine Society. Abstract P2-
572, page 416, 2001. 
 
Anderson, JW, Konz, EC, Frederich, RC, and Wood, CL. Long-term Weight 
Maintenance: A Meta-Analysis of US Studies.  American Journal of Clinical Nutrition 
74:579-584, 2001. 
    
Anderson, JW and Konz, EC. Benefits and Risk of Anti-Obesity Agents (Letter to the 
Editor).  American Journal of Clinical Nutrition 71:844-845, 2000. 
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Daly, AE, Konz, EC, Soler, NG, Anderson, JW, Yergler, C, and Carpenter, P. Successful 
Long-term Maintenance of Substantial Weight Loss: One Program’s Experience. 
Journal American Dietetics Association 100:1456, 2000. 
 
Konz, EC and Anderson, JW. Comparison of Weight Loss Strategies. Obesity Research 
8 (Supplement 1):77S, 2000. 
 
Anderson, JW, Konz, EC, and Jenkins, DJA. Health Advantages and Disadvantages of 
Weight-Reducing Diets: A Computer Analysis and Critical Review. Journal of 
American College of Nutrition 19:578-590, 2000. 
 
Anderson, JW and Konz, EC. Orlistat: First of a New Generation of Drugs for the 
Treatment of Obesity. Today’s Therapeutic Trends 17:243-255, 1999. 
 
Anderson, JW, Konz, EC, Frederich, RC, and Wood, CL. Long-term Weight 
Maintenance: A Meta-Analysis of US Studies. Obesity Research 7 (Supplement1):43S, 
1999. 
ADDRESSES, LECTURES, POSTERS, or WORKSHOPS 
 
Body Composition and Metabolic Adaptations in Diabetic versus Non-Diabetic Women 
after Weight Loss • Graduate Center for Nutritional Sciences Seminar Series • University 
of Kentucky, Lexington, KY • December 8, 2004 
 
Low-energy Diet Effects on Percentage Weight and Body Fat Changes in Women with 
and without Type 2 Diabetes • North American Association for the Study of Obesity 
Conference • Las Vegas, NV • November 14-18, 2004 
 
Effect of an Intensive Weight Loss Program on Long-term Weight Maintenance • 
American College of Nutrition Conference • Nashville, TN • October 9-12, 2003 
 
Fighting the “Freshman 15” • University of Kentucky 101 – Academic Orientation • 
University of Kentucky, Lexington, KY • October 3, 2002 
 
Obesity Treatment Approaches • Nutrition and Food Science 101 – Human Nutrition and 
Wellness • Lexington Community College, Lexington, KY • April 4, 2002 
 
Obesity Treatment Approaches • Nutrition and Food Science 212 – Introductory Nutrition 
• University of Kentucky, Lexington, KY • March 18 and March 20, 2002 
    
Effects of Weight Gain and Loss on Co-Morbid Conditions • Nutrition Week • San Diego, 
CA • February 23-27, 2002 
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Energy Balance and Healthy Body Weight • Nutrition and Food Science 101 – Human 
Nutrition and Wellness • University of Kentucky, Lexington, KY • October 24, 26, and 
29, 2001  
 
Obesity: Classification, Body Composition and Treatment Approaches • Nutrition and 
Food Science 212 – Introductory to Nutrition • University of Kentucky, Lexington, KY • 
October 12 and October15, 2001 
 
Effects of Weight Gain and Loss on Co-Morbid Conditions • North American Association 
for the Study of Obesity Conference • Quebec City, Canada • October 7-10, 2001 
 
Lifestyle Intervention Reduces Multiple Risk Factors in Obese Patients with Poorly 
Controlled Insulin-Requiring Type 2 Diabetes Mellitus • Proceedings of the 83rd Annual 
Endocrine Society Meeting • Denver, CO • June 20-23, 2001. 
 
Comparison of Diet and Drug Weight Loss Approaches in Clinical and Research 
Practices • North American Association for the Study of Obesity Conference • Long 
Beach, CA • October 29 to November 2, 2000 
 
Eat For the Health of It • University of Kentucky College of Medicine Mini-Medical 
School • Lexington, KY • September 19, 2000 
 
Obesity Treatment Approaches- The Real Truth • Nutrition and Food Science 510 – 
Advanced Nutrition • University of Kentucky, Lexington, KY • April 17, 2000 
 
Long-term Weight Maintenance: A Meta-Analysis of US Studies • Veteran’s 
Administration Medical Center Research Week • Lexington, KY • April 17-21, 2000 
 
Fad Diets – Pros and Cons • Annual Endocrinology Conference • Embassy Suites, 
Lexington, KY • April 7-8, 2000 
 
Obesity Treatment Approaches- The Real Truth • Nursing 842 – Community Health 
Nursing • University of Kentucky, Lexington, KY • March 22, 2000. 
 
Obesity Treatment: Combating the Diet Craze- The Real Truth • Bluegrass District 
Dietetic Association • February Seminar • Lexington, KY • February 12, 2000 
 
Long-term Weight Maintenance: A Meta-Analysis of US Studies • North American 
Association for the Study of Obesity • Charleston, SC • November 14-18, 1999 
 
Long-term Weight Maintenance: A Meta-Analysis of US Studies • University of Kentucky 
Life Sciences Day • Lexington, KY • November 1, 1999 
 
 
